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Several genetic and lifestyle 
factors influence the risk for 
Alzheimer’s disease (AD), a 
complex neurodegenerative 
disorder. This thesis focuses on the 
characterization of the effects of 
UBQLN1 gene and dietary lipids on 
the molecular mechanisms of AD 
in preclinical models and human 
brain. These findings advance 
our knowledge of AD molecular 
pathogenesis and may be applied in 
the development of novel therapeutic 
approaches and intervention 
strategies in the future.
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ABSTRACT
Alzheimer’s disease (AD) is the most common cause of dementia in the elderly and is listed amongst
the top global health challenges by World Health Organization. AD is a multifactorial disease, which
is affected by a complex interplay between genetic and environmental factors. The initial cause of AD
is unclear, but it is increasingly evident that abnormal trafficking, processing, accumulation, and
aggregation of disease-associated proteins in the brain underlie the disease. Currently, there are no
disease-modifying therapies or cures available for this disease. Since the incidence of AD is expected
to exponentially increase, due to aging of the population, there is an urgent need to find ways to
reduce the risk, identify novel biomarkers, and harness potential therapeutic targets. For these
purposes, a better understanding of the underlying molecular mechanisms of AD pathogenesis is
required. The aim of this thesis was to characterize the effect of genes and dietary manipulation on
AD-related proteins and pathways, in particular those related to Ά-amyloid (AΆ), tau, and
neuroinflammation. The special emphasis was on the AD-associated risk gene UBQLN1 and on the
influence of dietary lipid composition.
The goal in study I was to review the role of ubiquilin-1 in AD pathogenesis and as a potential
therapeutic target in AD on the basis of recent literature. In study II, the aim was to experimentally
characterize the expression and function of ubiquilin-1 in human brain as well as in both, in vitro and
in vivo models of AD. Ubiquilin-1 has previously been shown to regulate the levels, processing,
trafficking, degradation and accumulation of several AD-associated proteins. Study II provides
evidence for a novel function for ubiquilin-1 as Ά-site APP cleaving enzyme-1 (BACE1)–interacting
protein. This interrelationship was found to increase BACE1 stability by diverting it from the
lysosomal degradation pathway and this may subsequently affect AΆ accumulation. Although
ubiquilin-1 has previously been shown to alleviate the effects of different types of stress, it was not
found to have a similar role during AD-associated neuroinflammation in mouse brain or in cell-based
models. Together with previous reports, these data indicate that ubiquilin-1 has an evident, but
complex role in AD molecular pathogenesis. Based on its several AD-associated functions, ubiquilin-
1 might be a plausible therapeutic target. However, a deeper understanding of its multifaceted role
and functions is necessary.
Studies III and IV investigated the effects of dietary manipulation on AD-related molecular
mechanisms and cognitive changes in aging mice. In study III, the four month intervention with the
high-fat diet (HFD) was found to increase tau expression, and tau exon 10 inclusion, independently
of AD or type 2 diabetes-related genetic background. HFD-induced changes in tau expression were
correlated with a poorer performance in cognitive tests, but were not associated with central or
peripheral insulin signaling, neuroinflammation or the expression of tau exon 10 splicing factors.
These findings suggest that HFD may accelerate tau-related pathology and associate with the risk or
progression of AD and other neurodegenerative tauopathies.
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TIIVISTELMÄ
Alzheimerin tauti (AT) on yleisin dementiaa aiheuttava sairaus ikääntyvillä. AT:iin ei ole
olemassa hoitoa, jolla voitaisiin estää taudin puhkeaminen tai hidastaa sen etenemistä. Myöhäisiällä
puhkeava AT on monitekijäinen sairaus, jonka syntyyn tiedetään vaikuttavan joukko geneettisiä sekä
ympäristöön ja elämäntapoihin liittyviä riskitekijöitä. Näiden riskitekijöiden yhteisvaikutuksesta
alttius patologisille solutason muutoksille lisääntyy ikääntymisen myötä ja AT:iin liittyvien
proteiinien, kuten taun ja amyloidiprekursoriproteiinista (APP) pilkottavan Ά-amyloidin (AΆ),
epänormaali prosessointi, hajotus ja kertyminen yleistyvät. Proteiinien epänormaali kertyminen sekä
siihen liittyvät stressitilat puolestaan ovat vahingollisia hermosoluille ja johtavat lopulta
laajamittaiseen aivokudoksen tuhoutumiseen. Tästä huolimatta AT:n perimmäinen syy sekä siihen
liittyvät biologiset mekanismit ovat edelleen suurelta osin heikosti tunnettuja. AT:n riskitekijöiden
tunnistaminen ja taudin taustalla vaikuttavien solu- ja molekyylitason mekanismien
yksityiskohtainen selvittäminen on ehdottoman tärkeää taudin ennaltaehkäisemiseksi ja uusien
terapiamuotojen kehittämiseksi. Tässä väitöskirjatutkimuksessa tavoitteena oli kartoittaa tiettyjen
riskigeenien ja ruokavalion ravintoaineiden vaikutusta AT:in liittyviin molekyylitason
mekanismeihin AT-potilaiden aivokudosnäytteissä sekä erilaisissa solu- ja eläinmalleissa sekä
kognitiivisiin muutoksiin hiirillä.
Kahdessa ensimmäisessä osatyössä selvitettiin AT:n riskigeenin, ubikiliini-1:n, kytkeytymistä
AT:n patologiaan. Aikaisemman kirjallisuuden perusteella ubikiliini-1 säätelee aivoissa useiden
AT:iin liittyvien proteiinien tasoja sekä hajotusta ja voi siten liittyä AT:n varhaisiin solutason
muutoksiin. Toisessa osatyössä AT-potilaiden aivokudosnäytesarjasta sekä solu- ja
eläinmallipohjaisista kokeista saadut tulokset osoittivat uuden yhteyden ubikiliini-1:n ja APP:a
pilkkovan Ά-sekretaasi-entsyymin (BACE1) välillä. Tässä tutkimuksessa ubikiliini-1:n havaittiin
lisäävän BACE1:n tasoja soluissa estämällä sen kulkeutumisen soluissa lysosomaaliseen hajotukseen.
Tämä puolestaan voi johtaa taudissa sakkautuvan AΆ:n lisääntyneeseen tuotantoon sekä kertymiseen
ja siten taudin patologian etenemiseen. Vaikka aikaisemmissa tutkimuksissa ubikiliini-1:n on todettu
suojaavan soluja erilaisissa stressitiloissa, ei vastaavanlaista yhteyttä havaittu tässä tutkimuksessa
ubikiliini-1:n ja AT:iin keskeisesti liittyvän neuroinflammaation välillä. Näiden tulosten sekä
aikaisempien löydösten perusteella ubikiliini-1:llä vaikuttaa olevan tärkeä, mutta monitahoinen
merkitys AT:n patogeneesissä.
Kolmannessa ja neljännessä osatyössä oli pyrkimyksenä selvittää ruokavalion rasvahappojen ja
eräiden muiden ravintoaineiden vaikutusta AT:n patogeneesiin sekä kognitiivisiin muutoksiin
hiirimalleilla. Aikaisemmissa tutkimuksissa on näytetty, että runsaasti tyydyttyneitä rasvoja sisältävä
ruokavalio, ylipaino ja tyyppi 2:n diabetes (T2D) lisäävät AT:n riskiä. Kolmannessa osatyössä
runsaasti tyydyttyneitä rasvahappoja sisältävän rasvadieetin todettiin merkittävästi lisäävän AT:ssa
keskeisen tau-proteiinin tasoja, mRNA:n ilmentymistä sekä vaihtoehtoista silmukointia, jonka
seurauksena tau-proteiinien isoformien suhteellinen määrä muuttui hiirimallin aivoissa. Nämä
VI
In study IV, nine-month intervention with special lipid-based diets containing fish oil (FO), fish
oil and plant sterols (FOPS) or a special multinutrient combination including precursors and cofactors
for neuronal membrane formation (Fortasyn) were found to alleviate the odor recognition impaiment
of the AD mice. In contrast, only Fortasyn diet alleviated the spatial learning deficits of the AD mice.
All diets markedly inhibited the APP-cleaving enzymes, Ά- and ·-secretase, in the brain of AD mice,
but this was translated to reduce AΆ levels only in mice fed with FOPS-diet. The alleviated cognitive
impairment by the dietary intervention was neither related to changes in neuroinflammation nor
oxidative stress. Therefore, this implies that additional supplementation with specific nutrients may
improve the cognitive benefits of fish oil-containing diets through AΆ-independent mechanisms.
Together, the data from studies III and IV indicate that modulation of dietary lipid and nutrient
composition may be a potential approach for delaying the progression of AD-related pathological
changes and the subsequent cognitive decline.
In summary, the results obtained from the studies in this thesis provide novel information about
the functional role of specific genetic and environmental factors associated with AD pathogenesis.
These findings may be applied to the identification of novel pharmacological targets, predictive
and/or diagnostic biomarkers as well as the development of refined strategies to intervene with
disease progression, in order to advance general well-being in the aging societies and help the
management of neurodegenerative disorders.
National Library of Medicine Classification: WT 155, QU 470, QU 477, QT 235, QU 86
Medical Subject Headings: Alzheimer Disease; Protein Aggregation, Pathological; Genes; Diet; Diet, High-Fat;
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rasvadieetistä johtuvat tau-muutokset liittyivät heikentyneeseen suoriutumiseen muistia ja
kognitiivista suoriutumista mittaavissa käyttäytymiskokeissa. Muutokset olivat osittain yhteydessä
rasvadieetillä olleilla hiirillä havaittuun painon nousuun, mutta suurelta osin riippumattomia
T2D:een liittyvistä glukoosi- ja insuliinisignaloinnin häiriöistä tai aivojen neuroinflammaatiosta.
Tulosten perusteella runsaasti tyydyttyneitä rasvoja sisältävällä ruokavaliolla voi olla yhteys tau-
patologiaan sekä heikentyneeseen muistiin ja oppimiseen ja se voi näin ollen altistaa AT:lle ja muille
hermorappeumasairauksille.
Ravinnosta saatavan kalaöljyn on aikaisemmin osoitettu pienentävän AT:n riskiä. Neljännessä
osatyössä erilaisten kalaöljypohjaisten rasvadieettien (kalaöljy, kalaöljy + kasvisterolit tai Fortasyn)
havaittiin merkittävästi parantavan AT:n siirtogeenisten hiirten heikentynyttä suoriutumista
hajumuistia ja -tunnistusta mittaavassa testissä. Lisäksi Fortasyn-ravintolisän, joka sisältää mm.
erilaisia solukalvojen rakennusaineiksi tarvittavia lipidejä ja vitamiineja, havaittiin tehostavan
kalaöljypohjaisen ruokavalion hyödyllistä vaikutusta AT-hiirten sijaintimuistiin. Vaikka jokaisen
kalaöljypohjaisen dieetin havaittiin tehokkaasti vähentävän APP:a pilkkovien Ά- ja ·-
sekretaasientsyymien aktiivisuutta, ei tämä heijastunut vähentyneeseen AΆ:n määrään. Nämä
tulokset tukevat ravinnon kalaöljyn hyödyllisiä vaikutuksia AT:iin liittyviin molekyylitason ja
kognitiivisiin muutoksiin. Lisäksi tutkimus osoittaa, että erityiset lisäravinteet saattavat tehostaa
kalaöljyn positiivisia vaikutuksia AΆ-patologiasta riippumattomin mekanismein. Kaiken kaikkiaan
kolmas ja neljäs osatyö osoittavat, että ravinnon rasvasisällöllä voi olla merkitystä AT:n riskin,
etenemisen ja oireiden kannalta.
Tämä väitöskirjatyö valaisee tutkittujen geneettisten ja ravintoperäisten tekijöiden merkitystä
AT:n patogeneesissä sekä kognitiivisissa muutoksissa. Tätä uutta tietoa voidaan mahdollisesti
tulevaisuudessa hyödyntää AT:a ennakoivien tai diagnostisten biologisten merkkiaineiden sekä
uusien terapiamuotojen kehittämisessä. Siten nämä tutkimustulokset voivat edistää hyvinvointia
ikääntyvässä yhteiskunnassa sekä auttaa muistisairauksien hoidossa ja ennaltaehkäisyssä.
Luokitus: WT 155, QU 470, QU 477, QT 235, QU 86
Yleinen Suomalainen asiasanasto: Alzheimerin tauti; patogeneesi; proteiinit; geenit; ruokavaliot; ravinto;
ravintovalmisteet; ravintorasvat; lipidit; kalaöljyt; kognitio; koe-eläinmallit; hiiret
IX
Acknowledgements
This  study  was  carried  out  at  the  Institute  of  Clinical  Medicine  –  Neurology,  Institute  of
Biomedicine and A.I. Virtanen Institute for Molecular Sciences, School of Medicine, Faculty
of Health Sciences, University of Eastern Finland during the years 2011-2015.
I  want  to  express  my  most  sincere  gratitude  to  my  primary  supervisor  Associate
Professor Annakaisa Haapasalo for all your support, encouragement and never-ending faith
on me and my research. Thank you for sharing with me the great knowledge that you have
and for guiding me through all the aspects of this project. I deeply appreciate that you have
given me the  independence to  do and learn the  things  by myself  and grow as  a  scientist,
while you still  were always available when I needed your help, even with the most trivial
issues.  I  also  owe  my  deepest  gratitude  to  my  supervisor  Professor  Mikko  Hiltunen  for
choosing me to work on this project. Your dedication and enthusiasm in science is truly
inspirational and has encouraged me on this path. I am also genuinely thankful to you for
your support and for giving me confidence and pushing me forward when I needed that. I
also  wish  to  express  my  gratitude  to  my  supervisor  Professor  Hilkka  Soininen  for  your
valuable  guidance and comments  on my work during these  years.  My warmest  gratitude
also belongs to my supervisor Dr. Kaisa Kurkinen, who is the spirit of our working group.
You have taught me many valuable skills and have always been available for my concerns.
I am sincerely grateful to Professor Heikki Tanila, who has had a remarkably important
role in all of my papers. I wish to thank you and your group, especially Hennariikka Koivisto,
Susanna Kemppainen and Pasi Miettinen for your major contribution to the studies in this
thesis and for teaching me all I know about animal experiments. Without your expertise and
kind support along these years this would have been much more complicated.
I would like to thank all the present and former members of our working group, it has
been my greatest fortune to work in this enthusiastic,  inspired, and supportive team. I  am
most grateful to Petra Mäkinen for the priceless help and patient quidance with the practical
parts of my studies. Most of all, I wish to thank you for sharing the passion for our common
hobby  and  being  such  a  good  friend  to  me  during  the  past  years.  Thank  you  Henna
Martiskainen for the nicest company at the office,  during congress trips and also off duty,
and for showing me a great example how to perform at the critical moment when defending
your thesis. Your friendship and support has been of greatest importance. Thank you Timo
Sarajärvi  and  Teemu  Natunen  for  always  being  so  kind  and  willing  to  aid  a  younger
colleague. Thank you Mikael Marttinen infecting your young enthusiasm around you. Thank
you Seppo Helisalmi and Marjo Laitinen for your help with theoretical and practical issues
concerning the genetics and DNA lab work. Thank you Stina Leskelä, Ville Juutilainen and
Eveliina Tahvanainen, it has been a pleasure to participate in the thesis projects of so talented
young scientists and students. Also, thank you Stina and Eveliina for helping me with the
experimental part of study II. I also would like to thank all the other current and former co-
workers in the group. The help from you all has been extremely valuable and enabled me to
complete my thesis.
I  wish  to  thank  also  all  the  co-authors,  who  have  contributed  to  these  studies:  Ville
Leinonen, Jussi Pihlajamäki, Markku Laakso, Tuomas Rauramaa, Kari Airenne, Tiina
Pirttimäki, Jussi Paananen, Mitja Kurki, Rashid Giniatullin, Rajsa Giniatullina, Hanna-Maija
VIII
rasvadieetistä johtuvat tau-muutokset liittyivät heikentyneeseen suoriutumiseen muistia ja
kognitiivista suoriutumista mittaavissa käyttäytymiskokeissa. Muutokset olivat osittain yhteydessä
rasvadieetillä olleilla hiirillä havaittuun painon nousuun, mutta suurelta osin riippumattomia
T2D:een liittyvistä glukoosi- ja insuliinisignaloinnin häiriöistä tai aivojen neuroinflammaatiosta.
Tulosten perusteella runsaasti tyydyttyneitä rasvoja sisältävällä ruokavaliolla voi olla yhteys tau-
patologiaan sekä heikentyneeseen muistiin ja oppimiseen ja se voi näin ollen altistaa AT:lle ja muille
hermorappeumasairauksille.
Ravinnosta saatavan kalaöljyn on aikaisemmin osoitettu pienentävän AT:n riskiä. Neljännessä
osatyössä erilaisten kalaöljypohjaisten rasvadieettien (kalaöljy, kalaöljy + kasvisterolit tai Fortasyn)
havaittiin merkittävästi parantavan AT:n siirtogeenisten hiirten heikentynyttä suoriutumista
hajumuistia ja -tunnistusta mittaavassa testissä. Lisäksi Fortasyn-ravintolisän, joka sisältää mm.
erilaisia solukalvojen rakennusaineiksi tarvittavia lipidejä ja vitamiineja, havaittiin tehostavan
kalaöljypohjaisen ruokavalion hyödyllistä vaikutusta AT-hiirten sijaintimuistiin. Vaikka jokaisen
kalaöljypohjaisen dieetin havaittiin tehokkaasti vähentävän APP:a pilkkovien Ά- ja ·-
sekretaasientsyymien aktiivisuutta, ei tämä heijastunut vähentyneeseen AΆ:n määrään. Nämä
tulokset tukevat ravinnon kalaöljyn hyödyllisiä vaikutuksia AT:iin liittyviin molekyylitason ja
kognitiivisiin muutoksiin. Lisäksi tutkimus osoittaa, että erityiset lisäravinteet saattavat tehostaa
kalaöljyn positiivisia vaikutuksia AΆ-patologiasta riippumattomin mekanismein. Kaiken kaikkiaan
kolmas ja neljäs osatyö osoittavat, että ravinnon rasvasisällöllä voi olla merkitystä AT:n riskin,
etenemisen ja oireiden kannalta.
Tämä väitöskirjatyö valaisee tutkittujen geneettisten ja ravintoperäisten tekijöiden merkitystä
AT:n patogeneesissä sekä kognitiivisissa muutoksissa. Tätä uutta tietoa voidaan mahdollisesti
tulevaisuudessa hyödyntää AT:a ennakoivien tai diagnostisten biologisten merkkiaineiden sekä
uusien terapiamuotojen kehittämisessä. Siten nämä tutkimustulokset voivat edistää hyvinvointia
ikääntyvässä yhteiskunnassa sekä auttaa muistisairauksien hoidossa ja ennaltaehkäisyssä.
Luokitus: WT 155, QU 470, QU 477, QT 235, QU 86
Yleinen Suomalainen asiasanasto: Alzheimerin tauti; patogeneesi; proteiinit; geenit; ruokavaliot; ravinto;
ravintovalmisteet; ravintorasvat; lipidit; kalaöljyt; kognitio; koe-eläinmallit; hiiret
XI
List of Original Publications,
This dissertation is based on the following original publications:
I Takalo M, Haapasalo A, Natunen T, Viswanathan J, Kurkinen KMA, Tanzi RE,
Soininen H, Hiltunen M. Targeting ubiquilin-1 in Alzheimer’s disease. Expert
Opinion on Therapeutic Targets 17:795-810, 2013
II Natunen T#, Takalo M#, Kemppainen S, Leskelä S, Marttinen M, Kurkinen KMA,
Pursiheimo JP, Sarajärvi T, Viswanathan J,  Gabbouj S,  Solje E, Tahvanainen E,
Pirttimäki  T,  Kurki  M,  Paananen  J,  Rauramaa  T,  Miettinen  P,  Mäkinen  P,
Leinonen V, Soininen H, Airenne K, Tanzi RE, Tanila H, Haapasalo A*, Hiltunen
M*. Relationship between ubiquilin-1 and BACE1 in human Alzheimer’s disease
and APdE9 transgenic mouse brain and cell-based models. Article in press in
Neurobiology of Disease. #* These authors contributed equally to this study.
III Takalo M, Haapasalo A, Martiskainen H, Kurkinen KMA, Koivisto H, Miettinen
P,  Khandelwal  VKM,  Kemppainen  S,  Kaminska  D,  Mäkinen  P,  Leinonen  V,
Pihlajamäki  J,  Soininen  H,  Laakso  M,  Tanila  H,  Hiltunen  M. High-fat diet
increases tau expression in the brain of T2DM and AD mice independently of
peripheral metabolic status. Journal of Nutritional Biochemistry 25:634-641, 2014
IV Koivisto  H,  Grimm  M,  Rothhaar  T,  Berkecz  R,  Lütjohan  D,  Giniatullina  R,
Takalo M, Miettinen P, Lahtinen HM, Giniatullin R, Penke B, Janáky T, Broersen
L, Hartmann T, Tanila H. Special lipid-based diets alleviate cognitive deficits in
the APPswe/PS1dE9 transgenic mouse model of Alzheimer’s disease
independent of brain amyloid deposition. Journal of Nutritional Biochemistry
25:157-169, 2014
The publications were adapted with the permission of the copyright owners.
X
Lahtinen, Vinoth Khandelwal and Dorota Kaminska from the University of Eastern Finland;
Rudolph Tanzi from the Massachusetts General Hospital and Harvard Medical School,
United States of America; Marcus Grimm, Tatjana Rothhaar and Tobias Hartmann from the
University of Saarland, Germany; Ròbert Berckecz, Botond Penke and Tamás Janáky from
the University of Szeged, Hungary; Dieter Lütjohann from the University of Bonn, Germany;
Laus Broersen from the Danone Research Center for Specialized Nutrition, The Netherlands;
and Juha-Pekka Pursiheimo from the University of Turku.
I  also  wish  to  thank  Docent  Tomi  Rantamäki  from  the  University  of  Helsinki  and
Associate Professor Anna-Lena Ström from Stockholm University for your valuable
comments and constructive criticism regarding my thesis during the review process. I thank
Dr. Thomas Dunlop for excellent language review.
I would like to thank Esa Koivisto, Sari Palviainen, Tuija Parsons, Kari Kotikumpu, Kari
Törrönen, Riikka Pellinen, Joanna Huttunen, Hanne Tanskanen, Jari Nissinen and all the
other personnel of the Faculty of Health Sciences, who have provided their help in
administrative matters and other practical issues at work during these years.
My warmest thanks belong to my friends and relatives, who all have made my life so
much better. Special thanks to my dearest friends Jenna, Sanna and Tuire, whom I have had
the priviledge to know for almost all my life. I have been lucky to have you to grow up and
live my life with!
With all my heart, I want to thank my brother Anssi and my sister Eeva and her family,
Janne and Olli, for all the shared joys and sorrows. I want to thank my mother’s partner Erkki,
my uncle Martti, and father and mother in-law, Jari and Kaija. The support from all of you
has meant a great deal for me and us. Most importantly, I wish to thank my mother Arja for
all  the  help,  support  and  encouragement  you  have  ever  given  me.  Thank  you  for  always
listening to my worries and apologies for the stress and nightmares I may have caused you.
Thank you Mom for making me who I am and making this all possible.
Finally,  Mikael,  I  can’t  thank  you  enough  for  giving  me  all  your  support  and  being
amazingly patient and understanding during this stressfull and time-consuming process. It
has been utmost important to know that you have been watching out for me during this time
of slight disorientation. I am lucky to be in love with my best friend.
This  study  was  funded  by  the  Academy  of  Finland,  VTR  grant  V16001  of  Kuopio
University Hospital (ADGEN), Sigrid Jusélius Foundation, the Strategic Funding of the
University of Eastern Finland (UEF-Brain), FP7, Grant Agreement no 601055, VPH Dementia
Research Enabled by IT VPH-DARE@IT, BIOMARKAPD project in the JPND program and
Doctoral Program of Molecular Medicine (DPMM).
Kuopio, November 11th, 2015
Mari Takalo
XI
List of Original Publications,
This dissertation is based on the following original publications:
I Takalo M, Haapasalo A, Natunen T, Viswanathan J, Kurkinen KMA, Tanzi RE,
Soininen H, Hiltunen M. Targeting ubiquilin-1 in Alzheimer’s disease. Expert
Opinion on Therapeutic Targets 17:795-810, 2013
II Natunen T#, Takalo M#, Kemppainen S, Leskelä S, Marttinen M, Kurkinen KMA,
Pursiheimo JP, Sarajärvi T, Viswanathan J,  Gabbouj S,  Solje E, Tahvanainen E,
Pirttimäki  T,  Kurki  M,  Paananen  J,  Rauramaa  T,  Miettinen  P,  Mäkinen  P,
Leinonen V, Soininen H, Airenne K, Tanzi RE, Tanila H, Haapasalo A*, Hiltunen
M*. Relationship between ubiquilin-1 and BACE1 in human Alzheimer’s disease
and APdE9 transgenic mouse brain and cell-based models. Article in press in
Neurobiology of Disease. #* These authors contributed equally to this study.
III Takalo M, Haapasalo A, Martiskainen H, Kurkinen KMA, Koivisto H, Miettinen
P,  Khandelwal  VKM,  Kemppainen  S,  Kaminska  D,  Mäkinen  P,  Leinonen  V,
Pihlajamäki  J,  Soininen  H,  Laakso  M,  Tanila  H,  Hiltunen  M. High-fat diet
increases tau expression in the brain of T2DM and AD mice independently of
peripheral metabolic status. Journal of Nutritional Biochemistry 25:634-641, 2014
IV Koivisto  H,  Grimm  M,  Rothhaar  T,  Berkecz  R,  Lütjohan  D,  Giniatullina  R,
Takalo M, Miettinen P, Lahtinen HM, Giniatullin R, Penke B, Janáky T, Broersen
L, Hartmann T, Tanila H. Special lipid-based diets alleviate cognitive deficits in
the APPswe/PS1dE9 transgenic mouse model of Alzheimer’s disease
independent of brain amyloid deposition. Journal of Nutritional Biochemistry
25:157-169, 2014
The publications were adapted with the permission of the copyright owners.
X
Lahtinen, Vinoth Khandelwal and Dorota Kaminska from the University of Eastern Finland;
Rudolph Tanzi from the Massachusetts General Hospital and Harvard Medical School,
United States of America; Marcus Grimm, Tatjana Rothhaar and Tobias Hartmann from the
University of Saarland, Germany; Ròbert Berckecz, Botond Penke and Tamás Janáky from
the University of Szeged, Hungary; Dieter Lütjohann from the University of Bonn, Germany;
Laus Broersen from the Danone Research Center for Specialized Nutrition, The Netherlands;
and Juha-Pekka Pursiheimo from the University of Turku.
I  also  wish  to  thank  Docent  Tomi  Rantamäki  from  the  University  of  Helsinki  and
Associate Professor Anna-Lena Ström from Stockholm University for your valuable
comments and constructive criticism regarding my thesis during the review process. I thank
Dr. Thomas Dunlop for excellent language review.
I would like to thank Esa Koivisto, Sari Palviainen, Tuija Parsons, Kari Kotikumpu, Kari
Törrönen, Riikka Pellinen, Joanna Huttunen, Hanne Tanskanen, Jari Nissinen and all the
other personnel of the Faculty of Health Sciences, who have provided their help in
administrative matters and other practical issues at work during these years.
My warmest thanks belong to my friends and relatives, who all have made my life so
much better. Special thanks to my dearest friends Jenna, Sanna and Tuire, whom I have had
the priviledge to know for almost all my life. I have been lucky to have you to grow up and
live my life with!
With all my heart, I want to thank my brother Anssi and my sister Eeva and her family,
Janne and Olli, for all the shared joys and sorrows. I want to thank my mother’s partner Erkki,
my uncle Martti, and father and mother in-law, Jari and Kaija. The support from all of you
has meant a great deal for me and us. Most importantly, I wish to thank my mother Arja for
all  the  help,  support  and  encouragement  you  have  ever  given  me.  Thank  you  for  always
listening to my worries and apologies for the stress and nightmares I may have caused you.
Thank you Mom for making me who I am and making this all possible.
Finally,  Mikael,  I  can’t  thank  you  enough  for  giving  me  all  your  support  and  being
amazingly patient and understanding during this stressfull and time-consuming process. It
has been utmost important to know that you have been watching out for me during this time
of slight disorientation. I am lucky to be in love with my best friend.
This  study  was  funded  by  the  Academy  of  Finland,  VTR  grant  V16001  of  Kuopio
University Hospital (ADGEN), Sigrid Jusélius Foundation, the Strategic Funding of the
University of Eastern Finland (UEF-Brain), FP7, Grant Agreement no 601055, VPH Dementia
Research Enabled by IT VPH-DARE@IT, BIOMARKAPD project in the JPND program and
Doctoral Program of Molecular Medicine (DPMM).
Kuopio, November 11th, 2015
Mari Takalo
XIII
Contents
1 INTRODUCTION ......................................................................................................................1
2 REVIEW OF THE LITERATURE .............................................................................................3
2.1 Clinical and neuropathological features of Alzheimer’s disease ...................................... 3
2.1.1 Ά-amyloid plaques .......................................................................................................... 5
2.1.2 Neurofibrillary tangles  .................................................................................................. 6
2.1.3 The amyloid cascade hypothesis  .................................................................................. 8
2.2 Molecular mechanisms of Alzheimer’s disease  ................................................................. 9
2.2.1 APP and AΆ production ................................................................................................ 9
   2.2.1.1 APP biochemistry and trafficking  .......................................................................... 9
   2.2.1.2 APP proteolytic processing  ................................................................................... 10
2.2.2 BACE1 ........................................................................................................................... 12
   2.2.2.1 BACE1, the Ά-secretase enzyme ............................................................................ 12
   2.2.2.2 BACE1 trafficking and processing  ....................................................................... 14
2.2.3 Tau  ................................................................................................................................ 16
   2.2.3.1 Tau structure and expression ................................................................................ 16
   2.2.3.2 Tau function and post-translational regulation  .................................................. 18
2.2.4 Ubiquilin-1  ................................................................................................................... 19
   2.2.4.1 Ubiquilin-1 structure, function and interactome  ................................................ 19
   2.2.4.2 Ubiquilin-1 and cell stress  ..................................................................................... 22
   2.2.4.3 Ubiquilin-1 and protein aggregation in neurodegeneration .............................. 22
2.3 The effect of genes and environment on Alzheimer’s disease  ....................................... 24
2.3.1 Genetics of Alzheimer’s disease  ................................................................................. 24
   2.3.1.1 Causative mutations in APP, PSEN1, and PSEN2  .............................................. 24
   2.3.1.2 Common risk variants and susceptibility genes  ................................................. 25
2.3.2 Environmental risk factors of Alzheimer’s disease: Effects of dietary lipids .......... 27
3 AIMS OF THE STUDY ............................................................................................................ 32
4 MATERIAL AND METHODS ............................................................................................... 33
4.1 cDNA constructs, siRNAs and viral vectors..................................................................... 33
4.2 Cell culture experiments .................................................................................................... 34
4.2.1 Cell lines and transfections  ......................................................................................... 34
4.2.2 Cycloheximide timecourse assay  ............................................................................... 35
4.2.3 Immunofluorescence and microscopy  ....................................................................... 35
4.2.4 Preparation of co-cultures of embryonic mouse primary cortical neurons with BV2
microglial cells, lentivirus-mediated gene transductions, and experimentally induced
neuroinflammation ............................................................................................................... 36
4.3 Human brain samples ........................................................................................................ 37
4.4 Animal experiments............................................................................................................ 38
4.4.1 Animals  ........................................................................................................................ 38
4.4.2 Hippocampal injections of lentiviral vectors ............................................................. 38
4.4.3 Diets and experimental designs .................................................................................. 39
XII
XIII
Contents
1 INTRODUCTION ......................................................................................................................1
2 REVIEW OF THE LITERATURE .............................................................................................3
2.1 Clinical and neuropathological features of Alzheimer’s disease ...................................... 3
2.1.1 Ά-amyloid plaques .......................................................................................................... 5
2.1.2 Neurofibrillary tangles  .................................................................................................. 6
2.1.3 The amyloid cascade hypothesis  .................................................................................. 8
2.2 Molecular mechanisms of Alzheimer’s disease  ................................................................. 9
2.2.1 APP and AΆ production ................................................................................................ 9
   2.2.1.1 APP biochemistry and trafficking  .......................................................................... 9
   2.2.1.2 APP proteolytic processing  ................................................................................... 10
2.2.2 BACE1 ........................................................................................................................... 12
   2.2.2.1 BACE1, the Ά-secretase enzyme ............................................................................ 12
   2.2.2.2 BACE1 trafficking and processing  ....................................................................... 14
2.2.3 Tau  ................................................................................................................................ 16
   2.2.3.1 Tau structure and expression ................................................................................ 16
   2.2.3.2 Tau function and post-translational regulation  .................................................. 18
2.2.4 Ubiquilin-1  ................................................................................................................... 19
   2.2.4.1 Ubiquilin-1 structure, function and interactome  ................................................ 19
   2.2.4.2 Ubiquilin-1 and cell stress  ..................................................................................... 22
   2.2.4.3 Ubiquilin-1 and protein aggregation in neurodegeneration .............................. 22
2.3 The effect of genes and environment on Alzheimer’s disease  ....................................... 24
2.3.1 Genetics of Alzheimer’s disease  ................................................................................. 24
   2.3.1.1 Causative mutations in APP, PSEN1, and PSEN2  .............................................. 24
   2.3.1.2 Common risk variants and susceptibility genes  ................................................. 25
2.3.2 Environmental risk factors of Alzheimer’s disease: Effects of dietary lipids .......... 27
3 AIMS OF THE STUDY ............................................................................................................ 32
4 MATERIAL AND METHODS ............................................................................................... 33
4.1 cDNA constructs, siRNAs and viral vectors..................................................................... 33
4.2 Cell culture experiments .................................................................................................... 34
4.2.1 Cell lines and transfections  ......................................................................................... 34
4.2.2 Cycloheximide timecourse assay  ............................................................................... 35
4.2.3 Immunofluorescence and microscopy  ....................................................................... 35
4.2.4 Preparation of co-cultures of embryonic mouse primary cortical neurons with BV2
microglial cells, lentivirus-mediated gene transductions, and experimentally induced
neuroinflammation ............................................................................................................... 36
4.3 Human brain samples ........................................................................................................ 37
4.4 Animal experiments............................................................................................................ 38
4.4.1 Animals  ........................................................................................................................ 38
4.4.2 Hippocampal injections of lentiviral vectors ............................................................. 38
4.4.3 Diets and experimental designs .................................................................................. 39
XII
XV
6.2.1 High-fat diet increases tau expression and exon 10 inclusion in the brain of female
mice independently of genotype, peripheral or central insulin signaling or
neuroinflammation: Study III ............................................................................................... 63
6.2.2 Additional dietary supplements improve beneficial effects of fish oil-based diets:
Study IV .................................................................................................................................. 67
7 CONCLUSIONS  ...................................................................................................................... 69
REFRENCES ................................................................................................................................ 70
XIV
4.4.4 Behavioral tests ............................................................................................................. 42
   4.4.4.1 Spontaneous explorative activity  ......................................................................... 42
   4.4.4.2 Marble burying  ...................................................................................................... 42
   4.4.4.3 Odor recognition  .................................................................................................... 42
   4.4.4.4 The Morris swim navigation (watermaze) task  .................................................. 43
4.4.5 Brain dissections and sample preparation  ................................................................ 43
4.5 Immunohistochemistry ...................................................................................................... 43
4.6 Biochemical assays .............................................................................................................. 45
    4.6.1 Custom exon chip analysis of human brain tissue samples ..................................... 45
    4.6.2 mRNA analysis of mouse brain tissue samples ......................................................... 46
    4.6.3 Phospholipid, sterol and hyperoxide (FOX1) assays ................................................ 47
    4.6.4 Protein extraction and Western blot ........................................................................... 47
    4.6.5 Immunoprecipitation ................................................................................................... 48
    4.6.6 AΆ measurement .......................................................................................................... 48
    4.6.7 Ά- and ·-secretase activity assays ............................................................................... 49
    4.6.8 Extracellular tau measurement ................................................................................... 49
    4.6.9 TNF΅ and IL1Ά measurements ................................................................................... 49
    4.6.10 Neuronal viability ...................................................................................................... 49
4.7 Statistical analyses .............................................................................................................. 50
5 RESULTS  .................................................................................................................................. 51
5.1 Influence of ubiquilin-1 on different aspects of Alzheimer’s disease pathogenesis:
Studies I and II  .......................................................................................................................... 51
5.1.1 Ubiquilin-1 expression is decreased, with respect to severity of neurofibrillary
pathology, in human brain  .................................................................................................. 51
5.1.2 Ubiquilin-1 overexpression decreases neuronal viability and increases BACE1
protein levels in embryonic mouse cortical neuron and BV2 microglia co-cultures  ...... 51
5.1.3 Ubiquilin-1 overexpression moderately increases BACE1 levels and activity in
adult APdE9 mice hippocampi  ........................................................................................... 53
5.1.4 Ubiquilin-1 overexpression increases BACE1 stability by diverting it from
lysosomal pathway in cultured neuronal cells  .................................................................. 54
5.2 Molecular and behavioral effects of dietary manipulation in mice: Studies III and IV  55
5.2.1 High-fat diet increases tau expression and exon 10 inclusion in mouse brain
regardless of peripheral metabolic status: Study III  .......................................................... 56
5.2.2 Special fish oil-based diets alleviate cognitive deficits in the APdE9 mice
independent of Ά amyloid deposition: Study IV  ............................................................... 57
6 DISCUSSION  .......................................................................................................................... 60
 6.1 Complex role of ubiquilin-1 in Alzheimer’s disease pathogenesis: Studies I and II  ... 60
 6.2 The effect of dietary lipid composition on Alzheimer’s disease-related pathogenesis
and cognitive decline: Studies III and IV ................................................................................ 63
XV
6.2.1 High-fat diet increases tau expression and exon 10 inclusion in the brain of female
mice independently of genotype, peripheral or central insulin signaling or
neuroinflammation: Study III ............................................................................................... 63
6.2.2 Additional dietary supplements improve beneficial effects of fish oil-based diets:
Study IV .................................................................................................................................. 67
7 CONCLUSIONS  ...................................................................................................................... 69
REFRENCES ................................................................................................................................ 70
XIV
4.4.4 Behavioral tests ............................................................................................................. 42
   4.4.4.1 Spontaneous explorative activity  ......................................................................... 42
   4.4.4.2 Marble burying  ...................................................................................................... 42
   4.4.4.3 Odor recognition  .................................................................................................... 42
   4.4.4.4 The Morris swim navigation (watermaze) task  .................................................. 43
4.4.5 Brain dissections and sample preparation  ................................................................ 43
4.5 Immunohistochemistry ...................................................................................................... 43
4.6 Biochemical assays .............................................................................................................. 45
    4.6.1 Custom exon chip analysis of human brain tissue samples ..................................... 45
    4.6.2 mRNA analysis of mouse brain tissue samples ......................................................... 46
    4.6.3 Phospholipid, sterol and hyperoxide (FOX1) assays ................................................ 47
    4.6.4 Protein extraction and Western blot ........................................................................... 47
    4.6.5 Immunoprecipitation ................................................................................................... 48
    4.6.6 AΆ measurement .......................................................................................................... 48
    4.6.7 Ά- and ·-secretase activity assays ............................................................................... 49
    4.6.8 Extracellular tau measurement ................................................................................... 49
    4.6.9 TNF΅ and IL1Ά measurements ................................................................................... 49
    4.6.10 Neuronal viability ...................................................................................................... 49
4.7 Statistical analyses .............................................................................................................. 50
5 RESULTS  .................................................................................................................................. 51
5.1 Influence of ubiquilin-1 on different aspects of Alzheimer’s disease pathogenesis:
Studies I and II  .......................................................................................................................... 51
5.1.1 Ubiquilin-1 expression is decreased, with respect to severity of neurofibrillary
pathology, in human brain  .................................................................................................. 51
5.1.2 Ubiquilin-1 overexpression decreases neuronal viability and increases BACE1
protein levels in embryonic mouse cortical neuron and BV2 microglia co-cultures  ...... 51
5.1.3 Ubiquilin-1 overexpression moderately increases BACE1 levels and activity in
adult APdE9 mice hippocampi  ........................................................................................... 53
5.1.4 Ubiquilin-1 overexpression increases BACE1 stability by diverting it from
lysosomal pathway in cultured neuronal cells  .................................................................. 54
5.2 Molecular and behavioral effects of dietary manipulation in mice: Studies III and IV  55
5.2.1 High-fat diet increases tau expression and exon 10 inclusion in mouse brain
regardless of peripheral metabolic status: Study III  .......................................................... 56
5.2.2 Special fish oil-based diets alleviate cognitive deficits in the APdE9 mice
independent of Ά amyloid deposition: Study IV  ............................................................... 57
6 DISCUSSION  .......................................................................................................................... 60
 6.1 Complex role of ubiquilin-1 in Alzheimer’s disease pathogenesis: Studies I and II  ... 60
 6.2 The effect of dietary lipid composition on Alzheimer’s disease-related pathogenesis
and cognitive decline: Studies III and IV ................................................................................ 63
XVII
Abbreviations
aa Amino acid
AD Alzheimer’s disease
ADAM A disintegrin and
metalloprotease family
ALP Autophagosome-lysosome
pathway
ALS Amyotrophic lateral sclerosis
APdE9 Transgenic mouse line bearing
human APP with the
“Swedish” mutations and
human PSEN1 with a deletion
of exon 9
Aph1 Anterior pharynx-defective 1
ApoE Apolipoprotein E
APP Amyloid precursor protein
ARF6 ADP ribosylation factor 6
Asp-Pro-
rich
repeats
Asparagine- and proline-rich
repeats
Ά Ά-amyloid peptide
BACE1 Ά-site APP cleaving enzyme 1
BBB Blood brain barrier
BSA Bovine serum albumin
CAA Cerebral amyloid angiopathy
CNS Central nervous system
CSF Cerebrospinal fluid
DLBD Diffuse Lewy body disease
DMEM Dulbecco’s modified eagles
medium
EGFP-F Enhanced farnesylated green
fluorescent protein
EH Epidermal growth factor
substrate 15 homology domain
eIF2΅ Eukaryotic translation
initiation factor 2΅
EOAD Early onset Alzheimer’s
disease
ER Endoplasmic reticulum
FAD Familial Alzheimer’s disease
FBS Fetal bovine serum
FO Fish oil
FOPS Fish oil and Plant sterol
FTD Frontotemporal degeneration
GAPDH Glyceraldehyde 3-phosphate
dehydrogenase
GFAP Glial fibrillary acidic protein
GFP Green fluorescent protein
GGA Golgi-localized ·-ear
containing ADP ribosylation-
binding factor
GlcNAc N-acetyl-D-glucosamine
GTT Glucose tolerance test
GWAS Genome-wide association
studies
HFD High-fat diet
HMW High molecular weight
IFN-· Interferon gamma
IGF2 Insulin-like growth factor 2
IL1Ά Interleukin 1Ά
i.p. Intra-peritoneal
ITT Insulin tolerance test
LEL Late endosomes/lysosomes
LPC Lysophosphatidylcholine
LPS Lipopolysaccharide
MAPT Tau gene
MAP Microtubule associated protein
MCI Mild cognitive impairment
mRFP Monomeric red fluorescent
protein
MT Microtubule
mTOR Protein kinase mammalian
target of rapamycin
MUFA Monounsaturated fatty acid
Nct Nicastrin
NFT Neurofibrillary tangle
NINCDS-
ADRDA
National Institute of
Neurological and
Communicative Disorders and
Stroke and the Alzheimer’s
Disease and Related Disorders
Association
PBS Phosphate-buffered saline
PC Phosphatidylcholine
PD Parkinson’s disease
PDL Poly-D-lysine
PE Phosphatidylethanolamine
PEN2 Presenilin enhancer-2
PET Positron emission tomography
PFA Paraformaldehyde
PHF Paired helical filament
XVI
XVII
Abbreviations
aa Amino acid
AD Alzheimer’s disease
ADAM A disintegrin and
metalloprotease family
ALP Autophagosome-lysosome
pathway
ALS Amyotrophic lateral sclerosis
APdE9 Transgenic mouse line bearing
human APP with the
“Swedish” mutations and
human PSEN1 with a deletion
of exon 9
Aph1 Anterior pharynx-defective 1
ApoE Apolipoprotein E
APP Amyloid precursor protein
ARF6 ADP ribosylation factor 6
Asp-Pro-
rich
repeats
Asparagine- and proline-rich
repeats
Ά Ά-amyloid peptide
BACE1 Ά-site APP cleaving enzyme 1
BBB Blood brain barrier
BSA Bovine serum albumin
CAA Cerebral amyloid angiopathy
CNS Central nervous system
CSF Cerebrospinal fluid
DLBD Diffuse Lewy body disease
DMEM Dulbecco’s modified eagles
medium
EGFP-F Enhanced farnesylated green
fluorescent protein
EH Epidermal growth factor
substrate 15 homology domain
eIF2΅ Eukaryotic translation
initiation factor 2΅
EOAD Early onset Alzheimer’s
disease
ER Endoplasmic reticulum
FAD Familial Alzheimer’s disease
FBS Fetal bovine serum
FO Fish oil
FOPS Fish oil and Plant sterol
FTD Frontotemporal degeneration
GAPDH Glyceraldehyde 3-phosphate
dehydrogenase
GFAP Glial fibrillary acidic protein
GFP Green fluorescent protein
GGA Golgi-localized ·-ear
containing ADP ribosylation-
binding factor
GlcNAc N-acetyl-D-glucosamine
GTT Glucose tolerance test
GWAS Genome-wide association
studies
HFD High-fat diet
HMW High molecular weight
IFN-· Interferon gamma
IGF2 Insulin-like growth factor 2
IL1Ά Interleukin 1Ά
i.p. Intra-peritoneal
ITT Insulin tolerance test
LEL Late endosomes/lysosomes
LPC Lysophosphatidylcholine
LPS Lipopolysaccharide
MAPT Tau gene
MAP Microtubule associated protein
MCI Mild cognitive impairment
mRFP Monomeric red fluorescent
protein
MT Microtubule
mTOR Protein kinase mammalian
target of rapamycin
MUFA Monounsaturated fatty acid
Nct Nicastrin
NFT Neurofibrillary tangle
NINCDS-
ADRDA
National Institute of
Neurological and
Communicative Disorders and
Stroke and the Alzheimer’s
Disease and Related Disorders
Association
PBS Phosphate-buffered saline
PC Phosphatidylcholine
PD Parkinson’s disease
PDL Poly-D-lysine
PE Phosphatidylethanolamine
PEN2 Presenilin enhancer-2
PET Positron emission tomography
PFA Paraformaldehyde
PHF Paired helical filament
XVI
1 Introduction
Age-related dementia is listed as one of the high priority global public health challenges by
World Health Organization (WHO). It is estimated that almost 50 million people worldwide
suffer  from  dementia  and  the  number  is  predicted  to  triple  by  the  year  2050  (World
Alzheimer Report 2014). The vast majority of dementia is defined as Alzheimer’s disease
(AD)  (Qiu  et  al.,  2009).   AD  is  characterised  by  a  gradual  decline  in  both  memory  and
cognitive functions, which significantly interfere with basic daily life (Morris et al., 1993). AD
is one of the leading causes of disability and the sixth highest cause of death in those of 65
years of age and older (Qiu et al., 2009). The prevalence of AD increases exponentially with
age and approximately a third of individuals older than 85 years have some signs of dementia
(Mayeux and Stern, 2012, Qiu et al., 2009). More than 70% of these are caused by AD. Without
either  a  cure  or  disease-modifying  therapies,  the  number  of  affected  individuals  will
drastically  increase  during  the  following  decades  (Kumar  et  al.,  2015).  Together  with
prolonged life expectancies, and the resultant increase in the average age of the population,
this will cause enormous global social, economic and medical challenges. It has been
suggested that  a  therapy providing even a  modest  delay in  the  onset  of  AD,  would yield
hundreds  of  billions  of  savings  in  global  medical  care  costs  (Changing  the  Trajectory  of
Alzheimer’s Disease, a report by Alzheimer’s association). However, the currently approved
drugs for the treatment of AD patients provide only relatively short-term symptomatic
improvements and have no effect on the underlying pathogenic mechanisms or progression
of the disease. For successful clinical drug trials, it will be necessary to improve methods to
accurately and efficiently identify individuals at increased risk for AD already at the early
stages  of  disease  and  find  biomarkers  that  correlate  well  with  the  clinical  onset  and
progression of AD.
At the biological level, AD is a progressive neurodegenerative disease, which leads to
massive atrophy of affected brain areas. It is increasingly evident that abnormal processing,
accumulation,  and  aggregation  of  specific  proteins  or  protein  fragments  in  the  brain
underlies  most  neurodegenerative  diseases,  including  AD  (Ross  and  Poirier,  2004).  Two
pathological hallmark aggregates found in AD brain are extracellular amyloid plaques and
intraneuronal  neurofibrillary  tangles  (NFTs).  Amyloid  plaques  are  formed  as  a  result  of
accumulation of Ά-amyloid peptides (AΆ) that aggregate together, whereas NFTs consist of
filaments of abnormally phosphorylated tau protein. Other central players in AD molecular
pathogenesis are the Ά-secretase, namely BACE1 (Ά-site APP cleaving enzyme 1), and the ·-
secretase. These two are the key enzymes responsible for AΆ peptide production. The
amyloid cascade hypothesis postulates, that AΆ deposition is an early and initial event in AD.
Via direct and indirect mechanisms, it triggers a cascade of other pathological incidences,
which eventually together lead to neuronal cell death and onset of clinical disease. How tau
aggregation contributes to AD onset, is less understood. However, tau deposition is sufficient
to cause several other brain disorders, most of which are AΆ-independent, suggesting that
tau is more than just a byproduct of AΆ accumulation in AD. Although these
neuropathological changes in AD brain are relatively well characterized, the primary cause
of AΆ accumulation, NFT formation, synaptic loss and neurodegeneration still remains partly
unresolved. An understanding of these fundamental mechanisms and the molecular players
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32 Review of the literature
2.1 CLINICAL AND NEUROPATHOLOGICAL FEATURES OF ALZHEIMER’S
DISEASE
AD is distinguished from normal age-related cognitive changes with a slow but inevitably
progressing decline, which is severe enough to cause social and occupational incapacity and
interfere with daily life (criteria by The National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders
Association, NINCDS/ADRDA and The Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, DSM-IV) (McKhann et al., 1984, McKhann, 1994). AD onset
generally takes place around 65 years of age at the earliest, although in some rare cases, AD
can be diagnosed decades earlier. Usually, the first symptoms include difficulties to recall,
and take advantage of, recently learned information. Problems to perform complex tasks,
such  as  organizing,  planning,  problem  solving  and  reasoning,  are  also  common.  Patients
often have difficulties in recognition, time management, and spatial orientation, with
changes  in  mood  and  personality  also  being  typical.  Gradually,  the  disease  progresses  to
affect all intellectual functions and even the most basic daily functions become challenging.
Loss of speech and ability to move independently are often associated with the most
advanced stages.  Eventually,  AD leads  to  premature  death,  on average,  eight  to  ten years
after the initial clinical diagnosis (Tarawneh and Holtzman, 2012).
2
involved is therefore urgently needed, in order to discover new potential diagnostic and
therapeutic targets.
The major risk factor for AD is advanced age.  Normally AD is diagnosed at the age of
~65 years at the earliest. However, approximately 5% of all AD cases occur earlier, even
decades before the age of 65. About 10% of these early onset AD (EOAD) cases are familially
inherited AD (FAD) and are caused by autosomal dominant mutations in three genes, that
encode  the  amyloid  precursor  protein  (APP),  presenilin-1  (PS1),  and  presenilin-2  (PS2)
proteins, individually. All mutations in APP, PSEN1, and PSEN2 lead  to  increases  in  the
levels or accumulation of AΆ and thus support the amyloid cascade hypothesis (Borchelt et
al., 1996, Citron et al., 1992, Gessel et al., 2012, Murakami et al., 2002, Potter et al., 2013). On
the other hand, no clear genetic association between increased AΆ production and the more
common late onset form of AD (LOAD) have been found. LOAD is a heterogeneous disease,
which  is  associated  with  a  complex  interplay  between  common  genetic  risk  variants  and
environmental factors. The most important risk factors of LOAD after age are positive family
history of dementia, Ή4 allele of the apolipoprotein E encoding gene (APOE Ή4), and female
gender. In addition, combined data from epidemiologic and experimental studies suggest
that co-morbidities and metabolic factors, such as hypertension, dyslipidemia, overweight
and obesity, type 2 diabetes mellitus (T2DM), vascular disorders, depression, brain traumas,
and stress increase the risk of AD (Sindi et al., 2015). Importantly, most of these risk factors
are  modifiable  through  certain  drugs  and  lifestyle  choices,  such  as  smoking,  alcohol
consumption and dietary manipulation. Since there is neither cure nor disease-modifying
therapies available for AD, it  is of great importance to recognize and harness all  plausible
ways to intervene with disease development or progression.
The aim of this thesis was to characterize the functional mechanisms of specific genes
and dietary manipulation on AD-related proteins and pathways, such as BACE1, ·-secretase,
APP, AΆ and tau, and neuroinflammation. Special emphasis was on the AD-associated gene
UBQLN1,  encoding  the  ubiquilin-1  protein,  and  possible  mechanisms  of  its  action  in  this
disease.  In  previous  studies,  ubiquilin-1  has  been  shown  to  be  an  important  regulator  of
cellular functions, such as protein trafficking, degradation and aggregation, which are linked
to mechanisms of AD and neurodegeneration (Bertram et al., 2005, El Ayadi et al., 2012,
Haapasalo et al., 2010, Hiltunen et al., 2006, Lu et al., 2009, Mah et al., 2000, Stieren et al.,
2011). In addition, the influence of dietary fatty acid composition on AD-related molecular
and behavioral changes in mice was investigated in detail. The results obtained from these
studies provide novel information regarding the underlying molecular mechanisms of AD
in  experimental  models,  which  can  be  applied  in  order  to  recognize  effective  prevention
strategies, identify novel biomarkers, and find new pharmacological therapeutic targets for
AD.
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5(Coric et al., 2012, Cummings et al., 2013, Doody et al., 2013, Haapasalo and Kovacs, 2010,
Salloway et al., 2009, Sugino et al., 2015).
Increasing amount of data suggest that biomarkers in combination with detailed
neuropsychiatric assessment can significantly increase the specificity and accuracy of AD
diagnosis (Cummings et al., 2013, Jack et al., 2011). Nowadays, cerebrospinal fluid (CSF)
biomarker levels (AΆ, total tau, phospho-tau), structural and/or functional brain imaging
[magnetic  resonance  imaging  (MRI)  and  positron  emission  tomography  (PET)],  family
history as well as genetic information are increasingly applied to yield earlier and more
specific and sensitive diagnosis (McKhann et al., 2011). The first appearing sign of evolving
AD  pathology  is  AΆ accumulation,  which  is  followed  by  tau-related  changes  and  brain
atrophy (Figure 1) (Bateman et al., 2012, Fagan et al., 2014, Jack et al., 2010, Klunk et al., 2004,
Sunderland et al., 2003). Although progression of both AΆ- and tau-related pathologies in the
brain can be estimated based on their levels in the CSF (Blennow et al., 2012, Sunderland et
al., 2003), the final definition of the diagnosis is still based on neuropathological findings in
detailed post mortem histological examination. Two characteristic neuropathological lesions
found in AD brain are the Ά-amyloid plaques formed of AΆ peptides in the brain parenchyma
and the intraneuronal NFTs, which are composed of hyperphosphorylated and misfolded
tau protein (Goedert et al., 1991). These features are accompanied by increased activation of
brain inflammatory cells, astrocytes and microglia (Heneka et al., 2015). In addition, massive
neuronal cell death, which is preceded by oxidative stress and neuroinflammation, impaitred
neurotransmission, synaptic dysfunction and loss, axonal degeneration and dystrophy of
dendritic trees, is centrally involved in this disease’s pathogenesis (Crews and Masliah, 2010,
Nimmrich  and  Ebert,  2010).  At  the  macroscopic  level  in  the  brain,  the  neuronal  loss  is
observed as symmetric cortical atrophy of the hippocampus and the medial temporal lobes
with an accompanying dilatation of the lateral ventricles (Scheltens et al., 1995).
2.1.1 Ά-Amyloid Plaques
Synaptic  and neuronal  loss  in  AD is  believed to  result  from the  abnormal  processing and
deposition of specific proteins into the lesions described above. The Ά-amyloid plaques are
formed  from  AΆ peptides,  which  are  themselves  produced  from  APP  through  sequential
proteolytic cleavages conducted by the Ά- and ·-secretase enzymes (Glenner and Wong, 2012,
Kang et al., 1987, Masters et al., 1985, Selkoe, 1994). Soluble AΆ monomers have a strong
tendency  to  self-aggregate  and  accumulate  as  oligomers  that  can  readily  stick  together  to
form  insoluble  fibrils.  Eventually  they  form  amyloid  plaques  in  the  brain  parenchyma  or
cerebral blood vessel walls (cerebral amyloid angiopathy, CAA)(Masters et al., 1985). During
AD, AΆ accumulates mainly in the isocortex, while allocortex, brain stem, and cerebellum are
affected to a lesser extent. A considerable number of amyloid plaques are commonly found
in  the  brain  of  elderly  individuals  with  good  cognitive  health.  However,  these  so  called
diffuse amyloid plaques, are morphologically different from the dense core amyloid plaques,
typically detected in the post mortem brain of AD sufferers. In contrast to the diffuse plaques,
dense-core plaques contain AΆ peptides orientated in a Ά-pleated sheet conformation and are
associated with neurotoxic effects, such as presence of abnormal neuronal processes
(dystrophic neurites), activation of astrocytes and microglia, and degeneration of nearby
synapses  and neurons.  The distribution of  amyloid plaques  in  AD brain  does  not  seem to
4
A positive diagnosis of AD is usually made when the first symptoms become so evident
that the patient seeks clinical examination. This raises major concerns, because at the time
when the cognitive changes start to appear, the brain pathology is already well developed
and likely  to  be  irreversible.  In  order  to  successfully  prevent  these  irreversible  changes,  it
would be necessary to start treating the patients at the time when the brain pathology is not
yet fully developed and potentially modifiable,  preferably even 15 to 20 years prior to the
cognitive dysfunction (Figure 1)(Jack et al., 2010). However, due to difficulties to accurately
and efficiently identify individuals at risk, it has been challenging to develop disease-
modifying therapies for AD. Thus, currently all approved AD drugs [N-methyl-D-aspartate
(NMDA) receptor antagonists and cholinesterase inhibitors] provide only symptomatic
improvements and have no effect on the underlying pathogenic mechanisms or progression
of  the  disease.  Moreover,  all  disease-modifying therapies  that  have so  far  reached clinical
trials have consistently failed, if not because of dose-limiting side-effects, then mostly due to
the fact that the treatment has been started too late regarding the progression of pathology
Figure 1. Progression of neuropathological events during the course of Alzheimer’s disease (AD).
$ǃ accumulation in the brain precedes mild cognitive impairment (MCI) and clinical dementia at
least by 15 years and progresses only gradually after the symptoms have occurred. This can be
detected as reduced Aǃ levels in the cerebrospinal fluid (CSF). Progression of neurofibrillary
pathology and neuronal injury correlate better with the clinical symproms. However, increased
total and phosphorylated tau can also be detected in the CSF already 10-15 years before the
onset of clinical symptoms. The brain structure may be already severely and irreversibly
damaged when the first clinical signs occur and the diagnosis is made. The optimal time for
starting  a  therapy  against  Aǃ and  tau  accumulation  (indicated  with  dashed  ellipses)  would
therefore precede the onset of clinical dementia (indicated with vertical dashed lines) by years.
This would require early, efficient and accurate identification individuals destined to progress
towards AD.  (Adapted from Jack, et al., 2010, The Lancet Neurology 9:119-128, with the kind
permission of Elsevier).
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5(Coric et al., 2012, Cummings et al., 2013, Doody et al., 2013, Haapasalo and Kovacs, 2010,
Salloway et al., 2009, Sugino et al., 2015).
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7NFTs, the other hallmark aggregates of AD brain, are composed of hyperphosphorylated tau
protein, which is misfolded in the form of paired helical filaments (PHFs), straight filaments
(SF), and twisted ribbon-like assemblies (Grundke-Iqbal et al., 1986). NFTs in the brain can
be detected in three modalities that are thought correlate to different stages: diffuse pre-
tangles existing in normal-appearing neurons, mature intraneuronal tangles occuring in
dystrophic neurons, and extracellular “ghost” tangles left behind after neuronal death
(Augustinack et al., 2002, Braak et al., 1994, Su et al., 1993). In contrast to the Ά-amyloid
plaques, the spreading of NFTs in the brain is highly hierarchical and predictable.
Progression of the neurofibrillary pathology is well correlated with neurodegeneration, as
well as with the severity, neuropsychiatric profile and duration of the disease.  Six stages of
AD can be classified on the basis of NFT distribution and this Braak staging has been used as
part of diagnostic criteria since 1997 (Figure  2)(NI-RI consensus 1997) (Braak and Braak,
1995). At the transentorhinal stage (Braak stages I-II), neurofibrillary pathology can be
detected at the transentorhinal and entorhinal cortex and individuals are usually clinically
asymptomatic or may suffer from mild cognitive defects. At the limbic stage (Braak stages
III-IV), the pathology affects the whole hippocampus and extends to neocortical association
areas. These individuals are usually detected with a mild to moderate clinical disease
phenotype. At the neocortical stage (Braak stages V-VI), the pathology covers the whole
associative neocortex and patients are usually diagnosed with severe AD (Figure  2). The
Braak staging is based on post mortem immunostaining of phosphorylated tau with the AT8
antibody, which detects AD-specific phosphorylation of tau at amino acid positions serine
199 and 202, and Threonine 205 (see also Chapter 2.2.3.2) (Braak et al., 2006). Despite the clear
correlation between tau accumulation and disease progression, the pathogenic mechanisms
of tau in AD are not that well established. It is still under debate whether tau-related changes
have a causative role or whether they occur as a byproduct of other pathological events in
AD,  such  as  AΆ accumulation.  However,  it  is  worth  mentioning,  that  tau
hyperphosphorylation and accumulation are not specific for AD, but is associated several
brain disorders, most of which are AΆ-independent (Spillantini and Goedert, 2013).
Furthermore, although mutations in the tau encoding gene (MAPT) are not associated with
AD, some specific ones are known to be sufficient to cause other neurodegenerative diseases,
such as a familial form of frontotemporal degeneration (FTD). Together these data argue for
an underlying role of tau deposition in AD, and beyond.
6
follow any well predictable regional pattern, correlate with neurodegeneration, or associate
with the progression and duration of the disease (Ingelsson et al.,  2004).  This,  however, is
likely because AΆ-related changes mostly take place at the very early stages of the disease.
Thus,  AΆ accumulation  reaches  or  has  already  reached  a  saturation  plateau  at  the  time
clinical signs of AD begin to clearly manifest themselves (Figure 1) (Ingelsson et al., 2004,
Serrano-Pozo et al., 2011). In addition, some evidence implies that soluble AΆ oligomers,
rather than fibrils or plaques, are responsible for the toxic effects and correlate better with
the degree of synaptic loss and cognitive decline (Findeis, 2007, Mucke et al., 2000, Selkoe,
2008).
2.1.2 Neurofibrillary tangles
Figure 2. Progression of neurofibrillary pathology at the different Braak stages. NFTs are detected
from post mortem brain slices with AT8 antibody, which detects tau phosphorylated at amino
acid positions Ser199, Ser202 and Thr205. At transentorhinal stage (Braak stages I and II), the
pathology initiates at the transentorhinal and entorhinal regions and progresses to the
hippocampus. These stages are usually asymptomatic. At the limbic stage (Braak stages III and
IV), the hippocampal pathology advances and NFTs spread to the medial temporal lobe. At these
stages, the first signs of MCI or early AD usually occur. At the neocortical stage (Braak stages V
and VI), the neurofibrillary pathology covers the whole isocortex and the patients usually have
fully developed AD. (Adapted from Braak et al., 2006, Acta Neuropathol 112:389-404, with kind
permission of Springer Science and Business Media).
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9sufficient  to  cause  FAD (see Chapter 2.3.1)(www.AlzGene.org). Furthermore, longitudinal
progression studies and biomarker findings in FAD patients imply that AΆ-related changes
in the brain and CSF are the first to appear and probably precede the clinical symptoms by
decades (Figure  1)(Bateman et al., 2012, Jack et al., 2011).  Although the vast majority of
patients develop AD without these mutations and there is no clear proof of increased AΆ
production during LOAD, these disease forms show highly similar neuropathological and
clinical manifestations to EOAD.  Moreover, data from several studies suggest that
malfunction of AΆ clearance and degradation mechanisms could be a common feature of AD
and may explain increased AΆ accumulation during LOAD (Baranello et al., 2015).
Additionally supporting the amyloid cascade theory, findings from AD animal models
indicate that AΆ accumulation precedes and accelerates tau pathology (Eckert et al., 2008,
Ferrari et al., 2003, Gotz et al., 2001, Jin et al., 2011, Lewis et al., 2001), while tau is shown to
modulate AΆ toxicity (Ittner et al., 2010, Jin et al., 2011, Rapoport et al., 2002, Roberson et al.,
2007,  Vossel  et  al.,  2010).  Based on the  strong evidence from epidemiological,  genetic  and
mechanistic studies, AΆ is a key pathological substance in AD, and therefore drugs targeted
to  halt  AΆ accumulation  in  early  stages  of  the  disease  have  been  a  logical  target  for
therapeutic intervention for long (Moulder et al., 2013). However, as all therapies targeted
towards AΆ have thus far failed to convincingly reduce CSF AΆ levels and have had at best
very limited clinical  benefits,  it  seems to  be  increasingly  apparent  that  reducing AΆ is  not
necessarily enough to prevent the progression of AD (Coric et al., 2012, Doody et al., 2013,
Haapasalo and Kovacs, 2010, Salloway et al., 2009). This has raised a question whether
targeting  other  pathologies  centrally  involved  in  AD,  such  as  tau  aggregation  and
hyperphosphorylation, neuroinflammation,  or mitochondrial dysfunction might aquire
more beneficial effects.
2.2 MOLECULAR MECHANISMS OF ALZHEIMER’S DISEASE
2.2.1 APP and AΆ production
2.2.1.1 APP biochemistry and trafficking
Amyloidogenic AΆ peptides are produced as part of the normal physiological metabolism of
APP (Haass et al., 1992b, Haass et al., 1993a). APP is a ubiquitously expressed protein whose
physiological function is only partially understood (Findeis, 2007, Zheng and Koo, 2011). The
half-life  of  APP  is  short.  Large  quantities  of  APP  are  synthesized  in  the  endoplasmic
reticulum (ER) and metabolized in other subcellular compartments shortly after
(Weidemann et al., 1989, Zheng and Koo, 2011). Newly translated APP is transported from
the ER via Golgi apparatus/trans-Golgi network (TGN) to the plasma membrane (PM)
through the secretory pathway (Haass et al., 2012, Lichtenthaler, 2012). During its transit,
APP undergoes several post-translational modifications to form the mature protein
(Weidemann  et  al.,  1989,  Zheng  and  Koo,  2011).  From  the  PM,  APP  is  internalized  by  a
dynamin-dependent endocytosis in clathrin-coated vesicles with the assistance of a
‘YENPTY’ internalization motif in its C-terminus (Lai et al., 1995). Afterwards, a significant
amount of APP is degraded in lysosomes or metabolized in endosomes, while a fraction is
targeted to a recycling pathway (Haass et al., 1992a). APP is positioned on a membrane with
8
2.1.3 The amyloid cascade hypothesis
The most prominent theory elucidating the occurrence of molecular events in AD, the so
called ‘amyloid cascade hypothesis’, postulates that AΆ accumulation is the primary
initiating  event  in  AD  (Hardy  and  Higgins,  1992).  According  to  the  hypothesis,  AΆ
deposition triggers secondary pathological events, including oxidative stress,
neuroinflammation, tau hyperphosphorylation and the subsequent NFT formation (Figure
3). As a consequence, these changes, together lead to synaptic and neuritic injury, neuronal
loss and the onset of dementia. Although detailed molecular mechanisms of AD still partially
remain  a  mystery,  the  amyloid  cascade  hypothesis  is  strongly  supported  by  AD  genetics,
clearly  demonstrating  that  mutations  inducing  lifelong  increase  in  AΆ accumulation  are
Figure 3. A hypothesized model of the occurrence of pathological events in AD. According to
amyloid cascade hypothesis, AD-related pathological cascade is initiated as a result of abnormal
increase in Aǃ levels or oligomerization. In familial early onset cases (EOAD), the lifelong
elevation in Aǃ accumulation is caused by mutations in APP or PSEN1 or -2 genes or APP gene
duplications. In contrast, a novel protective A673T variant in APP, is associated with lifelong
decrease in APP processing and Aǃ production, and thus reduced risk of late onset AD (LOAD).
Down syndrome, which is caused by trisomy of the chromosome 21, on which the APP gene
resides,  is  often  associated  with  early  onset  familial  AD  (FAD).  In  LOAD,  deficiencies  in  Aǃ
clearance, degradation or folding systems are initiated by a complex interplay between genetic
and  environmental  risk  factors  together  with  age-related  changes.  It  is  also  plausible  that
abnormal tau splicing and/or phosphorylation occur in early stages of LOAD pathology. Increased
$ǃ levels or misfolding lead to Aǃ oligomerization, aggregation and plaque formation. Later
hypephosphorylation and aggregation of tau occurs, which leads to NFT formation, synaptic
dysfunction, neuronal damage and death and eventually cognitive deterioration and dementia.
Neuroinflammation and oxidative stress are also central features of AD pathology.
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(Haass et al., 2012). The latter starts with the ΅ -secretase-mediated cleavage on the PM (Haass
et al., 2012, Sisodia, 1992). This cleavage is mediated by a group of relatively non-sequence-
specific ‘A disintegrin and metalloprotease’ (ADAM) -family proteases, namely ADAM9,
ADAM10, and ADAM17 (Asai et al., 2003, Lichtenthaler, 2012). The ΅-cleavage blocks AΆ
formation  by  cutting  APP  in  the  middle  of  the  AΆ peptide  sequence  (Sisodia  et  al.,  1990,
Sisodia, 1992). Instead, it generates a soluble APP΅-fragment (sAPP΅) and a membrane
bound  ΅-C-terminal  fragment  (CTF΅,  C83).  In  the  next  phase,  ·-secretase  cleaves  the
remaining  CTF΅ at  the  transmembrane  domain,  leading  to  a  release  of  APP  intracellular
domain (AICD) (Gu et al., 2001) (Sastre et al., 2001) and a truncated AΆ-fragment, called p3
(Haass et al., 1993b). The function of the ΅-fragments is not fully known, although sAPP΅ has
been suggested to display neurotrophic and neuroprotective properties and lead to reduction
of BACE1 levels, subsequent GSK3Ά inhibition and decreased tau phosphorylation (Deng et
al., 2015, Furukawa et al., 1996, Mattson et al., 1993, Meziane et al., 1998, Ring et al., 2007),
AICD has  been implicated to  function in  transcriptional  regulation (von Rotz  et  al.,  2004),
and p3 is assumed to be non-pathogenic (Dulin et al., 2008). Inactivation of the ΅-secretase
has been shown to increase AΆ production, while its overexpression has the opposite effect
(Postina et al., 2004). This finding suggests that ΅-secretase-mediated cleavage may compete
with the Ά-secretase-mediated one, and thus, stimulation of ΅-secretase could be a potential
therapeutic target in AD (Lichtenthaler, 2012, Postina et al., 2004).  Interestingly, two rare
mutations in ADAM10, the principal ΅-secretase in neurons (Jorissen et al., 2010, Kuhn et al.,
2010), were recently identified to co-segregate with LOAD (Kim et al., 2009b). Both mutations
were  found  to  disturb  the  normal  folding  and  function  of  ΅-secretase  and  shift  APP
processing towards the amyloidogenic pathway. Subsequently, these mutations had the
effect of increasing AΆ peptide production, neuroinflammation and plaque burden in vivo
(Suh et al., 2013). Although this association is yet to be confirmed by others, this information
underlines the potential importance of anti-amyloidogenic ΅-cleavage in AD pathogenesis.
In the Ά-amyloidogenic processing of APP, it is first cleaved at the N-terminal site of the
Ά sequence by the Ά-secretase activity (Figure 4). Similar to ΅-cleavage, Ά-cleavage releases
a  soluble  APPΆ-fragment  (sAPPΆ)  into  the  lumen  or  extracellular  space  and  generates  a
membrane bound CTFΆ (C99). In contrast to the sAPP΅, the sAPPΆ has been shown to have
pro-apoptotic effects, cause neurodegeneration and possibly hold other poorly understood
toxic features (Nikolaev et al., 2009). In the following step, the CTFΆ is further processed by
the ·-secretase to generate different AΆ species and the AICD (Dries and Yu, 2008). The ·-
secretase is a complex heterotetrameric aspartyl protease, which requires four necessary
subunits to form a fully functional enzymatic activity. Presenilin-1 and -2 (PS1 and -2) are the
active components of the enzyme containing the catalytic core of the protease (Li et al., 2000,
Rogaev et al., 1995, Sherrington et al., 1995, Wolfe et al., 1999), PS enhancer-2 (PEN2) activates
and stabilizes the Presenilins, and nicastrin (Nct) and anterior pharynx defective (Aph) -1a
or  -1b  together  form  an  initial  scaffold  during  the  assembly  of  the  ·-secretase  complex
(Francis et al., 2002, Goutte et al., 2002, Yu et al., 2000). Instead of a single site cleavage, CTFΆ
is processed in a series of stepwise cleavages by the ·-secretase (Figure 5) (Haass et al., 2012).
In the two alternative paths, the CTFΆ is  first cleaved after amino acid (aa) 49 or 48 (Ή-site
cleavage), next at positions aa 46 or 45 (Ί-site cleavage), and finally after any residue located
between aa 37 and 43 (·-site cleavage) (Qi-Takahara et al., 2005, Sastre et al., 2001, Takami et
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its large amino (N) terminal ectodomain at the lumen or extracellular space, the C-terminal
tail in the cytosol, and AΆ sequence within the transmembrane domain (Dyrks et al., 1988,
Kang et al., 1987). Since APP and all the proteases participating in its processing are
membrane-bound proteins, they need to be in close vicinity to form a complex in order for
the proteolysis to take place. Thus, subcellular trafficking of these proteins largely defines
the path by which APP will be metabolized.
2.2.1.2 APP proteolytic processing
The  proteolytic  processing  of  APP  can  take  two  alternative  pathways  (Figure  4). The
amyloidogenic  route  is  predominant  in  neurons  and  ends  up  with  the  release  of  AΆ.  The
alternative  pathway  prevents  the  formation  of  AΆ and  is  prevailent  in  non-neuronal  cells
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Figure 4. APP proteolytic processing. The non-amyloidogenic processing starts with the cleavage
by Į-secretase, which leads to generation of soluble APPĮ (sAPPĮ) and the C-terminal fragment
(CTF), C83. Soluble APPĮ has been suggested to display neurotrophic and neuroprotective
properties as well as reduce BACE1 levels and tau phosphorylation. In the next step, Ǆ-secretase
cleaves C83, releasing P3-fragment and the APP intracellular domain (AICD). The function of P3
is not well known, but it has not been found to have neurotoxic effects. AICD is suggested to
function in transcriptional regulation of several genes. The amyloidogenic processing is initiated
by ǃ-secretase cleavage and leads to the release of sAPPǃ and formation of membrane-bound
APP  CTF,  C99.   In  contrast  to  sAPPɲ, sAPPǃ may have pro-apoptotic and neurodegenerative
effects. Later, C99 is further processed by Ǆ-secretase, which leads to production of AICD and
neurotoxic ǃ-amyloid peptide (Aǃ), which aggregates into oligomers, fibrils and ǃ-amyloid
plaques in the extracellular space.
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findings,  BACE1  is  currently  one  of  the  leading  targets  in  the  development  of  therapies
against AD. However, identification and thorough characterization of BACE1 subtrates is
pivotal  in  order  to  find  a  safe  way  to  modulate  BACE1  in  clinical  trials.  Indeed,  recent
investigations have revealed several physiological substrates for BACE1, which play key
roles central biochemical processes in the nervous system, such as myelination, neurogenesis,
neuronal  network  function,  cell  adhesion,  and  axon  guidance  (Cai  et  al.,  2012,  Cole  and
Vassar, 2007, Hemming et al., 2009, Kuhn et al., 2012, Vassar et al., 2014). Also the ubiquitous
nature of BACE1 implies that it may have other yet unidentified physiological substrates
(Cheret et al., 2013, Harrison et al., 2003, Hitt et al., 2012, Hu et al., 2015, Laird et al., 2005,
Petrus and Lee, 2014, Rajapaksha et al., 2011, Savonenko et al., 2008, Wang et al., 2014).
BACE1 is substantially expressed in the brain and at significantly lower levels in most
other tissues. Normally BACE1 protein is highly produced in neurons and to a lesser extent
in  astrocytes  and  microglia  (Vassar  et  al.,  1999).  Several  studies  have  shown  that  BACE1
protein levels and activity are increased in AD brain as compared to age-matched healthy
controls (Fukumoto et al., 2002, Holsinger et al., 2002, Li et al., 2004, Tyler et al., 2002, Yang
et  al.,  2003).  In  addition,  BACE1  levels  are  upregulated  in  neurons  and  astrocytes  under
different  AD-associated  stress  conditions,  such  as  oxygen  and  energy  deprivation  and
inflammation (Blasko et al., 2004, Cho et al., 2007, Deng et al., 2014, O'Connor et al., 2008,
Tamagno et al., 2002, Velliquette et al., 2005, Wang et al., 2015, Zhang et al., 2007).
Mechanistically, stress-induced induction in BACE1 levels may be triggered via
transcriptional activation or by post-translational mechanisms (Cole and Vassar, 2007). For
instance, HFD-associated inflammation and inflammation induced by the treatment with
either lipopolysaccharide (LPS) or proinflammatory cytokine interferon-· (IFN-·), has been
shown to promote Bace1 mRNA expression through activation of JAK2 – ERK1/2 – STAT-1
signaling pathway and by binding of NFΎB to the Bace1 gene promoter region in in vitro and
in vivo models (Cho et al., 2007, Wang et al., 2015). On the other hand, elevated BACE1 levels
in human AD brain have been proposed to arise from post-transcriptional events, since no
alterations in BACE1 mRNA levels have been observed in most studies (Holsinger et al., 2002,
Johnston et al., 2005). It has been suggested that increased translation of BACE1 might be
mediated by the eukaryotic translation initiation factor 2΅ (eIF2΅), whose activity, under
stress, is stimulated by phosphorylation of the amino acid serine at position 51 (O'Connor et
al., 2008). Recently, partial silencing of the PERK-eIF2΅ pathway was shown to reduce
BACE1 protein levels, AΆ production, amyloid burden, neurodegeneration, and memory
deficits in an AD mouse model (Devi and Ohno, 2014). Another study recently reported that
inhibition of monoacylglycerol lipase (MAGL), the primary enzyme that metabolizes the
endocannabinoid  2-arachidonoylglycerol  (2-AG)  in  the  brain,  robustly  suppresses  BACE1
translation, AΆ formation, neuroinflammation as well as improves both hippocampal
synaptic  function  and  spatial  learning  in  an  AD  mouse  model.  This  is  mediated  by  the
activation of PPAR· and NFΎB transcription factor signaling pathways and upregulation of
the small non-coding RNA, miR-188-3p (Chen et al., 2012, Zhang et al., 2014). Importantly,
the expression of miR-188-3p and its murine ortholog has been shown to be decreased in the
AD brain and in the brain of AD mice (Zhang et al., 2014). Together, these data point to the
idea that different cellular stress conditions may result in increased BACE1 levels which, in
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al., 2009, Weidemann et al., 2002). This cleavage cascade explains the existence of AΆ peptides
with various lengths (AΆ37-43). While AΆ40 is the predominant form of AΆ, AΆ42 is more prone
to aggregate (Findeis, 2007, Jarrett et al., 1993). Indeed, it has been suggested that an increased
ratio of AΆ42 to AΆ40, rather than the overall  AΆ amount is pathologically significant in AD
(Findeis, 2007). The generated AΆ peptides are subsequently secreted into the extracellular
space between the synaptic terminals. Because of their sticky nature, different extracellular
Ά species form oligomers and fibrils, which are neurotoxic in vitro and in vivo (Findeis, 2007,
Selkoe, 2008).
2.2.2 BACE1
2.2.2.1 BACE1, the Ά-secretase enzyme
The  Ά-secretase-mediated  cleavage  of  APP  is  the  initial  and  the  rate-limiting  step  in  AΆ
production. In the late 1990’s a transmembrane aspartyl protease called Ά-site APP cleaving
enzyme 1 (BACE1, also known as memapsin or aspartyl protease 2) was identified as being
responsible for the Ά-secretase activity (Hussain et al., 1999, Lin et al., 2000, Sinha et al., 1999,
Vassar et al., 1999, Yan et al., 1999). This protein was shown to exhibit all the molecular and
functional properties of this secretase and modulation of its levels was shown to have direct
consequences on APP processing in cells (Vassar et al., 1999). Given that AΆ production and
plaque formation have later been shown to be abolished by Bace1 knockdown in animal
models, it is plausible that BACE1 is also the sole Ά-secretase enzyme (Cai et al., 2001, Luo et
al., 2003, Roberds et al., 2001). Importantly, knockdown of Bace1 seems to be relatively well
tolerated in animals (Luo et al., 2003, Roberds et al., 2001). Because of these promising
Figure 5. Sequential processing of APP by Ǆ-secretase. The Ǆ-secretase cleaves APP at Ǆ, ǅ and
İ-sites. Aǃ peptides with varying lengths are produced via two main production lines. The
predominant production line is initiated with the İ-site cleavage after amino acid 49, followed by
ǅ-site cleavage after amino acid 46 and finalized by Ǆ-site cleavage after amino acid 43, 40, 38
or 37. Aǃ42 generation  is  initiated  by  İ-site  cleavage  after  amino  acid  48,  followed  by  ǅ-site
cleavage after amino acid 45 and finalized by Ǆ-site cleavage after amino acid 42 or 39. The Ǆ-
secretase cleavage sites and the resulting Aǃ-peptides are indicated in the APP sequence. Sites
for the initiatial Į- and ǃ-cleavages are also indicated.
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APP  processing  at  the  PM  (Cordy  et  al.,  2003,  Ehehalt  et  al.,  2003).  Conversely,  non-
amyloidogenic APP processing likely occurs outside the lipid rafts as the ΅-secretase is
localized in the non-raft regions of the memrane (Kojro et al., 2001). Several membrane lipids
have been shown to regulate raft localization of BACE1 and stimulate its activity in vitro
(Kalvodova et al., 2005). Interestingly, lipid rafts derived from AD brains were recently found
to exhibit altered lipid profiles and associate with a facilitated interaction between APP and
BACE1 as compared to control subjects (Diaz et al., 2015, Fabelo et al., 2014). Together these
data point to a critical role of certain lipids in amyloidogenic processing of APP.
Subcellular sorting of BACE1 is regulated by several factors. Endocytosis and sorting
into early endosomes is regulated by ADP ribosylation factor 6 (ARF6) (Sannerud et al., 2011).
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Figure 7. Schematic presentation of BACE1 and APP subcellular trafficking. BACE1 traffics from
endoplasmic reticulum (ER) via trans-Golgi network (TGN) to plasma membrane (PM). BACE1 is
re-internalized  via  ARF6-mediated  endocytosis  and  directed  to  recycling  pathway  or  late
endosomes/lysosomes (LELs) for degradation. APP traffics from ER to TGN and PM and is re-
internalized in clathrin-coated vesicles. Potential sites for APP and BACE1 interaction are lipid
rafts,  early  and  late  endosomes  (EE/LE)  and  TGN.  BACE1  trafficking  is  indicated  with  black
arrows. APP trafficking is indicated with grey arrows.
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turn, may eventually lead to increased AΆ production and accumulation, further potentiating
neuroinflammation as well as neuronal dysfunction and loss during AD developement.
2.2.2.2 BACE1 trafficking and processing
BACE1  is  a  501  aa-long  type-I  transmembrane  protein  (Figure  6)(Vassar et a., 1999). It is
initially synthesized in the ER as a zymogen, and, like APP, it traffics from the ER through
TNG to the PM via the secretory vesicle pathway (Figure 7) (Haniu et al., 2000). In the TGN,
BACE1 undergoes N-glycosylation, the catalytic protease domain of BACE1 is folded, and
its  N-terminal  signal  sequence and pro-peptide  domains  are  removed to  yield the  mature
enzyme (Benjannet et al., 2001, Capell et al., 2000, Haniu et al., 2000). From the PM, BACE1
is re-internalized by endocytosis, after which it cycles between the Rab5-positive early
endosomes, Rab11-positive recycling endosomes, the TGN, and the cell surface, until it is
targeted to Rab7-positive late endosomes and lysosomes (LELs) for disposal (Figure 7) (Huse
et al., 2000, Koh et al., 2005, Pastorino et al., 2002). Besides lysosomes, BACE1 can be degraded
via the ubiquitin-proteasome system (UPS), autophagy and by endoproteolysis (Huse et al.,
2000, Qing et al., 2004, Wu et al., 2015).
Endocytosis of BACE1 occurs through a mechanism that is distinct from that undergone
by  APP,  and  these  two  proteins  are  only  united  in  clathrin-coated  vesicles  or  at  early
endosomes (Vassar et al., 2014). In particular, early endosomes, have the optimal pH of ~4.5
for  Ά-secretase  activity,  making  them  a  major  site  for  AΆ production  (Ehehalt  et  al.,  2003,
Kalvodova et al., 2005, Rajendran et al., 2006, Sannerud et al., 2011). However, some of
BACE1 activity has also been reported in other acidic compartments, including the TGN. It
is noteworthy that a causative ‘Swedish’ mutation in APP (APPswe) leads to a more efficient
cleavage of APP by BACE1, particularly in the TGN (Haass et al., 2012). This implies that
increased BACE1-mediated cleavage of APP via an altered subcellular localization of APP
and BACE1 interactions may be sufficient to cause AD.
In membraneous compartments, BACE1 localizes to lipid rafts and this is at least partly
regulated by the palmitoylation of BACE1 (Ehehalt et al., 2003, Kalvodova et al., 2005, Riddell
et al., 2001, Vetrivel et al., 2009). Lipid rafts are cholesterol and sphingolipid-enriched
membrane microdomains, which are thought to be the focal points for the amyloidogenic
Figure 6. Schematic presentation of BACE1 protein structure. BACE1 is a 501 amino acids long
protein, which contains a signal peptide (SP) and a pro-domain (Pro) in the N-terminus, two
consensus motifs, DTGS and DTGT, in the protease domain and loop-domain, transmembrane
domain (TM) and cytosolic  domain (CD) at  the C-terminus.  Glycosylation sites are indicated
with black circles, phosphorylation site with black asterisk and ubiquitination site with black
triangle above the protein structure. Three disulfide bonds (S–S) are present in the folded
protein. aa, amino acid.
SP Pro DTGS Loop TM CDDTGT
S S
S S
S S
(501 aa)
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APP  processing  at  the  PM  (Cordy  et  al.,  2003,  Ehehalt  et  al.,  2003).  Conversely,  non-
amyloidogenic APP processing likely occurs outside the lipid rafts as the ΅-secretase is
localized in the non-raft regions of the memrane (Kojro et al., 2001). Several membrane lipids
have been shown to regulate raft localization of BACE1 and stimulate its activity in vitro
(Kalvodova et al., 2005). Interestingly, lipid rafts derived from AD brains were recently found
to exhibit altered lipid profiles and associate with a facilitated interaction between APP and
BACE1 as compared to control subjects (Diaz et al., 2015, Fabelo et al., 2014). Together these
data point to a critical role of certain lipids in amyloidogenic processing of APP.
Subcellular sorting of BACE1 is regulated by several factors. Endocytosis and sorting
into early endosomes is regulated by ADP ribosylation factor 6 (ARF6) (Sannerud et al., 2011).
ER
LEL
EE/LE
TGN
BACE1
APP
Clathrin
Nucleus
ARF6
GGAs
EEA1, TfR
Rab7
Lipidraft
ɴ
ɶ-secretase
ɲ-secretase
Nucleus
Figure 7. Schematic presentation of BACE1 and APP subcellular trafficking. BACE1 traffics from
endoplasmic reticulum (ER) via trans-Golgi network (TGN) to plasma membrane (PM). BACE1 is
re-internalized  via  ARF6-mediated  endocytosis  and  directed  to  recycling  pathway  or  late
endosomes/lysosomes (LELs) for degradation. APP traffics from ER to TGN and PM and is re-
internalized in clathrin-coated vesicles. Potential sites for APP and BACE1 interaction are lipid
rafts,  early  and  late  endosomes  (EE/LE)  and  TGN.  BACE1  trafficking  is  indicated  with  black
arrows. APP trafficking is indicated with grey arrows.
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turn, may eventually lead to increased AΆ production and accumulation, further potentiating
neuroinflammation as well as neuronal dysfunction and loss during AD developement.
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The expression of tau isoforms in the central nervous system (CNS) is strictly regulated.
Whereas only the shortest 0N3R-tau isoform is expressed during embryogenesis, the ratio of
4R-tau and 3R-tau isoforms is maintained at equality in adult humans (Goedert et al., 1989,
McMillan et al., 2008) (Kosik et al., 1989). The one-to-one ratio of 3R-tau to 4R-tau seems to
be essential for maintaining normal brain function, while disregulation of exon 10 splicing is
linked to neurodegenerative disorders. Several familial MAPT genetic mutations are
associated with neurodegenerative tauopathies (diseases that display abnormal levels or
forms of the protein) lead to abnormal exon 10 splicing and thus an imbalance between 4R-
tau  and  3R-tau  isoforms  (Lee  et  al.,  2001).  Although  the  role  of  aberrant  tau  splicing  is  a
matter of debate in AD, it has been demonstrated that increased levels of 3R tau may play a
role in the progression of tau pathology during AD (Connell et al., 2005, Espinoza et al., 2008,
Glatz et al., 2006, Ingelsson et al., 2006). This idea is supported by the finding that the early
onset tau pathology in individuals with Down syndrome (trisomy 21) may be associated with
a relative increase in 3R-tau expression (Shi et al., 2008). Several serine/arginine-rich splicing
factors (Srsfs), including Tra2Ά, ASF/SF2, SC35, Srp30c and Srp55, act on alternative splicing
of tau exon 10 and their function is regulated via phosphorylation by a number of kinases,
such as GKS3Ά, PKA and Dyrk1A (Liu and Gong, 2008, Qian and Liu, 2014). Interestingly,
Ά has  been  shown  to  regulate  GSK3Ά-mediated  activation  of  SC35,  whereas  Dyrk1A  is
Figure 8. Illustration of tau protein structure, modifications and isoforms. Six major isoforms are
created by alternative splicing of N-terminal exons 2 (E2) and 3 (E3) and C-terminal exon 10
(E10). C-terminal microtubule-binding domain contains either four (4R) or three (3R) repeat-
sequences, depending on the presence of exon 10, encoding the 2nd repeat. Two (2N), one (1N)
or none (0N) of the N-terminal inserts can be included in the protein. The proline-rich (PXXP)
domain is located in the middle of the protein and mediates the interaction with specific protein
domains. Phosphorylation sites are indicated with black circles. The sites (S191, S202/T205)
specific for AT8 antibody, often used to assess AD-related tau phosporylation, are indicated with
grey circles. Sumoylation site (L340) is indicated with an asterisk, nitration site (T29) is indicated
with a star. OGlcNAc occurs on several S and T residues.
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BACE1 sorting into LELs is reduced by addition of N-acetyl-D-glucosamine (GlcNAc) sugar
moieties, which recently was shown to be increased in the AD brain (Kizuka et al., 2015). In
animals, inhibition of GlcNAcylation was found to direct BACE1 into LELs, which reduced
its  co-localization  with  APP,  subsequently  decreasing  AΆ production,  plaque  burden  and
cognitive deficits (Kizuka et al., 2015). Sorting of BACE1 in endosomes and lysosomes is also
controlled by the carboxyl-terminal sorting signals, such as acidic di-leucine motifs and
addition of ubiquitin at Lys501 (Huse et al., 2000, Kang et al., 2012, Koh et al., 2005, Pastorino
et al., 2002). These signal motifs are recognized by adaptor proteins, called Golgi-localized ·-
ear containing ADP ribosylation-binding factor (GGA) -1, -2, and -3 (Kang et al., 2010, Tesco
et al., 2007), Phosphorylation of BACE1 at Ser498 seems to regulate this interaction (Pastorino
et al., 2002, Walter et al., 2001). Several studies suggest that GGAs retarget BACE1 from
endosomes towards the TGN (GGA1) or lysosomes for degradation (GGA3) (Cole and
Vassar, 2007, Kang et al., 2010, Tesco et al., 2007). As a consequence, GGAs shorten the time
of  endosomal  co-localization  of  APP  and  BACE1,  which  subsequently  may  reduce  AΆ
production. In line with this, depletion of GGA3 has been shown to increase BACE1 levels
and activity by reducing its lysosomal targeting and degradation (Kang et al., 2010, Sarajarvi
et al., 2009, Tesco et al., 2007). Interestingly the levels of GGA1, GGA3 and DHCR24/Seladin-
1, a protein regulating GGA3 levels during stress, have been shown to be decreased in AD
brain (Greeve et al., 2000, Kang et al., 2010, Sarajarvi et al., 2009, Tesco et al., 2007). Altogether,
these data imply that subcellular sorting of BACE1 may have a pivotal role in AΆ generation.
Therefore, a comprehensive understanding of BACE1 intracellular trafficking mechanisms
may provide new insights into AD pathogenesis and therapeutic strategies.
2.2.3 Tau
2.2.3.1 Tau structure and expression
The human tau encoding gene (MAPT)  is  located on the  chromosome 17q21 and the  full-
length protein is encoded by 13 exons. Six major tau isoforms are produced by the alternative
splicing of three exons (Figure 8) (Goedert et al., 1989). The C-terminal part of the protein has
a microtubule-binding domain, which includes four repeat-sequences encoded by exons 9,
10,  11  and  12.  The  alternative  inclusion  or  exclusion  of  exon  10  (2nd repeat) leads to the
expression of three tau isoforms with four repeat-sequences (4R-tau) and three isoforms
containing  only  three  repeat-sequences  (3R-tau).  These  4R-tau  and  3R-tau  isoforms  differ
with respect of the presence of N-terminal exons 2 and 3. As a consequence, each 4R-tau and
3R-tau isoform may either include both exons 2 and 3 (2N4R and 2N3R), only exon 2 (1N4R
and 1N3R) or neither of them (0N4R and 0N3R). Besides the microtubule binding motif on
its C-terminus and the “projection domain” on its N-terminus, tau also contains a proline-
rich domain in the middle region. The microtubule-binding domain interacts with
microtubules, whereas the projection domain projects away from them. The proline-rich
domain functions as a binding site for proline-directed kinases and other proteins with SRC-
homology 3 (SH3) –domain (Mandelkow and Mandelkow, 2012).
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length protein is encoded by 13 exons. Six major tau isoforms are produced by the alternative
splicing of three exons (Figure 8) (Goedert et al., 1989). The C-terminal part of the protein has
a microtubule-binding domain, which includes four repeat-sequences encoded by exons 9,
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behavioral tasks (Kim et al., 2009, Li et al., 2007, Planel et al., 2007, Shcubert et al., 2003).
Furthermore, it has been shown that tau is transiently hyperphosphorylated during
hibernation and anesthesia-associated hypothermia, a condition which is often followed by
temporal deterioration and cognitive decline. These studies together suggest that tau
phosphorylation level is altered during several different physiological and pathological
conditions (Avila et al., 2012, Planel et al., 2007). It has been shown that many kinases, such
as  GSK3Ά,  cdk5,  MAPK (ERK),  JNK,  MARK,  PKA,  CK1,  CaMKII,  PKC,  Fyn,  and Src,  and
phosphatases, including protein phosphatase 1 and 2A (PP1 and PP2A, respectively), act on
tau phosphorylation sites. Of these, at least GSK3Ά and MAPK are involved in aberrant tau
phosphorylation during AD, whereas PP2A has been shown to associate with abnormal tau
phosphorylation in a subgroup of FTD (Goedert et al., 2000). Because O-GlcNAc competes
with  phosphorylation  for  the  same  sites  on  the  same  residues,  it  has  been  suggested  to
indirectly regulate tau phosphorylation (Liu et al., 2002). Furthermore, tau ubiquitination as
well as nitration (which is a reaction catalyzed by reactive nitrogen species during oxidative
stress) have been found in AD and other neurodegenerative tauopathies (Cripps et al., 2006,
Reynolds et al., 2006). Altogether, these studies imply that post-translational modifications
are important regulators of normal tau function and pathology. Besides post-translational
covalent modifications, accumulating evidence from recent studies suggest that pathological
tau is abnormally truncated and possesses an aberrant conformation. These truncated and
misfolded tau species can be internalized by nearby neurons, probably via synaptic contacts.
This provides an explanatory mechanism by which tau pathology propagates through the
brain areas during disease progression, spreading dysfunction (Calafate et al., 2015,
Matsumoto et al., 2015, Medina and Avila, 2014, Sokolow et al., 2015).
2.2.4 Ubiquilin-1
2.2.4.1 Ubiquilin-1 structure, function and interactome
Several proteins that have been identified as regulators of protein folding, processing,
subcellular targeting and degradation, have also been linked to the pathogenesis of certain
neurodegenerative diseases. One such protein is ubiquilin-1 [also known as PLIC-1 (protein
linking integrin-associated protein with cytoskeleton-1 (Haapasalo et al., 2010). Ubiquilin-1
belongs  to  a  highly  conserved  group  of  ubiquitin-like  proteins,  which  deliver
polyubiquitinated proteins to the proteasome for degradation (Kleijnen et al., 2003, Ko et al.,
2002, Mah et al., 2000, Marin, 2014). In humans, Ubiquilin-1 is encoded by the UBQLN1 gene,
which consists of eleven exons. The full-length ubiquilin-1 protein contains two characteristic
functional protein domains: the N-terminal ubiquitin-like domain (UBL) mediates the
interaction with the 26S proteasome by directly binding to S5a-component of the 19S
proteasomal subunit, and the C-terminal ubiquitin-associated domain (UBA) that cooperates
with poly-ubiquitin chains attached to the proteins destined for degradation (Figure 9). The
presence of these highly specified domains indicates that ubiquilin-1 functions as a shuttle
between the proteasome and misfolded or accumulated proteins (Kleijnen et al., 2003, Ko et
al., 2002, Mah et al., 2000). A central region of ubiquilin-1 consists of conserved asparagine-
and proline-rich (Asn-Pro-rich) repeats. These repeats interact with specific domains of other
proteins, such as epidermal growth factor substrate 15 homology (EH) –domain that is
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upregulated  in  Down  syndrome  (Chen  et  al.,  2010,  Shi  et  al.,  2008).  Furthermore,  altered
expression of Tra2Ά and Srp55 has been observed in the tissues of obese humans and rodents
and a recent study reported that chronic T2DM in obese rats alter tau exon 10 splicing, so
that 3R-tau isoforms become overrepresented (Jiang et al., 2003)(Jung et al., 2011, Kondo et
al., 2004, Liu and Gong, 2008, Pihlajamaki et al., 2011). Since obesity and TD2M are risk factors
for AD, these data imply that these metabolic factors may predispose to AD by shifting the
balance between the different tau isoforms. In the functional point of view, 4R-tau is known
to interact with microtubules more strongly than 3R-tau and thus diverse tau isoforms may
differentially affect microtubule dynamics and function (Trinczek et al., 1995). Another recent
paper suggested that a plausible mechanism, for the underlying neurodegeneration during
abnormal tau splicing, is related to impaired endosomal vesicle trafficking and increased
cellular stress (Wren et al., 2015). In summary, the imbalance between tau isoforms seems to
be sufficient to cause neurodegeneration.
2.2.3.2 Tau function and post-translational regulation
Tau  is  expressed  in  several  tissues,  but  it  is  most  abundant  in  the  axons  of  CNS  neurons
where  the  distances  are  long  and  the  significance  of  microtubular  integrity  cannot  be
understated  (Goedert  et  al.,  1989,  Gu  et  al.,  1996).  Indeed,  the  primary  function  of  tau  is
believed to stand on the promotion and stabilization of microtubule assembly as well as on
microtubule-associated axonal transport of different molecular cargo (Lee and Leugers,
2012).  Tau  shares  a  significant  structural  homology  with  two  other  family  members  of
microtubule-associated proteins (MAPs), MAP2 and MAP4 (Chapin and Bulinski, 1991). The
evidence from tau knockout animal models lend support to the fact that the some of the
functions of tau may be compensated by the other MAPs. Despite this functional
redundancy, however, only tau has been associated with neurodegenerative diseases, which
clearly  illustrates  that  the  different  MAPs  are  likely  to  have  very  distinct  roles  (Grundke-
Iqbal et al., 1986, Kosik et al., 1986).
Tau is post-translationally modified by a number of different moeities, including
phosphorylation, O-linked GlcNAcylation, nitration, ubiquitination, and sumoylation
(Figure  8). Phosphorylation of tau at dozens of individual residues is a strictly regulated
dynamic process, which has an important physiological role. Fetal tau is significantly more
phosphorylated than the adult tau, suggesting that phosphorylation has a role in neuronal
development (Lee and Leugers, 2012). Phosphorylation of adult tau defines how tightly tau
can be bound to microtubules and leads to conformational changes in tau, which may alter
its ability to interact with other proteins. However, the most important evidence regarding
the critical role of tau phosphorylation arises from the fact that abnormal
hyperphosphorylation of tau precedes its aggregation of into NFTs and similar deposits in
AD, FTD, and other neurodegenerative diseases. In AD, tau is phosphorylated at sites that
are normally unphosphorylated in adult tau or exceedingly phosphorylated at the sites that
are normally phosphorylated (Grundke-Iqbal et al., 1986). For instance, strong
phosphorylation of tau at epitopes recognized by the AT8 antibody is detected during
neuronal development, but also prior to tau aggregation in AD pathogenesis (Lee ang
Leugers, 2012). Abnormal tau phosphorylation is also commonly observed in animal models
with experimentally induced diabetes and this has been found to associate with decline in
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upregulated  in  Down  syndrome  (Chen  et  al.,  2010,  Shi  et  al.,  2008).  Furthermore,  altered
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2.2.3.2 Tau function and post-translational regulation
Tau  is  expressed  in  several  tissues,  but  it  is  most  abundant  in  the  axons  of  CNS  neurons
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with experimentally induced diabetes and this has been found to associate with decline in
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Figure 10. Schematic representation of suggested protein interactions and functions of ubiquilin-
1. Ubiquilin-1 interacts with numerous proteins, which have a role in neurodegeneration, neuronal
development and signaling, vesicle trafficking and endocytosis, cell stress and immune response,
protein aggregation and degradation, cell spreading, migration, apoptosis and tumorigenesis as
well as spermiogenesis. AD, Alzheimer’s disease; ALP, autophagosome and lysosome pathaway; ALS,
amyotrophic lateral sclerosis; APP, amyloid precursor protein; BCLb, B-cell lymphoma; bHLHs, basic helix-
loop-helix transcription factors; CD47/IAP, integrin-associated protein; C9ORF72, Chromosome 9 open
reading frame 72 encoding gene; DLBD, diffuse Lewy body disease; EH, epidermal growth factor substrate
15 homology; Earsin and Herp, ER-resident proteins; Esp15, epidermal growth factor receptor pathway
substrate protein 15; FTD, frontotemporal degeneration; GABAAR, Ǆ-aminobutyric acid type A receptor;
HERC-3, HECT and RLD domain-containing E3 ubiquitin protein ligase 3; HCV, hepatitis C virus; KSHV,
Kaposi’s sarcoma-associated herpes virus; LC3, microtubule-associated protein 1A/1B-light chain 3; Mbt,
mycobacterium tuberculosis; mTOR, mammalian target of rapamycin; nAChR, nicotinic acetylcholine
receptor; Nct, nicastrin; NFT, neurofibrillary tangle; Orai1, calcium release-activated calcium channel protein
1; Pen-2, presenilin enhancer-2; PDI, protein disulfideisomerase; PolyQ, polyglutamine expansion proteins;
PS1, PS2, presenilin-1, -2; SPEM1, spermatid maturation; SQSTM1/P62, sequestosome 1; TLR3-Trif, Toll-
like receptor-Trif; UPS, ubiquitin-protesome system.
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present in a number of proteins that regulate endocytosis and vesicle sorting, suggesting that
ubiquilin-1 may be involved in intracellular vesicular trafficking (Mah et al., 2000).
Ubiquilin-1  is  ubiquitously  expressed in  most,  if  not  all,  tissues  (Marin,  2014).  In  the
human  brain,  Ubiquilin-1  is  present  in  neurons  and  inside  the  cells  it  localizes  to  the
cytoplasm, ER, and to a lesser extent in the nucleus and peripheral parts of the cell (Mah et
al., 2000). Four alternatively splicedUBQLN1 gene  derived  transcript  variants  (TVs)  have
been identified in human brain (Figure 9) (Bertram et al., 2005, Lu et al., 2009). These TVs
encode four protein isoforms, which differ in their domain composition, implying that they
might have unique interactomes and functions (Haapasalo et al., 2011). Compared to TV1,
which is the full-length form of ubiquilin-1, TV2 lacks the exon 8, encoding parts of Asn-Pro-
rich repeats. TV2 may therefore have an altered ability to interact with certain proteins. TV3
does not harbor exons 2, 3, and 4, and thus the TV3 protein contains only a fraction of the N-
terminal UBL domain. This may prevent the binding to the proteasome and thus this isoform
may not be able to efficiently deliver polyubiquitinated proteins for proteasomal
degradation. The smallest isoform, TV4, is encoded by only exons 1, 2, and 3, and this protein
has a unique 32-aa insertion in its C-terminus. Consequently, TV4 completely lacks the C-
terminal UBA domain and a large part of Asn-Pro-rich repeats, which may interfere with its
ability to interact with poly-ubiquitinated and other protein targets. However, the
physiological functions of individual isoforms are not well known (Haapasalo et al., 2011).
Figure 9. Schematic representation of ubiquilin-1 protein structure and transcript variants (TVs).
The full length ubiquilin-1 protein, TV1, is encoded by 11 exons of the UBQLN1. Ubiquilin-1 has
a ubiquitin-like domain (UBL) in the N-terminus, which interacts with the S5a domain of the 19S
proteasomal subunit. The C-terminus contains the ubiquitin-associated domain (UBA), which
mediates the interaction with polyubiquitinated proteins. The TV2 lacks the exon 8. Exons 2, 3
and 4 are excluded from the TV3. The TV4 protein is encoded only exons 1, 2 and 3 and has a
unique  C-terminus.  Asparagine  and  proline  (Asn-Pro)  -rich  repeats  are  indicated  with  black
circles.
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able to replicate this association (Arias-Vasquez et al., 2007) (Slifer et al., 2006) (Bensemain et
al., 2006, Brouwers et al., 2006, Martin et al., 2012, Smemo et al., 2006). Supporting the genetic
data, the risk allele of UBQ-8i single nucleotide polymorphism (SNP) has been reported to
alter the mRNA ratio of TV2 to TV1 and cause a pathological phenotype in vivo in the fruit
fly model organism, Drosophila melanogaster (Ganguly  et  al.,  2008,  Gross  et  al.,  2008).  In  a
recent study, ubiquilin-1 protein levels were reported to be significantly decreased in the
brain  of  LOAD  patients  (Stieren  et  al.,  2011).  Although  this  was  not  associated  with  any
particular UBQLN1 genotype, this data implies that ubiquilin-1 function may be diminished
during AD. On top of that, mutations in UBQLN2 (ubiquilin-2 gene), which encodes a protein
highly homologous to ubiquilin-1, have been recently shown to cause rare familial
amyotrophic lateral sclerosis (ALS), a devastating disease affecting upper and lower
motoneurons (Deng et al., 2011). Although these mutations are not associated with AD, this
finding further underlines the role of ubiquilin family proteins in neurodegenerative
disorders.
From the functional point of view, ubiquilin-1 was originally identified as a PS1 and -2
interacting protein, which later has been demonstrated to specifically increase the
accumulation and aggresomal targeting of ubiquitinated high-molecular weight (HMW) PS-
complexes in several studies (Ganguly et al., 2008, Li et al., 2007, Mah et al., 2000, Massey et
al., 2004, Massey et al., 2005, Thomas et al., 2006, Viswanathan et al., 2011, Zhang and Li,
2015). This function of ubiquilin-1 may partially be isoform-dependent, since TV3, which
lacks the proteasome-interacting UBL domain, has been found to enhance PS1 accumulation
and aggresomal localization (Viswanathan et al., 2011). However, the possible functional
consequences of the interrelationship between ubiquilin-1 and the presenilins are yet to be
discovered.  In  addition  to  PSs,  ubiquilin-1  also  seems  to  modulate  the  levels  of  other  ·-
secretase components, Pen-2 and Nct, but the effects of this interaction have been
inconclusive (Massey et al., 2005, Viswanathan et al., 2011). Importantly, number of studies
have reported that modulation of ubiquilin-1 levels in cultured cells alters APP processing,
maturation, trafficking and proteolysis, consequently affecting AΆ production and secretion
in a PS/·-secretase-independent mechanism (El Ayadi et al., 2012b)(Hiltunen et al., 2006,
Stieren et al., 2011, Viswanathan et al., 2013, Zhang et al., 2007). Accordingly, the data
regarding ubiquilin-1 effects on APP in Drosophila melanogaster have led to the proposition
that ubiquilin-1 plays a role in APP processing also in vivo (Gross et al., 2008, Li et al., 2007).
However, as these data have been fairly inconsistent and suggested that both
downregulation and overexpression may increase APP maturation, aggregation, and
processing,  this  interrelationship  may  be  cell-type-specific  and  needs  to  be  confirmed  in
additional models. Nevertheless, the mechanistic studies suggest that ubiquilin-1 functions
as  an  important  regulator  of  PS1-  and  2  levels  and  as  a  molecular  chaperone  for  APP.
Therefore, it is plausible that dysregulation of ubiquilin-1 levels or function in AD brain may
have consequences on AΆ accumulation.
Finally, ubiquilin-1 has been shown to localize in NFTs, dystrophic neurites, and Hirano
bodies  in  the  AD  brain,  and  in  Lewy  bodies  in  Parkinson’s  disease  (PD)  brain,  as  well  as
diffuse Lewy body disease (DLBD) (Mah et al., 2000, Mizukami et al., 2014, Satoh et al., 2013).
A recent study reported that early NFT changes are associated with upregulation or nuclear
translocation of ubiquilin-1 in hippocampal neurons (Mizukami et al., 2014). However,
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Functional studies in in vitro and in vivo models have proven that ubiquilin-1 regulates
the trafficking, function, levels and degradation of numerous proteins (Figure 10). The
diversity of the ubiquilin-1 interactome suggests that it is involved in a variety of
physiological and related pathophysiological functions. In addition to proteasomal targeting,
several studies have indicated that ubiquilin-1 may also mediate the clearance of cellular
waste and pathogens via the autophagosome-lysosome pathway (ALP) (N'Diaye et al., 2009,
Rothenberg et al., 2010, Sakowski et al., 2015, Viswanathan et al., 2011, Wu et al., 2002).
Ubiquilin-1  by  itself  is  a  target  for  ALP  and  it  has  been  suggested  to  interact  with
autophagosomes through the UBA domain (Rothenberg et al., 2010, Viswanathan et al.,
2011). When protein accumulation exceeds the capacity of the UPS or ALP, ubiquilin-1 has
been shown to target unwanted proteins into intracellular inclusion bodies, termed
aggresomes (Johnston et al., 1998, Kopito, 2000, Massey et al., 2004, Olzmann et al., 2008,
Viswanathan et al., 2011). Structurally, these juxtanuclear inclusions closely resemble
characteristic intracellular inclusions containing aggregated proteins associated with AD and
other neurodegenerative diseases. Accumulating evidence implies that these structures may
be cytoprotective, since they sequester potentially harmful proteins into restricted
compartments, which may later be safely disposed through the ALP (Haapasalo et al., 2010)
(Haapasalo et al., 2011).
2.2.4.2 Ubiquilin-1 and cell stress
Several studies provide evidence that ubiquilin-1 plays a role during different cellular stress
conditions (Figure 10)(Lim et al., 2009, Liu et al., 2014, Lu et al., 2009, N'Diaye et al., 2009)
(Kim et al., 2008). Ubiquilin-1 protects cells from starvation-induced apoptosis in an
autophagy-dependent mechanism (N'Diaye et al., 2009). Moreover, the levels of ubiquilin-1
are  up-regulated  during  the  unfolded  protein  response  (UPR)  and  it  has  been  shown  to
protect cells from ER-stress-associated apoptotic cell death (Ko et al., 2002, Lim et al., 2009,
Lu et al., 2009). All ubiquilin-1 TVs, except TV4, have been shown to reduce the induction of
UPR-inducible stress genes, subsequently leading to enhanced cell survival during ER-stress
and hypoxia (Lu et al., 2009). The beneficial effect of ubiquilin-1 during acute stress has been
suggested to occur by enhancing the proteasomal disposal of ER-associated degradation
(ERAD) substrates (Kim et al., 2008, Lim et al., 2009). Supporting this idea, ubiquilin-1 down-
regulation in vivo in Caenorhabditis elegans and  in  mice  has  been  found  to  result  in  the
accumulation of misfolded and polyubiquitinated proteins during induced ER-stress,
oxidative  stress  and  ischemia  (Lim  et  al.,  2009,  Liu  et  al.,  2014).  Accordingly, ubiquilin-1
overexpression was recently reported to protect mice from oxidative stress and ischemic
stroke-induced neuronal injury and motor defects (Liu et al., 2014). Together this data
indicate that ubiquilin-1 may protect cells from stress by inhibiting the accumulation of
damaged proteins.
2.2.4.3 Ubiquilin-1 and protein aggregation in neurodegeneration
During recent years, ubiquilin-1 has been linked to AD pathogenesis in many ways (Figure
10). Several studies have demonstrated that certain genetic variants in UBQLN1 are
associated with an increased risk of developing AD(Bertram et al., 2005, Golan et al., 2008,
Kamboh et al.,  2006, Slifer et al.,  2005, Yue et al.,  2015),  although not all  studies have been
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et al., 1994), or elevate BACE1 affinity towards APP and result in an overall increased total
Ά production (such as Swedish KM670/671NL mutation near the Ά-secretase cleavage site)
(Mullan et al., 1992, Weggen and Beher, 2012). Besides these gene mutations, copy number
variations, such as APP gene duplications and chromosome 21 trisomy (Down syndrome) on
which APP resides, cause autosomal dominant early onset AD (Rovelet-Lecrux et al., 2006,
Rumble et al., 1989, St George-Hyslop et al., 1987a, St George-Hyslop et al., 1987b, Tanzi et
al., 1987a, Tanzi et al., 1987b). Taken together, all these data imply that lifelong exposure to
increased AΆ levels  is  sufficient  to  cause  FAD and therefore  the  imbalance  in  AΆ levels  is
likely to be a defining molecular event in AD. This concept recently gained further support
as a novel APP A673T variant was found to be associated with reduced risk of LOAD and
better cognition (Jonsson et al., 2012). This variation is located near the Ά-secretase cleavage
site and therefore makes APP a poorer substrate for Ά-secretase cleavage, subsequently
reducing overall AΆ production. This finding provides additional proof for the hypothesis
that AΆ may present the driving force of not only FAD, but also LOAD.
2.3.1.2 Common risk variants in susceptibility genes
Differening from FAD, the more common late onset form of AD (LOAD) is not caused by
mutations leading to simple pathogenic outcomes, such as altered APP metabolism. Instead,
LOAD  is  a  heterogeneous  disease,  which  results  from  a  complex  combination  of  various
genetic risk variants and environmental factors. Most of the identified LOAD risk loci are
frequent in population, but display only very small effect size. The strongest known genetic
risk factor for LOAD is the Ή4 variant of the apolipoprotein E (ApoE)-encoding gene
(APOE)(Table 1)(Strittmatter et al., 1993).  Approximately 50% LOAD patients have an APOE
Ή4  allele  carriers.  Individuals  carrying  one  Ή4  allele  have  four-fold  increased  risk  for
developing AD, while those who are homozygous for the Ή4 allele are at 10-fold greater risk.
The presence of this risk allele also decreases the age of disease onset in a dose-dependent
fashion. In contrast, another variant of this gene, APOE, the Ή2 allele (in short notation, APOE
Ή2), has been demonstrated to associate with reduced risk of AD or later age of onset
(Benjamin et al., 1994). ApoE has several essential functions in the CNS and it is not entirely
clear which of those are important for AD pathogenesis.  A plausible mechanism might be
reduced clearance and/or increased formation of AΆ in the presence of the Ή4 genotype, but
many other mechanisms have also been suggested (Bales et al., 2009, Castellano et al., 2011,
Chen et al., 2010, Deane et al., 2008, Hamanaka et al., 2000, Keene et al., 2011, LaDu et al.,
1994, Morris et al., 2010, Ramanan et al., 2014, Reiman et al., 2009, Verghese et al., 2013, Wolf
et al., 2013). Importantly, the ApoE protein is the principal carrier of cholesterol in the brain
and the Ή4 isoform has the poorest cholesterol-binding capacity. Both epidemiological and
experimental data strongly support the direct role of cholesterol homeostasis in AΆ
accumulation  and  AD  risk  (Grimm  et  al.,  2013,  Puglielli  et  al.,  2003).  Interestingly,  recent
genome-wide association studies (GWAS) and next generation sequencing analysis have
identified several other risk loci in or nearby genes that are functionally linked to cholesterol
metabolism, transport, or uptake (Table 1) (www.Alzgene.org (Harold et al., 2009,
Hollingworth et al., 2011, Lambert et al., 2009, Naj et al., 2011). Although the impact of these
common  variants  on  AD  risk  are  small  (10-15%),  their  identification  has  broadened  the
picture  of  the  central  molecular  pathways  involved  in  LOAD  pathogenesis.  Besides  lipid
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further studies unraveling the possible relationship between tau and ubiquilin-1 have not
been  published  so  far.  Besides  AD  and  PD,  ubiquilin-1  has  been  found  to  regulate  the
accumulation and toxicity  of  expanded polyQ repeat  containing proteins,  such as  HTT in
Huntington’s disease (HD) and polyA containing proteins associated predominantly with
congenital malformation syndromes (Albrecht and Mundlos, 2005)(Doi et al., 2004, Safren et
al., 2014, Wang and Monteiro, 2007a, Wang and Monteiro, 2007b). Recently, ubiquilin-1 was
also reported to localize in the ubiquitin/sequestosome-1 (SQSTM1/p62) and TAR DNA-
binding protein 43 (TDP-43) –immunopositive intracellular inclusions in FTD and ALS brain
and mediate the stability and toxicity of these aggregates in vitro and in vivo (Brettschneider
et al., 2012, Hanson et al., 2010, Kim et al., 2009c). Interestingly, ubiquilin pathology in FTD
and ALS brains seems to strongly associate with the presence of a pathological C9ORF72
(C9orf72 gene)-associated genotype. The hexanucleotide repeat expansion located in this
recently identified gene is the most common genetic cause of both FTD and ALS (DeJesus-
Hernandez et al., 2011)(Renton et al., 2011). The C9orf72 protein was recently proposed to
regulate the endosomal trafficking system, which is necessary for the controlling, sorting and
degradation of proteins via the ALP or the UPS, implying a possible mechanistic link between
C9orf72 and ubiquilin-1 (Korolchuk et al., 2010, Levine et al., 2013) (Farg et al., 2014). Taken
together, ubiquilin-1 regulates several essential cellular functions and participates in
aggregation and degradation of numerous proteins abnormally accumulating in
neurodegenerative  diseases.  This  suggests  that  ubiquilin-1  might  represent  a  common
mechanistic link between distinct neurodenerative diseases. However, whether ubiquilin-1
augments or alleviates the pathology in these diseases, remains an open question.
2.3 THE EFFECT OF GENES AND ENVIRONMENT ON ALZHEIMER’S
DISEASE
2.3.1 Genetics of Alzheimer’s disease
2.3.1.1 Causative mutations in APP, PSEN1, and PSEN2
The  familial  component  is  the  second  most  important  risk  factor  for  AD  after  age.  It  is
estimated that heritability in AD may be as high as 80% (Gatz et al., 2006). However, only in
rare  cases  (<1%) is  AD inherited in  a  fully  penetrant,  autosomal  dominant,  fashion.  These
early onset familial AD (FAD) cases are caused by mutations in three genes: APP, PSEN1,
and PSEN2, which  encode  for  the  APP,  PS1,  and  PS2  proteins,  respectively  (Table 1)
(www.AlzGene.org, De Strooper et al., 1998, Glenner and Wong, 2012, Kang et al., 1987,
Masters et al., 1985, Selkoe, 2001, Wolfe et al., 1999). The vast majority of causative mutations
reside in PSEN1 gene, and  a  few  in  the  homologous  gene PSEN2. All PSEN1 and PSEN2
mutations increase the ratio of AΆ42 to AΆ40, by poorly understood mechanisms, thus
subsequently promoting AΆ oligomerization and formation of amyloid fibrils (Borchelt et al.,
1996, Chavez-Gutierrez et al., 2012, Jarrett et al., 1993, Potter et al., 2013, Weggen and Beher,
2012). In addition, there are more than 30 mutations in APP, each located within the AΆ
sequence or in the close vicinity of the Ά- or ·-secretase cleavage sites (Ringman et al., 2014).
Depending on the exact location, APP mutations either promote AΆ oligomerization (such as
the Arctic E693G mutation within AΆ sequence) (Nilsberth et al., 2001), increase the relative
amount of AΆ42 (such as London mutation located just beyond the C-terminus of AΆ) (Suzuki
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et al., 1994), or elevate BACE1 affinity towards APP and result in an overall increased total
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Table 1. Continues
Gene(s)
associated
with
variant
Protein Pathways Potential
Effect on APP
and tau
MS4A
cluster
Membrane-spanning 4-domains,
subfamily A
Immune response
NME8 NME/NM23 family member 8
PDL3 Phospholipase D family member 3 APP trafficking
and cleavage
PICALM Phosphatidylinositol binding clathrin
assembly protein
Synapse function
Endocytosis
APP trafficking
$ǃ clearance
PSEN1 Presenilin-1 APP processing Cleaves APP
PSEN2 Presenilin-2 APP processing Cleaves APP
PTK2B Protein tyrosine kinase 2 ǃ Synapse function
Neural development
SLC24A4 Solute carrier family 24
(sodium/potassium/calcium
exchanger), member 4
Neural development
Synapse function
Endocytosis
SORL1 Sortilin-related receptor, L(DLR class)
A repeats containing
Lipid metabolism
Synapse function
Endocytosis
APP trafficking
TREM2 Triggering receptor expressed on
myeloid cells 2
Immune response $ǃ clearance
ZCWPW1 Zinc finger, CW type with PWWP
domain 1
Neural development
Adapted from Karch et al., 2014, Neuron 83:11-26
2.3.2 Environmental risk factors for Alzheimer’s disease: Effects of dietary lipids
Besides advanced age, female gender, genetic background, family history of dementia,
depression and some other co-morbidities, there are several environmental and lifestyle
factors, which often co-occur and interact across the lifespan to determine the risk of
developing AD later in life (Table  2) (Sindi et al., 2015). Vascular and metabolic factors,
including hypertension, dyslipidemia, hyperglycemia, higher BMI (both overweight and
obesity),  T2DM,  as  well  as  cardio-  and  cerebrovascular  disorders  have  been  linked  to
increased AD risk in epidemiologic studies. Most of these are directly linked to lifestyle
factors, such as smoking, alcohol consumption, amount of physical exercise, dietary choices,
and the use of antihypertensive and cholesterol lowering drugs (statins) (Table 2). In
particular, dietary lipid composition has been implicated to be important in prevention and
as  a  treatment  strategy  for  cardiovascular  diseases  as  well  as  T2DM  and  is  proposed  to
influence AD risk and pathophysiology in epidemiological and experimental studies (Morris
and Tangney, 2014). Cholesterol dyshomeostasis increases the risk of AD. On the other hand,
plasma cholesterol levels are mainly affected by the saturated and polyunsaturated fatty acid
(SFA and PUFA, respectively) composition in the diet. It has been demonstrated that ‘typical
Western-type  diet’  containing  a  considerable  amount  of  red  meat,  dairy  products  and
processed foods, rich in SFAs, trans fats and cholesterol and may increase the risk of mild
cognitive impairment (MCI), dementia or AD (Barnard et al., 2014, Eskelinen et al., 2008,
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homeostasis,  most  of  the  LOAD  risk  genes  seem  to  play  a  role  in  immune
responce/inflammation or endosomal vesicle transport (Table  1) (Bertram et al., 2008,
Guerreiro et al., 2013, Harold et al., 2009, Hollingworth et al., 2011, Jonsson et al., 2013,
Lambert  et  al.,  2009,  Naj  et  al.,  2011).  It  is  noteworthy  that  many  of  these  common  risk
variants also appear to affect AΆ levels (Chan et al., 2008, DeMattos et al., 2004, Schmidt et
al., 2007, Spoelgen et al., 2006) or tau toxicity (Chapuis et al., 2013) (Shulman et al., 2014) in
the brain. Taken together, identification of common LOAD risk loci and the associated
molecular pathways have created whole new avenues for potential therapeutic targeting.
Whether these recently implicated pathological changes take place downstream or upstream
of AΆ accumulation is still under debate.
Table 1. List of AD-associated genes
Gene(s)
associated
with
variant
Protein Pathways Potential
Effect on APP
and tau
ABCA7 ATP-binding cassette, sub-family A
(ABC1), member 7
Lipid metabolism
Immune response
$ǃ clearance
AKAP9 A kinase (PRKA) anchor protein 9 Cell signaling
ADAM10 A disintegrin and metalloprotease 10 APP processing Cleaves APP
APP Amyloid ǃ (A4) precursor protein APP processing Cleavage
releases Aǃ
APOE
İ4)
Apolipoprotein E Lipid metabolism $ǃ clearance
BIN1 Bridging integrator 1 Endocytosis
Synapse function
Mediates tau
toxicity
CASS4 Cas scaffolding protein family
member 4
Cytoskeleton and
axonal transport
CELF1
(and
MADD)
Elav-like family member 1 Neural development Mediates tau
toxicity
CD2AP CD2-associated protein Synapse function
Endocytosis
Mediates tau
toxicity
CD33 CD33 molecule Immune response $ǃ clearance
CLU Clusterin Lipid metabolism
Immune response
$ǃ clearance
CR1 Complement component (3b/4b)
receptor 1
Immune responce $ǃ clearance
DSG2 Desmoglein 2
EPHA1 Ephrin type-A receptor 1 Immune response
Neural development
FERMT2 Fermitin family member 2 Cytoskeleton and
axonal transport
Mediates tau
toxicity
HLA-
DRB5-
HLA-DRB1
Major histocompatibility complex,
class II, DR ǃ5, ǃ1
Immune response
INPP5D Inositol polyphosphate-5-
phosphatase, 145 kDa
Immune response
MEF2C Myocyte enhancer factor 2C Neural development
Synapse function
Immune response
Adapted from Karch et al., 2014, Neuron 83:11-26
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Grimm et al., 2013, Laitinen et al., 2006, Luchsinger et al., 2002, Morris et al., 2003a).
Moreover,  this  type  of  diet  predisposes  to  weight  gain  and  obesity,  which  may  be
independent  risk  factors  for  AD  (Kivipelto  et  al.,  2005,  Mrak,  2009).  On  the  contrary,  a
Mediterranean-like diet, which consists mostly of vegetables and fish, and is therefore
enriched  with  PUFAs,  has  been  linked  to  a  reduced  risk  of  cognitive  decline  or  AD
((Barberger-Gateau et al., 2005, Eskelinen et al., 2008, Laitinen et al., 2006, Morris et al., 2003b,
Tangney et al., 2014). In particular, the consumption of marine fish and other sources of n-3
ǻΝ-3) PUFAs, which leads to decreased n-6/n-3 ratios, has been reported to lower the risk of
DHA SAFs
DHA
+ -
Cholesterol
Non-amyloidogenic
pathway
Amyloidogenic
pathway
De novo
synthesis
Raft
localization
ɴ-secretase:
- Activity
- Intracellular
colocalization
with APP
ɶ-secretase:
- Activity
- Raft localization
- PS1 levels and/or
Intracellular localization
ɴ levels, toxicity and oligomerization
ɲ-secretase:
- ADAM17
protein levels
- Expression
- Degradation
sAPPɲ levels
- +
Figure 11. An  illustrative  summary  of  the  possible  effects  of  DHA  on  Aǃ pathology.  DHA
decreases  Aǃ burden  and  toxicity  by  multiple  pleiotropic  effects.  DHA  increases  non-
amyloidogenic processing by increasing ADAM17 protein levels through increasing its expression
and decreasing degradation. Evidence of increased sAPPĮ levels supports this effect. DHA also
decreases amyloidogenic processing of APP by inhibiting ǃ- and Ǆ-secretases and altering their
subcellular and/or raft localization. DHA also decreases cholesterol levels and lipid raft
localization. In contrast, dietary SFAs increase the cholesterol levels. Cholesterol on the other
hand increases amyloidogenic processing by increasing the activity of ǃ- and Ǆ-secretases and
increasing protein levels of BACE1 and PS1. Cholesterol also decreases non-amyloidogenic
processing of APP by acting on ADAM10. (Adapted from Grimm et al. “Docosahexaenoic acid
reduces amyloid beta production via multiple pleiotropic mechanisms”, The J Biol Chem. 2011;
286:14028-39, with the permission of the American Society for Biochemistry and Molecular
Biology).
28
Table 2. Probable and possible factors increasing and reducing the risk of AD
APOE, apolipoprotein E-encoding gene; APP A673T,  protective  variant  in  amyloid  precursor
protein-encoging  gene;  DHA,  docosahexaenoic  acid;  GABA,  gamma-aminobutyric  acid;  MUFA,
monounsaturated fatty acid; NMDA, N-methyl-D-aspartate; NSAID, non-steroidal anti-
inflammatory drugs; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; T2DM, type 2
diabetes mellitus.
Risk-increasing factors Protective factors
Age
x >65
Genetic
x Family history
x APOE, İ4 allele
x Common variants in several
susceptibility genes
Genetic
x APP A673T, APOE İ2 allele
x Common variants in a few
susceptibility genes
Vascular and metabolic factors
x Midlife hypertension
x Cardiovascular diseases
x Cerebrovascular lesions
x Dyslipidemia/High
cholesterol
x Overweight or obesity
x Altered peripheral glucose
metabolism and insulin
sensitivity, T2DM
Lifestyle and dietary factors
x Cognitive reserve: Education,
social networks,  mental
exercise
x Physical exercise
x Moderate alcohol consumption
x ‘Mediterranean diet’ including
vegetables and fish, enriched
with MUFAs, PUFAs, and n-3
fatty acids
x Other dietary supplements
with potentially beneficial
effects: vitamins B6, B12,
vitamin C,D, E, DHA, uridine,
flavonoids, plant sterols,
curcumin, selenium
Lifestyle and dietary factors
x Smoking
x Heavy alcohol use
x ‘Typical Western diet’ rich in
SFAs, trans fats and
cholesterol
x Increased n-6/n-3 PUFA ratio
Drugs
x Antihypertensive drugs
x Statins
x NSAIDs (may also have
severe side-effects)
x Post menopausal hormone
therapy
x Cholinesterase inhibitors (for
treating behavioral symptoms
in AD)
x NMDA antagonists (for
treating behavioral symptoms
in AD)
x GABA transporter inhibitors
Others
x Female gender
x History of depression
x Stress
x Head injury
Others
x Female gender
x History of depression
x Traumatic brain injury
x Infectious agents
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Grimm et al., 2013, Laitinen et al., 2006, Luchsinger et al., 2002, Morris et al., 2003a).
Moreover,  this  type  of  diet  predisposes  to  weight  gain  and  obesity,  which  may  be
independent  risk  factors  for  AD  (Kivipelto  et  al.,  2005,  Mrak,  2009).  On  the  contrary,  a
Mediterranean-like diet, which consists mostly of vegetables and fish, and is therefore
enriched  with  PUFAs,  has  been  linked  to  a  reduced  risk  of  cognitive  decline  or  AD
((Barberger-Gateau et al., 2005, Eskelinen et al., 2008, Laitinen et al., 2006, Morris et al., 2003b,
Tangney et al., 2014). In particular, the consumption of marine fish and other sources of n-3
ǻΝ-3) PUFAs, which leads to decreased n-6/n-3 ratios, has been reported to lower the risk of
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Figure 11. An  illustrative  summary  of  the  possible  effects  of  DHA  on  Aǃ pathology.  DHA
decreases  Aǃ burden  and  toxicity  by  multiple  pleiotropic  effects.  DHA  increases  non-
amyloidogenic processing by increasing ADAM17 protein levels through increasing its expression
and decreasing degradation. Evidence of increased sAPPĮ levels supports this effect. DHA also
decreases amyloidogenic processing of APP by inhibiting ǃ- and Ǆ-secretases and altering their
subcellular and/or raft localization. DHA also decreases cholesterol levels and lipid raft
localization. In contrast, dietary SFAs increase the cholesterol levels. Cholesterol on the other
hand increases amyloidogenic processing by increasing the activity of ǃ- and Ǆ-secretases and
increasing protein levels of BACE1 and PS1. Cholesterol also decreases non-amyloidogenic
processing of APP by acting on ADAM10. (Adapted from Grimm et al. “Docosahexaenoic acid
reduces amyloid beta production via multiple pleiotropic mechanisms”, The J Biol Chem. 2011;
286:14028-39, with the permission of the American Society for Biochemistry and Molecular
Biology).
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Table 2. Probable and possible factors increasing and reducing the risk of AD
APOE, apolipoprotein E-encoding gene; APP A673T,  protective  variant  in  amyloid  precursor
protein-encoging  gene;  DHA,  docosahexaenoic  acid;  GABA,  gamma-aminobutyric  acid;  MUFA,
monounsaturated fatty acid; NMDA, N-methyl-D-aspartate; NSAID, non-steroidal anti-
inflammatory drugs; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; T2DM, type 2
diabetes mellitus.
Risk-increasing factors Protective factors
Age
x >65
Genetic
x Family history
x APOE, İ4 allele
x Common variants in several
susceptibility genes
Genetic
x APP A673T, APOE İ2 allele
x Common variants in a few
susceptibility genes
Vascular and metabolic factors
x Midlife hypertension
x Cardiovascular diseases
x Cerebrovascular lesions
x Dyslipidemia/High
cholesterol
x Overweight or obesity
x Altered peripheral glucose
metabolism and insulin
sensitivity, T2DM
Lifestyle and dietary factors
x Cognitive reserve: Education,
social networks,  mental
exercise
x Physical exercise
x Moderate alcohol consumption
x ‘Mediterranean diet’ including
vegetables and fish, enriched
with MUFAs, PUFAs, and n-3
fatty acids
x Other dietary supplements
with potentially beneficial
effects: vitamins B6, B12,
vitamin C,D, E, DHA, uridine,
flavonoids, plant sterols,
curcumin, selenium
Lifestyle and dietary factors
x Smoking
x Heavy alcohol use
x ‘Typical Western diet’ rich in
SFAs, trans fats and
cholesterol
x Increased n-6/n-3 PUFA ratio
Drugs
x Antihypertensive drugs
x Statins
x NSAIDs (may also have
severe side-effects)
x Post menopausal hormone
therapy
x Cholinesterase inhibitors (for
treating behavioral symptoms
in AD)
x NMDA antagonists (for
treating behavioral symptoms
in AD)
x GABA transporter inhibitors
Others
x Female gender
x History of depression
x Stress
x Head injury
Others
x Female gender
x History of depression
x Traumatic brain injury
x Infectious agents
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synapses (van Wijk et al., 2014). In line with this, Fortasyn, which is a specific multinutrient
combination designed to ameliorate synapse loss and dysfunction in AD, by providing
neuronal  membrane  precursors  and  cofactors,  such  as  UMP,  the n-3 PUFAs,  DHA  and
eicosapentaenoic acid (EPA), choline, phospholipids, folic acid, vitamins B12, B6, C, E, and
selenium, has been shown to improve cognitive performance, protect against AΆ42
pathology, enhance synaptic membrane formation and neurotransmitter signaling in rodent
models of AD (Broersen et al., 2013, Cansev et al., 2015, de Wilde et al., 2011, van Wijk et al.,
2014). Importantly, the same multinutrient composition, which is present in a medical food
product called Souvenaid has recently been shown to preserve brain functional networks and
increase memory performance in patients with mild AD (de Waal et al., 2014, Scheltens et al.,
2010, Scheltens et al., 2012). Another potential group of beneficial nutrients with regard to
AD neuropathology are plant sterols, which are cholesterol equivalents in plants obtained
from  nuts,  seeds,  legumes  and  unrefined  plant  oils  and  are  widely  used  as  cholesterol-
lowering dietary agents (Malar and Devi, 2014). The beneficial properties of plant sterols may
arise from their antioxidant capacity and the ability to scavenge free radicals formed during
the pathological process. Taking all this evidence together suggests that the modulation of
dietary composition may be a potentially practical way to influence AD risk or progression.
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AD in an APOE Ή4- allele dependent manner (Barberger-Gateau et al., 2005, Morris et al.,
2003b, Samieri et al., 2011, Vandal et al., 2014).
Further accumulating evidence from preclinical studies also lends support these initial
findings and this implies that dietary fatty acids may influence on AD-related pathology in
experimental models. A high-fat diet (HFD), enriched with SFAs, is a common way to induce
T2DM in rodents.  T2DM and AD are risk factors for each other (Carlsson, 2010, Irie et al.,
2008, Janson et al., 2004) and the diabetic phenotype (in other words peripheral
hyperinsulinemia, hyperglycemia and/or insulin resistance) has been found to induce AD-
type neuropathological changes in the brain of genetically and nutritionally modified rodent
models of both type 1 and type 2 diabetes (Jeon et al., 2012, Jung et al., 2011, Jung et al., 2013,
Kim et al., 2009a, Li et al., 2007, Moroz et al., 2008, Schubert et al., 2003). In addition,
accelerated AΆ burden, tau phosphorylation and/or levels as well as cognitive decline have
been observed after HFD administration in rodent models of AD (Hiltunen et al., 2012, Ho et
al., 2004, Julien et al., 2010, Kohjima et al., 2010, Leboucher et al., 2013, Oksman et al., 2006,
Takeda et al., 2010, Vandal et al., 2014). These HFD-induced changes have been reported to
co-occur with T2DM-related peripheral changes in some, but not in all studies, implying that
exacerbated AD pathology does not explicitly result from having a diabetic phenotype, but
may be linked to other diet-related factors such as diet-induced obesity, dyslipidemia or
aggravated neuroinflammation (Koga et al., 2014, Leboucher et al., 2013). Altogether, it is
increasingly evident that dietary SFAs contribute to the development or progression of AD-
type  neuropathological  changes,  although  the  mechanisms  by  which  they  influence  brain
pathology remain partially unknown.
Other experimental data provided support for a beneficial effect of long-term dietary
intake of docosahexaenoic acid (DHA), the major n-3 PUFA. DHA intake has been shown to
alleviate  cognitive  decline  as  well  as  brain  AΆ burden  and  tau  pathology  via  number  of
pleiotropic mechanisms in animal and cell models of AD (Figure 11) (Arsenault et al., 2011,
Calon et al., 2004, Green et al., 2007, Grimm et al., 2011, Kariv-Inbal et al., 2012, Lim et al.,
2005, Ma et al., 2007, Perez et al., 2010). More precisely, DHA has been shown to reduce AΆ
oligomerization, fibrillarization and toxicity (Florent et al., 2006, Hossain et al., 2009, Teng et
al., 2015, Wang et al., 2010). DHA also reduces AΆ production by both inhibiting Ά- and ·-
secretases and by increasing the activity of the ΅-secretase (Grimm et al., 2011, Oksman et al.,
2006, Sahlin et al., 2007, Zhao et al., 2011). It has been shown that DHA can alter lipid raft
structure and mediate a restribution in the subcellular localization of APP and thus affect its
co-localization with BACE1 (Grimm et al., 2011, Ma et al., 2007). Furthermore, DHA may
influence AD-related pathology through affecting cerebral insulin signaling and
inflammation (Ma et al., 2007, Zhao et al., 2011). In accordance to these effects, DHA depletion
has been found to result in dendritic pathology and cognitive defects in AD mice (Calon et
al., 2005). However, the evidence from systematic reviews suggest that DHA alone is not able
to sufficiently slow down AD pathology (Lim et al., 2006). Several studies have shown that
the combination of DHA and uridine monophosphate (UMP) can act synergistically in
stimulating membrane lipid synthesis, increasing dendritic spine density that lead to
improved learning and memory in rodents (Holguin et al., 2008, Sakamoto et al., 2007,
Wurtman et al., 2006). These effects are considered to be relevant for AD pathology, which
includes disturbances in membrane structure and lipid composition and subsequent loss of
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4 Materials and methods
4.1 cDNA CONSTRUCTS, siRNAs, AND VIRAL VECTORS
Different cDNA constructs containing the human BACE1 gene that produce the protein
namesake under different promoters and regulatory regions, the human full-length
ubiquilin-1 transcript variant 1 (TV1) or the human wild-type 0N4R-tau were used for cell
culture experiments in study II and are listed in Table 3.  Monomeric red fluorescent protein
(mRFP), enhanced farnesylated green fluorescent protein (EGFP-F), and empty plasmid
DNA (pcDNA3.1) were used as controls. 5’UTR-BACE1 and 5’3’UTR-BACE1 constructs were
a generous gift  from Professor Stefan Lichtenthaler (DZNE, Munich, Germany). Silencer™
Pre-designed siRNA targeted to exon 5 of the human ubiquilin-1 gene was used for
downregulation of ubiquilin-1 expression (Ambion). Silencer™ Negative control #1 siRNA
was used as a control in RNA interference experiments (Ambion). Genes encoding human
ubiquilin-1  TV1  and  GFP  under  CAG-promoter  in  HIV  vector  were  used  for  lentivirus-
mediated  gene  transfer  into  embryonic  mouse  primary  neurons  and  hippocampi  of  adult
APdE9 mice (Table 3). All lentiviral constructs were ordered from the National Virus Vector
Laboratory, A.I. Virtanen Institute, University of Eastern Finland. Lentiviral particles
containing empty HIV-plasmid with the CAG-promoter, but lacking the coding insert were
used as a transduction control.
32
3 Aims of the Study
AD is the leading cause of dementia in the elderly and is listed amongst the top health issues
today, by the WHO. LOAD is a heterogeneous and complex disease, which involves a poorly
understood interplay between a number of genes and environmental factors. Currently, there
is neither a cure nor effective disease-modifying therapies available for this disease. While
the  population  ages,  there  is  an  urgent  need  to  design  novel  prediction,  prevention  and
intervention approaches, and to identify novel biomarker and therapeutic targets. To reach
these aims, a better understanding of the molecular mechanisms underlying AD is required.
The specific aims of this thesis were:
1. To review the role of the AD risk gene UBQLN1 and  protein  product  in  AD
pathogenesis and consider its role as a potential therapeutic target in AD on the basis
of recent literature (Study I).
2. To characterize the expression and functional mechanisms of the UBQLN1 gene and
protein product in AD molecular pathogenesis in the human AD brain as well as in
vitro and in vivo models of AD (Study II).
3. To investigate the effect of genetic and dietary manipulation on tau-related changes
in aging mice (Study III).
4. To study the molecular and behavioral effects of nutritional supplements in fish oil-
based diets in the APPswe/PS1dE9 (APdE9) mouse model of AD (Study IV).
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3 Aims of the Study
AD is the leading cause of dementia in the elderly and is listed amongst the top health issues
today, by the WHO. LOAD is a heterogeneous and complex disease, which involves a poorly
understood interplay between a number of genes and environmental factors. Currently, there
is neither a cure nor effective disease-modifying therapies available for this disease. While
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in aging mice (Study III).
4. To study the molecular and behavioral effects of nutritional supplements in fish oil-
based diets in the APPswe/PS1dE9 (APdE9) mouse model of AD (Study IV).
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(Table  4).    For  HEK293-AP-APP cells,  culture  plates  were  coated with poly-D-lysine  (100
µg/ml, PDL; Sigma) before transfections. All transfections were performed using
Lipofectamine 2000-reagent (Invitrogen) in Opti-MEM® I –Reduced serum medium (Gibco)
according to manufacturer’s instructions. Medium was replaced 4 or 24 h later and proteins
were extracted 24 or 48 h after transfections, respectively. Protein samples were analyzed
with Western blot.
Table 4. Secondary cell lines
cell line Description Selection antibiotic Reference
SH-SY5Y-
APP751
Human neuroblastoma cells
stably overexpressing
APP751 isoform
200 µg/ml geneticin
(G418, Gibco)
(Sarajarvi et
al., 2009)
H4-pcDNA-A Human neuroglioma cells
stably overexpressing pcDNA
200 µg/ml geneticin
(G418, Gibco)
(Lu et al.,
2009)
H4-APP751 Human neuroglioma cells
stably overexpressing
APP751 isoform
200 µg/ml geneticin
(G418, Gibco)
(Hiltunen et
al., 2006)
H4-TV1
(clone-13)
Human neuroglioma cells
stably overexpressing TV1 of
human ubiquilin-1 (clone 13)
200 µg/ml geneticin
(G418, Gibco)
(Lu et al.,
2009)
HEK293-AP-
APP
Human embryonic kidney
cells stably overexpressing
APP695 isoform linked to
alkaline phosphatase
0.3µg/ml puromycin and
50µg/ml hygromycin B
(Invitrogen)
(Lichtenthaler
et al., 2003)
BV2 Mouse microglial cells (Gresa-
Arribas et al.,
2012)
4.2.2 Cycloheximide time course assay
Twenty-four  hours  after  transfection,  H4  pcDNA-A  and  H4  TV1-13  cells  transfected  with
5’3’UTR-BACE1 were treated with 30 µg/ml of cycloheximide to halt protein biosynthesis.
To assess protein stability, proteins were extracted at 0, 6, and 12 h time points, subjected to
Western blot and analyzed with BACE1-specific antibody (PA1-757; 1:1000). The half-life of
BACE1 was calculated by quantifying BACE1 protein levels with respect to different
treatment times. BACE1 protein intensities in Western blots at different time points were
normalized to BACE1 levels at 0 h.
4.2.3 Immunofluorescense and microscopy
SH-SY5Y-APP751 cells were plated on PDL-coated glass coverslips and transfected with
5’3’UTR-BACE and myc-TV1 or 5’3’UTR-BACE and pcDNA3.1, to assess subcellular
localization with fluorescent microscopy. Twenty-four h after transfections, cells were fixed
with  4%  PFA  for  15  min  at  room  temperature.  Next,  the  cells  were  permeabilized  in  PBS
containing 0.1% Triton-X100 (Sigma) for 10 min. Non-specific antibody staining was blocked
with PBS containing 1.5% goat IgG (Zymed) for 30 min. Cells were then incubated for 1.5 h
at room temperature with following primary antibodies (Table 7): BACE1 (D10E5; 1:250),
myc (1:100), Rab7 (1:50), TfR (1:200), EEA1 (1:100). This was followed by incubation with
Alexa Fluor488 goat anti-rabbit (1:500; Molecular Probes) and Alexa Fluor594 goat anti-
mouse (1:500; Molecular Probes) secondary antibodies for 1 h. Coverslips were mounted with
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Table 3. cDNA constructs, siRNAs and lentiviral vectors
cDNA construct Description Supplier or original
reference
5’3’UTR-BACE1 Human BACE1 containing endogenous
promoter and 5’- and 3’UTR regulatory
regions
Prof. Stefan Lichtenthaler
5’UTR-BACE1 Human BACE1 containing endogenous
promoter and 5’UTR regulatory region
Prof. Stefan Lichtenthaler
BACE1-myc Human BACE1 under CMV promoter and
containing 3’ myc-tag
TV1 TV1 of human ubiquilin-1 (Lu et al., 2009)
TV1-myc TV1 of human ubiquilin-1 containing
5’myc tag
(Viswanathan et al., 2011)
myc-TV1-mRFP TV1 of human ubiquilin-1 containing
5’myc and 3’mRFP tag
(Viswanathan et al., 2011)
0N4R-tau Human wild type 0N4R-tau GeneCopoeia
mRFP Monomeric red fluorescent protein
EGFP-F Enhanced green fluorescent protein,
farnesylated
Clontech
pcDNA3.1 Empty plasmid cDNA (Lu et al., 2009)
UBQLN1 siRNA Silencer™ Pre-designed siRNA targeted
to exon 5 of the human ubiquilin-1 gene
(GGCGCATGTACACAGATAT)
Ambion
Control siRNA Silencer™ Negative control #1 siRNA Ambion
TV1-HIV-pBOB TV1 of human ubiquilin-1 in lentiviral
vector under CAG-promoter
National Virus Vector
Laboratory, A.I. Virtanen
Institute, University of
Eastern Finland
GFP-HIV-pBOB Green fluorescent protein in lentiviral
vector under CAG-promoter
National Virus Vector
Laboratory, A.I. Virtanen
Institute, University of
Eastern Finland
HIV-pBOB-CAG Empty lentiviral vector and CAG-
promoter without coding insert
National Virus Vector
Laboratory, A.I. Virtanen
Institute, University of
Eastern Finland
4.2 CELL CULTURE EXPERIMENTS
4.2.1 Cell lines and transfections
Secondary cell lines used in study II are listed in Table 4.  The HEK293-AP-APP cell line was
a kind gift from prof. Stefan Lichtenthaler, DZNE, Munich, Germany (Table 4). Cells were
cultured in a humidified cell culture incubator in 5% CO2 atmosphere in Dulbecco’s Modified
Eagle’s  Medium  (DMEM),  supplemented  with  10%  fetal  bovine  serum  (FBS),  2  mM  L-
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and appropriate selective antibiotic
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promoter and 5’UTR regulatory region
Prof. Stefan Lichtenthaler
BACE1-myc Human BACE1 under CMV promoter and
containing 3’ myc-tag
TV1 TV1 of human ubiquilin-1 (Lu et al., 2009)
TV1-myc TV1 of human ubiquilin-1 containing
5’myc tag
(Viswanathan et al., 2011)
myc-TV1-mRFP TV1 of human ubiquilin-1 containing
5’myc and 3’mRFP tag
(Viswanathan et al., 2011)
0N4R-tau Human wild type 0N4R-tau GeneCopoeia
mRFP Monomeric red fluorescent protein
EGFP-F Enhanced green fluorescent protein,
farnesylated
Clontech
pcDNA3.1 Empty plasmid cDNA (Lu et al., 2009)
UBQLN1 siRNA Silencer™ Pre-designed siRNA targeted
to exon 5 of the human ubiquilin-1 gene
(GGCGCATGTACACAGATAT)
Ambion
Control siRNA Silencer™ Negative control #1 siRNA Ambion
TV1-HIV-pBOB TV1 of human ubiquilin-1 in lentiviral
vector under CAG-promoter
National Virus Vector
Laboratory, A.I. Virtanen
Institute, University of
Eastern Finland
GFP-HIV-pBOB Green fluorescent protein in lentiviral
vector under CAG-promoter
National Virus Vector
Laboratory, A.I. Virtanen
Institute, University of
Eastern Finland
HIV-pBOB-CAG Empty lentiviral vector and CAG-
promoter without coding insert
National Virus Vector
Laboratory, A.I. Virtanen
Institute, University of
Eastern Finland
4.2 CELL CULTURE EXPERIMENTS
4.2.1 Cell lines and transfections
Secondary cell lines used in study II are listed in Table 4.  The HEK293-AP-APP cell line was
a kind gift from prof. Stefan Lichtenthaler, DZNE, Munich, Germany (Table 4). Cells were
cultured in a humidified cell culture incubator in 5% CO2 atmosphere in Dulbecco’s Modified
Eagle’s  Medium  (DMEM),  supplemented  with  10%  fetal  bovine  serum  (FBS),  2  mM  L-
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and appropriate selective antibiotic
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dissected in DMEM containing 10% FBS (dissection medium), under the microscope. The
isolated  cortices  were  then  rinsed  with  HC-buffer  [Phosphate  buffered  saline,  PBS,
supplemented  with  1  mg/ml  bovine  serum  albumin  (BSA)  and  10  mM  glucose]  and
extracellular matrices were proteolytically-digested with 0.25% trypsin in DMEM for 20 min
at +37ɃC to yield a suspension of single cells.  The trypsin reaction was terminated with an
equal amount of DMEM containing 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin
(plating medium). Cell suspensions were then centrifuged at 200 x g for 5 min. The resultant
pellets  containing the  cells  were  re-suspended by triturating ~20 times  in  plating medium
and filtered through a 40 µM diameter mesh cell strainer. The cells were further centrifuged
at 150 x g for 5min, then re-suspended into Neurobasal-medium (Gibco), supplemented with
B27 (Gibco), 2 mM L-glutamine and 100 U/ml penicillin and 100 µg/ml streptomycin. Finally
cell numbers were counted with a hemocytometer and plated on 48- or 24-well plates at the
density of 200 000 or 345 000 cells/well, respectively.
On  the  fourth  day in vitro, primary cortical neurons were transduced with lentiviral
particles encoding human UBQLN1 TV1, GFP, or CAG-promoter without coding insert
(Figure 12A). Lentiviral particles were adjusted to a 25 MOI (multiplicity of infection) with
PBS. Next day, the medium containing lentiviruses was replaced. BV2 coculture cells were
carefully scraped in Neurobasal-BV2 medium, counted with hemocytometer and added at
one-to-five ratio (BV2 to neurons) on the neuronal cultures (Gresa-Arribas et al., 2012). Two
hours later, neuroinflammation was induced with the combined treatment 200 ng/ml of
lipopolysaccharide (LPS; Sigma) and 5 ng/ml of interferon-· (IFN-·; Sigma). Samples were
analyzed 48 h later. Evaluation of GFP-transduced samples under a fluorescent microscope
revealed a transduction efficacy of lentiviral particles of approximately 60%.
4.3 HUMAN BRAIN SAMPLES
The human neuropathological sample cohort analyzed in study II included temporal cortex
samples from sixty individuals (18 males and 42 females, mean age 80.6 ± 8.9) who were
examined at the Memory Clinic of the Department of Neurology, Kuopio University Hospital
(Table 5).  Among  these  individuals,  41  were  diagnosed  as  probable  AD  according  to  the
National Institute of Neurological and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria
(McKhann et al., 1984). After death, the subjects were autopsied and evaluated for AD-related
neurofibrillary pathology with immunostaining of paraffin sections with AT8 antibody,
which detects hyperphosphorylated tau (Braak et al., 2006). The subjects were classified
based on the degree of neurofibrillary pathology and divided in three groups according to
Braak staging: Braak stage 0-II (n=28), Braak stage III-IV (n=13), and Braak stage V-VI (n=19)
(Natunen et al., 2013a, Natunen et al., 2013b). Fresh frozen tissue samples from the same cases
were used for RNA and protein analysis. The Ethics Committee of the Kuopio University
Hospital, The Finnish National Supervisory Authority, and The Finnish Ministry of Social
Affairs and Health approved the study.
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Vectashield mounting media containing DAPI (Vector Labs). The stainined cells were then
imaged with a Zeiss Axio Imager using ApoTome.2 at 63 x magnification. Images were then
analyzed and quantified with Zeiss ZEN Module Colocalization analysis hardware.
4.2.4  Preparation of  co-cultures  of  embryonic  mouse primary cortical  neurons with BV2
microglial cells, lentivirus-mediated gene transductions, and experimentally induced
neuroinflammation
JAXC57BL/6J female mice were euthanized by cervical dislocation at the 18th day  of  the
pregnancy.  Pups  at  the  embryonic  day  18  (E18)  were  sacrificed  and  their  cortices  were
Figure 12. Experimental design of study II. A) Illustration of lentivirus-mediated transduction of
ubiquilin-1 TV1 or GFP in embryonic mouse primary cortical neurons on fourth day in vitro (DIV4).
On  DIV5,  the  viral  particles  were  removed  and  mouse  microglial  BV2  cells  were  added  on
neuronal cultures on 1:5 ration (BV2:neurons). Two hours later, neuroinflammation was induced
with 200 ng/ml of lipopolysaccharide (LPS) and 5 ng/ml of interferon-Ǆ (IFN-Ǆ). Samples were
collected for biochemical analyses on the seventh day. B) A schematic presentation of lentivirus-
mediated bilateral injections of TV1 or GFP into the hippocampi of five month old male APdE9
mice. Aǃ plaques start to appear at the age of 3 months. The mice were sacrificed at the age of
9.5 months.
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posterior,  and 2.7  mm ventral  (Bregma coordinates).  The viral  particles  were  injected at  a
speed of 0.2 µl/min by using a Hamilton 10 µl syringe and 28 G needle. Sham-operated mice
were used as controls. Post-operatively, the mice received 5 mg/kg of carprofene (Rimadyl
50  mg/ml)  sub-cutaneously  (s.c.)  and  were  allowed  to  recover  in  a  heated  chamber.  The
animals were then sacrificed at the age of 9.5 months (Figure 12B). Lentiviral particles were
estimated to infect ~20% of neurons of the dentate gyrus of the hippocampus, as judged by
immunohistochemical (IHC) analysis of postmorten fixed brain slices with antibody
specifically detecting human origing ubiquilin-1 (see Chapter 4.5).
4.4.3 Diets and experimental designs
The detailed composition of the experimental diets used in studies III and IV are listed in
Table 6 and the course of each experiment is shown in Figures 13A and B. In study III, the
combined effect of genetic and dietary manipulation was investigated, in both female and
male  mice,  with  four  different  genetic  backgrounds:  wild-type  (AwIw), APdE9 transgenic
(A+Iw), IGF2 transgenic (AwI+), and APdE9xIGF2 triple transgenic (A+I+) mice (Figure 13A)
(Hiltunen et al., 2012). Beginning at the age of five months (females) or eight months (males),
the  mice  were  fed  either  with  standard  laboratory  chow,  containing  5%  (w)  fat  and  no
cholesterol (standard diet, STD; R36; Lactamin, Sweden) or with a chow mimicking typical
Western-type high-fat diet (HFD) containing 21% (w) fat and 0.2% cholesterol (Table 6; n=4-
6 mice/group) (adjusted calories diet; TD 88137; Harlan Tekland, USA). Female mice
underwent a behavioral test battery at the age of 8 months and were sacrificed at nine months
of age (Hiltunen et al., 2012). Male mice went through the same behavioral test battery during
the two last weeks before sacrifice at the age of 12 months (Figure 13A). The weight gain of
all mice was monitored throughout the experiment. In addition, the female mice underwent
glucose and insulin tolerance tests (GTT and ITT, respectively) to assess peripheral metabolic
changes during experimental diet exposure. These tests were performed, and described in
more detail, in a previous study and used only for correlation analyses in study III (Hiltunen
et al., 2012).
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Table 5. Demographics of Neuropathological sample cohort
Neuropathological sample cohort (n=60)
Braak 0-II
(n=28)
Braak III-IV
(n=13)
Braak V-VI
(n=19)
Clinical Status:
control/demented
17/11 2/11 0/19
Age at death,
mean ± SD, (y)
79.2 ± 10.9 82.9 ± 6.8 81.3 ± 7.0
Gender: males/females 14/14 2/11 2/17
PMD, mean ± SD (h) 18.0 ± 19.6 15.8 ± 16.1 7.1 ± 5.0
Brain weight (g) 1250 ± 183 1104 ±156 1040 ± 183
4.4 ANIMAL EXPERIMENTS
4.4.1 Animals
Transgenic APdE9 mice were used as a model for AD in studies II, III and IV. APdE9 mice
overexpress chimeric mouse/human APPswe (mouse App695 harboring  a  humanised  AΆ
domain in conjunction with the “Swedish” familial mutations K959N and M596L) as well as
the human PS1- E9 (deletion  of  exon  9)  gene.  Both  genes  epression  being  controlled  by
independent mouse prion protein promoter elements (Jankowsky et al., 2004). In these mice,
the formation of amyloid plaques in the cortex and hippocampus starts at the age of three
months, proceeding faster in females. Transgenic mice overexpressing the mouse insulin-like
growth factor 2 (IGF2) gene and protein product exclusively in the pancreas were used as a
model for T2DM in the study III (Devedjian et al., 2000). In these mice, the pancreatic Ά-islet
cell hyperplasia leads to insulin overproduction and a subsequent development of resistance
to this hormone (Hiltunen et al., 2012). For the study III, these two mouse lines were crossbred
to create a triple transgenic APdE9xIGF2 mouse line. All mouse lines were backcrossed into
the common C57BL6/J line for at least 10 generations. Age-matched wild-type littermates
were used as controls in studies III and IV. Mice were housed in communal group cages until
behavioral testing began, in a controlled environment (temperature +22ɃC, humidity 50-60%,
lights period 07:00-19:00 h) with fresh food and water available, ad libitum. All animal
procedures  were  carried  out  according  to  the  European  Community  Council  Directives
(Directive 86/609/EEC) and Finnish guidelines, and approved by the Animal Experiment
Board of Finland.
4.4.2 Hippocampal injections of lentiviral vectors
The study design of lentiviral injections conducted in studuy II is shown in the Figure 12B.
Stereotactic injections of lentiviral particles into five-month-old APdE9 male mice
hippocampi  were  conducted  by  Prof.  Heikki  Tanila’s  group  at  the  A.I.V.  Institute  of
University of Eastern Finland.  Briefly, lentiviral vectors containing UBQLN1 TV1 and GFP
genes were adjusted to a titer of 1.28 x 109 in PBS. Mice were anesthetized with halothane
and placed in a stereotactic frame (model 900, David Kopf). UBQLN1 TV1 (n=8) and GFP
(n=8) containing lentiviral preparations in 2 µl volume were bilaterally injected to the dentate
gyrus  of  the  hippocampus  by  using  the  following  coordinates:  ±  3.2  mm  lateral,  2.7  mm
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Figure 13. Experimental designs of studies III and IV. A) The female mice in study III were fed
with high-fat diet (HFD) or standard diet (STD) for four months, starting at the age of five months.
Glucose tolerance (GTT) and insulin tolerance (ITT) tests were performed at the age of six and
seven months, respectively. Additional acute group went through GTT and ITT at the age of four
months. Before sacrifice at the age of nine months, the mice went through behavioral test battery.
Male mice started to receive HFD at the age of 8 months and the diet lasted for four months. The
experimental diets were fed to mice with four different genetic backgrounds. AwIw indicates the
wild-type mice, A+Iw indicates the APdE9 mice, AwI+ mice overexpress IGF2 in the pancreas and
are the model for type 2 diabetes and A+I+ mice have all three transgenes. B) In the study IV,
the female APdE9 mice were fed with special lipid-based diets including fish oil (FO), fish oil and
plant sterols (FOPS) or fish oil and selected nutritional composition called Fortasyn. APdE9 mice
and their wild-type littermates fed with control chow (STD) were used as a control group. Mice
were fed with experimental  diets for  nine months,  beginning at  the age of  five months.  Before
sacrificing at the age of 14 months, the mice went through a behavioral test battery.
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Table 6. Specific percentage composition of experimental diets
Control FO Fortasyn (FOPS) TWD
Carbohydrates
 Corn starch 35.57 35.57 32.78 35.32 15.00
 Casein 14.00 14.00 14.00 14.00 19.50
 Corn dextrin 15.50 15.50 15.50 15.50
 Sucrose 10.00 10.00 10.00 10.00 34.15
 Dextrose 10.00 10.00 10.00 10.00
 Cellulose 5.00
Fibers 5.00 5.00 5.00 5.00
 Mineral mix (AIN-93M-MX) 3.50 3.50 3.50 3.50
 Mineral mix (AIN-76, 170915) 3.50
 Vitamin mix (AIN-93-VX) 1.00 1.00 1.00 1.00 1.00
 Vitamin mix (Tecland 40060)
Fats
 Soy oil 1.90
 Coconut oil 0.90 0.10 0.10 0.10
 Corn oil 2.20 1.87 1.87 1.87
 Fish oil 3.03 3.03 3.03
 SFA (g/100 g fat) 26.54 23.00 23.00 23.00 61.80
 MUFA (g/100 g fat) 21.09 22.51 22.51 22.51 27.05
 PUFA (g/100 g fat) 45.77 44.11 44.11 44.11 4.80
 Ratio n6/n3 20.30 0.98 0.98 0.98 increased
Additions
 L-Cysteine 0.18 0.18 0.18 0.18
 Choline bitartrate (41.1%
choline)
0.25 0.25 0.25 0.25
 Tert-butylhydroquinone 0.0008 000.8 0.0008 0.0008
 Pyridoxine-HCl 0.0033
 Folic acid (90%) 0.0007
 Cyanocobalamin (0.1% in
mannitol)
0.0035
 Ascorbic acid (100% pure) 0.16
DĮ-Tocopheryl acetate
(500 IU/g)
0.47
 UMP disodium (24% H2O) 1.00
 Choline chloride (74.6%) 0.40
 Soy lectin 0.76
 Sodium selenite (46% min) 0.0002
 Stigmasterol (95%) 0.25
 Cholesterol (added) 0.15
 Cholesterol (from fat source) 0.05
 DL-methionine 0.30
 Calcium carbonate 0.40
 Andydrous milk fat 0.004
 Ethoxyquin 21.00
Total 100.0 100.0 100.0 100.0 100.0
Energy (kcal/100 g) 376.9 376.9 365.7 375.9 450.0
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 Corn dextrin 15.50 15.50 15.50 15.50
 Sucrose 10.00 10.00 10.00 10.00 34.15
 Dextrose 10.00 10.00 10.00 10.00
 Cellulose 5.00
Fibers 5.00 5.00 5.00 5.00
 Mineral mix (AIN-93M-MX) 3.50 3.50 3.50 3.50
 Mineral mix (AIN-76, 170915) 3.50
 Vitamin mix (AIN-93-VX) 1.00 1.00 1.00 1.00 1.00
 Vitamin mix (Tecland 40060)
Fats
 Soy oil 1.90
 Coconut oil 0.90 0.10 0.10 0.10
 Corn oil 2.20 1.87 1.87 1.87
 Fish oil 3.03 3.03 3.03
 SFA (g/100 g fat) 26.54 23.00 23.00 23.00 61.80
 MUFA (g/100 g fat) 21.09 22.51 22.51 22.51 27.05
 PUFA (g/100 g fat) 45.77 44.11 44.11 44.11 4.80
 Ratio n6/n3 20.30 0.98 0.98 0.98 increased
Additions
 L-Cysteine 0.18 0.18 0.18 0.18
 Choline bitartrate (41.1%
choline)
0.25 0.25 0.25 0.25
 Tert-butylhydroquinone 0.0008 000.8 0.0008 0.0008
 Pyridoxine-HCl 0.0033
 Folic acid (90%) 0.0007
 Cyanocobalamin (0.1% in
mannitol)
0.0035
 Ascorbic acid (100% pure) 0.16
DĮ-Tocopheryl acetate
(500 IU/g)
0.47
 UMP disodium (24% H2O) 1.00
 Choline chloride (74.6%) 0.40
 Soy lectin 0.76
 Sodium selenite (46% min) 0.0002
 Stigmasterol (95%) 0.25
 Cholesterol (added) 0.15
 Cholesterol (from fat source) 0.05
 DL-methionine 0.30
 Calcium carbonate 0.40
 Andydrous milk fat 0.004
 Ethoxyquin 21.00
Total 100.0 100.0 100.0 100.0 100.0
Energy (kcal/100 g) 376.9 376.9 365.7 375.9 450.0
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4.4.4.4 The Morris swim navigation (water maze) task
The Morris swim navigation task was used to measure spatial learning and memory. Before
the test, mice were familiarized with the water (20±0.5°C) environment and allowed to learn
how  to  find  the  hidden  platform.   The  test  was  performed  in  a  black  plastic  pool,  with  a
diameter of 120 cm. During the first four test days, mice were put through five 60-second
training trials per day with hidden escape platform placed at a constant location, and a
starting point varying between four different locations at the pool rim (South, West, North,
East). A 5 to 10 min recovery period was allowed between the training trials. If the mouse
failed to find the hidden platform within the 60 s, it was placed on it for 10 s before moving
on  to  the  next  animal.  To  assess  the  search  bias,  a  40-s  probe  trial  on  the  fifth  day  was
performed without the platform and the time spent near the former platform location was
measured.  The  escape  latency,  thigmotaxis  (wall-swimming  tendency),  swim  path,  and
swimming  speed  were  recorded  on  each  test  day  with  an  image  analyzer  (HVS,  Image®,
Hampton, UK).
4.4.5 Brain dissections and sample preparation
At the end of the experiments, animals were deeply anesthetized with
pentobarbital/chloralhydrate cocktail (60 mg/kg each) and transcardially perfused with 50 ml
of heparinized 0.9% ice-cold saline (NaCl) (Studies III and IV). One hemisphere was fixed
with in a 4% paraformaldehyde (PFA) containing solution for 4 h before being transferred to
and incubated in a 30% sucrose solution overnight at +4°C. This hemisphere was then stored
in cryoprotectant at -20ɃC for later use in histochemical analyses. The other hemisphere was
dissected on ice into cerebellar, hippocampal, and cortical (frontal, parietal and temporal
cortex) blocks. In addition, in study IV, 37 mice were euthanized by cervical dislocation
without  perfusion.  In  this  case,  the  brain  was  removed  and  rinsed  three  times  in  ice-cold
saline.  The  whole  left  cortex  was  dissected  as  one  block,  while  the  right  hemisphere  was
dissected  to  above  described  blocks.  Dissected  brain  blocks  were  snap  frozen  in  liquid
nitrogen and stored at -70ɃC for biochemical assays. Later, tissue blocks were weighed and
mechanically homogenized in ice-cold PBS (10 volumes of PBS/mg tissue) or the appropriate
analysis specific buffer. The homogenate in PBS was divided into two protein fractions (one
with 1:100 EDTA-free protease and HALT™ phosphatase inhibitor cocktails, and one
without), and a RNA fraction. In addition, the liver was collected and analyzed in studies III
and IV.
4.5 IMMUNOHISTOCHEMISTRY
Immunohistochemical (IHC) analysis of mouse brain sections was conducted by Prof. Heikki
Tanila’s group at the A.I.V. Institute of University of Eastern Finland. Shortly, one PFA-fixed
hemisphere was cut into 35 µm sections with an interval of 200 µm. The sections were pre-
treated  with  +80ɃC  0.05  M  sodium  citrate  solution  (pH  6.0)  for  30  min  before  primary
antibody incubations. The antibodies used for the histology experiments are listed in Table
7. Histological sections were incubated with primary antibodies detecting human Aɴ (pan-
Ά, 1:2000; W02, 1:1000), BACE1 (D10E5, 1:1000), activated micrglia (CD45, 1:2000) and
human ubiquilin-1 (U7258, 1:1000), at room temperature for 18 h on a shaker. Subsequently,
the  sections  were  rinsed  three  times  with  Tris-buffered  saline-Tween  20  (TBS-T)  and
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Experimental diets used in the study IV were isocalorific and differed regarding to their fatty
acid composition and other specific nutrients (Table 6) (all diets based on the standard AIN-
93M) (Reeves et al., 1993). Starting at the age of 5 months, APdE9 female mice were fed with
diets  containing  fish  oil  (FO,  n=17),  fish  oil  and  plant  sterols  (FOPS,  n=16)  or  fish  oil  and
specific nutrient combination providing neuronal membrane precursors and cofactors
[Fortasyn (n=17)], for 10 months (Figure 13B). APdE9 (n=18) and wild-type (n=20) mice fed
with normal laboratory mouse chow (control) were used as controls. All mice went through
a behavioral test battery at the age of 13 months and were sacrificed at the age of 14 months.
To monitor normal growth, the body weight was measured first weekly and then monthly.
4.4.4 Behavioral tests
The  behavioral  tests  mentioned  in  study  III  were  conducted  previously  and  described  in
detail in Hiltunen et al., 2012 (Hiltunen et al., 2012). The behavioral data obtained from this
study was only used for correlation analysis in the study III. In the study IV, the 12 month-
old mice underwent a 3-week neurological test battery, including the following tests in the
described order. A week before the behavioral test sessions, the mice were moved to to
individual cages. All tests were performed during the working hours (between 8 am and 4
pm).
4.4.4.1 Spontaneous explorative activity
Locomotor activity and spontaneous exploratory behavior was monitored in a transparent
test  cage  (length  26  cm,  width  26  cm,  height  39  cm)  fitted  with  automated  infrared
photodetection enabling separate monitoring of horizontal (ambulatory distance) and
vertical  exploratory  activity  (rearing)  (TruScan®,  Coulbourn  Instruments,  CO,  USA).
Recordings were made in two separate sessions, of a 10 minute time duration each, with a 48
h  retention  interval.  The  test  cage  was  cleaned  with  70  %  EtOH  between  each  animal  to
remove odor traces.
4.4.4.2 Marble burying
Marble burying task to study fear of new objects was conducted in the mouse home cage.  In
the afternoon, 1 liter of extra bedding was added on the bottom of the cage and nine glass
marbles (1 cm in diameter) were arranged on it. Next morning (16-18 h later), the number of
visible glass marbles was counted.
4.4.4.3 Odor recognition
This task was used to test olfactory recognition ability of mice and based on specific odors of
individual mice. Before the test, each mouse was allowed to get used to the presence of two
small odorless wooden balls (Step Systems, Lahti, Finland) in its home cage overnight. For
the odor recognition test, each mouse was presented with two wooden balls, one
impregnated with its own odor and one ball from the cage of the selected odor donor mouse.
During the 2 min test session, total time spent sniffing the balls and the number of visits (the
nose pointing to the ball at a distance < 2 cm) to each ball was recorded.
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Table 7. Continues
Antibody and
target epitope
Source
and
clonality
Cat. no Dilutions Supplier
WBa IFb IHCc
p-eIF2Į, Ser51 rbt,P 3597 1:1000 Cell Signaling
Tech.
p-GSK3ǃ, Ser9 rbt,P 1:1000 Cell Signaling
Tech
p-tau (AT8), p-
Ser199,
Ser202/Thr205
ms,M 1:1000 INNX
Rab-7 (B-3) sc-376362 1:50 Santa Cruz
RD3 isoforms ms,M 1:1000 Millipore
RD4 isoforms ms,M 1:1000 Millipore
Tau C-17 goat anti-
rbt,P
1:200 Santa Cruz
TfR ms,M 13-6800 1:1000 1:200 Zymed
Ubiquilin-1 rbt,P U7258 1:500-
1:1000
1:1000 1:1000 Sigma
Ubiquilin-1 rbt,P 1:500 Abcam
Ubiquitin, Lys63 rbt,P 05-1308 1:1000 Millipore
Ubiquitin, Lys48 rbt,P 05-1307 1:1000 Millipore
ǃ-actin ms,M Ab8226 1:1000 Abcam
ǃ-tubulin ms,M MAB3408 1:2000 Millipore
a) Western blot; b) Immunofluorescence; c) Immunohistochemistry
Ms, mouse; Rbt, rabbit; M, monoclonal; P, polyclonal
4.6 BIOCHEMICAL ASSAYS
4.6.1 Custom exon chip analysis of human brain tissue samples
The  RNA  samples  used  in  study  II  for  custom  exon  chip  analysis  were  extracted  and
validated previously (Natunen et al., 2013a). Briefly, RNA was from temporal cortex samples
was performed previously  by using a phenol-chloroform extraction method (21 samples) or
RNeasy Lipid Tissue Mini Kit (39 samples; Qiagen) (Natunen et al., 2013a). The quality of
RNA was determined with 2100 Bioanalyser (Agilent) and categorized according to the RNA
integrity number (RIN) (Martiskainen et al., 2015, Natunen et al., 2013a). The distribution of
RNA samples based on the RIN values was 15.1% (RIN<4), 41.5% (RIN<6), and 43.4%
(RIN<8). The post mortem delay did not correlate with RIN values (Pearson correlation, r=-
0.09, p=0.40) and the RNA quality was not associated with the expression of UBQLN1.
The  expression  microarray  was  performed  by  our  collaborators  at  the  Finnish
Microarray  and  Sequencing  Centre  in  Turku,  Finland.  Briefly,  the  global  expression  of
UBQLN1 analyzed with Agilent One-Color Microarray-Based exon Analysis by using five
probes individually targeted for UBQLN1 exons 2, 4, 6, 9, and 11. One hundred nanograms
of RNA was amplified and labeled with Cy3 using Low Input Quick Amp WT Labeling kit
(Agilent, product number 5190-2943). Samples were processed with the RNA Spike in kit
(Agilent, product number 5188-5282) and concentration of starting material and labeled
complementary RNA (cRNA) was measured by using NanoDrop ND-2000. The RNA and
cRNA quality was determined with Bioanalyzer and a RNA 6000 Nano kit (Agilent, product
number 5067-1511). Cy3-labeled cRNA (600 ng) was hybridized to 8x60K custom exon chip
(Agilent, Design ID 044312) for overnight at +65ɃC using Gene Expression Hybridization kit
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incubated with the appropriate anti primary host antibody secondary antibody (biotinylated
goat anti-mouse or goat anti-rabbit, Vector Laboratories 1:500; AlexaFluor488 goat anti-
rabbit,  1:250;  anti-mouse  IgG  CY3  conjugated  1:400,  Sigma-Aldrich)  for  2  h  at  room
temperature  on  a  shaker.  Sections  were  rinsed  three  times  with  TBS-T,  and  placed  into
StreptAvidin  (GE  Healthcare,  1:000)  solution.  After  rinsing  with  TBS-T,  sections  were
incubated with Nickel-enhanced DAB solution for 3 min. Detection was made with Olympus
BX40 microscope and DP50 camera, with image processing and analysis performed with the
Photoshop CS3 program. The final values were calculated from grayscale images by dividing
the selected area of interest with total hippocampal area.
Table 7. Primary antibodies
Antibody and
target epitope
Source
and
clonality
Cat. no Dilutions Supplier
WBa IFb IHCc
$ǃ1-16 (6E10) ms,M SIG39320 1:1000 BioSite
$ǃ (W02) ms,M MABN10 1:1000 Millipore
Akt rbt,P 1:1000 Cell Signaling
Tech.
APP, CTF rbt,P A8717 1:2000 Sigma
ARF6 (3A-1) ms,M sc-7971 1:1000 Santa Cruz
BACE1 rbt, P PA1-757 1:1000 Pierce
BACE1 (61-
3E7)
ms,M sc-33711 1:100 Santa Cruz
BACE1 (D10E5) rbt,M 5606 1:1000 1:250 1:1000 Cell Signaling
Tech.
CD45 1388 1:2000 Serotec
DAPI 1:5000 Sigma
DHCR24/
seladin-1
rbt,P 2033 1:1000 Cell Signaling
Tech.
EEA1 610456 1:100 BD Transduction
Labratories
eIF2Į rbt,P 9722 1:1000 Cell Signaling
Tech.
GAPDH (6C5) ms,M ab8245 1:
15000
Abcam
GFAP (C-
terminus)
ms,M G3893 1:1000 Sigma
GFP ms,M 118144600 1:1000 Roche
GGA1 rbt,P ab38454 1:100 Abcam
GGA3 ms,M 612310 1:2500 BD Transduction
Labs
GSK3ǃ rbt,P 1:1000 Cell Signaling
Tech
MAP2 m,M M9942 1:2000 Vector Labs
myc, clone 4A6 ms,M 05-724 1:1000 1:200-
1:100
Millipore
Pan-$ǃ 44-136 1:2000 BioSource
p-Akt, Ser473 rbt,P Cell Signaling
Tech.
a) Western blot; b) Immunofluorescence; c) Immunohistochemistry
Ms, mouse; Rbt, rabbit; M, monoclonal; P, polyclonal
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incubated with the appropriate anti primary host antibody secondary antibody (biotinylated
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Ms, mouse; Rbt, rabbit; M, monoclonal; P, polyclonal
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Table 8. Primers and target sequences
Target Primer sequence 5’-3’
Forward Reverse
MAPT
4R/3R
FAM6-TAAGACTCCTCCAGGGTCAG ACTTGGAGGTCACTTTGCTC
MAPT-Seq TAAGTCACCATCAGCTAGTA AGGTCACTTTGCTCAGGTCC
Tra2ǃ TACTCGAAGGCGTCATGTTG ATTCCATTGGCACGTTCTTT
Srsf9
(Srp30c)
TGCTCTGCGTAAACTGGATG AGGGCCTGAAAGGAGAGAAG
Srsf2
(Sc35)
CGAAGCGAGAGTCCAAGTCT GCCACCTGAGGCAGATTAAA
Srsf1
(Sf2/Asf)
CCTTCGTTGAGTTCGAGGAC TTTAAGTCCTGCCAGCTTCC
TnfĮ CGAGTGACAAGCCTGTAGCC GTGGGTGAGGAGCACGTAGT
Il1ǃ TGAGCACCTTCTTTTCCTTCA CGTTGCTTGGTTCTCCTTGT
Gapdh AACTTTGGCATTGTGGAAGG ACACATTGGGGGTAGGAACA
4.6.3 Phospholipid, sterol and hyperoxide (FOX1) assays
Lipid  profiling  of  the  samples  in  study  IV  was  performed  by  our  collaborators  at  the
University of Szeged, Hungary, and the FOX1 assay were done by prof. Rashid Giniatullin’s
group at A.I.V. Institute of University of Eastern Finland, and are described in detail in the
original publication (Koivisto et al., 2014). Briefly, the levels of phosphatidylcholine (PC) and
phosphatidylethanolamine (PE) and their derivatives were determined from the cortices of
saline-perfused mice using reversed-phase contrast liquid chromatography (Kinetex C18)
and mass spectrometry (Waters Q-TOF Premier). Sterols and oxysterols were measured from
both the liver and temporal cortex of non-perfused mice with gas-liquid chromatographic
and mass spectrometric (GC-MS; HP5890 Series II plus gas chromatograph and HP5971 mass
selective detector) analysis. The concentrations of lipid hydroperoxides in the cerebellum and
hippocampus were determined using ferrous ion oxidation in an xylenol orange assay and
by reading sample absorbance at 560 nm (FOX1) (Banerjee et al., 2003, Jiang et al., 1992).
4.6.4 Protein extraction and Western blot
Protein  extraction  from  the  frozen  human  brain  tissue  samples  used  in  study  II  was
conducted previously and described in detail in Natunen et al., 2013b (Natunen et al., 2013b).
Briefly, total proteins were extracted from the organic phase (phenol-ethanol supernatant)
obtained after extraction of DNA (Natunen et al., 2013a, Natunen et al., 2013b). The organic
phase  was incubated with three  volumes of  acetone at  room temperature  for  10  min.  The
protein fraction was then separated by centrifugation at 10000 x g for 10 min. The pellet was
re-suspended for 20 min before being washed two times with wash buffer (0.3 M guanidine
hydrochloride in 1:1 mixture of 95% ethanol and 2.5% glycerol) at room temperature. The
final wash was performed with ethanol, supplemented with 2.5% glycerol. The samples were
centrifuged at 8000 x g for 5 min and the protein pellets were air-dried for 10 min at room
temperature.  Pellets  were  dissolved  in  UREA-CHAPS  [9.5  M  urea  and  2%  3-[(3-
cholamidopropyl)-dimethylammonio]propanesulfonate, pH9.1] by shaking for 15 min.
Total proteins from mouse temporal cortex homogenates (in PBS supplemented with
EDTA-free  protease  and  HALT™  phosphatase  inhibitor  cocktails)  or  cultured  cells  were
extracted by using tissue protein extraction buffer (TPER; Pierce) supplemented with EDTA-
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(Agilent, Product number 5188-5242). The custom probes used in the analysis were designed
and validated with Agilent’s eArray application (Martiskainen et al., 2015). The chips were
washed with Gene Expression Wash Pack (Agilent Product number 5188-5327) washing
buffer and scanned with Agilent Technologies Scanner (model G2565CA). The numerical
data were obtained with Agilent Feature Extraction software (version 10.7.3). The expression
levels of UBQLN1 exons were normalized to the global expression of Ά-actin gene (ACTBL2).
The ACTBL2-normalized UBQLN1 expression in Braak stage 0-II was set to 100%.
4.6.2 mRNA analysis of mouse brain tissue samples
In study III,  RNA was extracted from mouse temporal cortex homogenates (in PBS) using
TRIzol®-Reagent (Invitrogen). One millilitre of TRIzol® was added per 50-100 mg of tissue
homogenate and incubated at room temperature for 5 min. Chloroform was then added in a
one-to-five ratio to tissue homogenate and tubes were shaken vigorously. The mixture was
further incubated at room temperature for 5 min and separated by centrifugation at 12000 x
g for 15 min at +4ɃC. The RNA was precipitated from the aqueous phase using 0.5 ml 2-
propanol per 1 ml of TRIzol®at room temperature for 10 min. The samples were then
centrifuged at 12000 x g for 10 min at +4ɃC and washed twice with 75% ethanol. RNA pellets
were then air-dried, dissolved in RNase-free water and stored at -80ɃC until needed or used
directly.
Complementary DNA was synthesized from equal amount of total RNA each sample
(200ng)  in  a  reaction mixture  including 10  mM dNTP,  1µl  random hexamers,  4µl  1x  First
Strand Buffer, 0.1 M DTT, 40 U/µl Rnase out and 10000 U SuperScript™ III reverse
transcriptase (Invitrogen) in a total volume of 11 µl. One µl of cDNA was used as a template
for 6FAM-fluorescent labeled forward primer (10 pmol/µl) and unlabeled reverse primer (10
pmol/µl; tau 4R/3R, Table 8) (Suh et al., 2010) in a master mix containing 1µl 1x Buffer, 15
mM MgCl2, 10 mM dNTP, 5 U/µl Hot Star Tag (Qiagen) in 10 µl final volume. Samples were
PCR-amplified in two separate runs; 31 PCR cycles were used to amplify 3R-tau and 23 cycles
were used to amplify 4R-tau at the 58ɃC annealing temperature. 3R-tau- and 4R-tau-specific
PCR products were separated with capillary electrophoresis by using a POP-6 denaturing
polymerase and 3100 Genetic Analyzer apparatus (Applied Biosystems). The peak heights
were determined with GeneScan analysis program (Applied Biosystems) and normalized to
the levels of glyceraldehyde 3-phosphatedehydrogenase (Gapdh) from the same samples. To
validate the specificity of PCR products, 3R-tau and 4R-tau fragments were detected with
agarose gel electrophoresis (1.5%). Subsequently, fragments were extracted from agarose gel
using QIAquick Gel Extraction kit (Qiagen). Extracted fragments were re-amplified with tau-
specific primers flanking exon 10 (tau-Seq, Table 8)  and  sequenced  with  3100  Genetic
Analyzer. The data was then analyzed with the Sequence Analyzer program (Applied
Biosystems). RNA extracted from the cortex of E18 mouse was used as a positive control for
3R-tau  fragment  in  the  analysis.  Specific  primers  were  designed  to  analyze  the  levels  of
housekeeping gene Gapdh, serine/arginine-rich splicing factors, Srsf10/Tra2Ά, Srsf9 (SRp30c),
Srsf2 (SC35), Srsf1 (SF2/ASF), and inflammatory cytokines, tumor necrosis factor ΅  (Tnf΅) and
interleukin 1Ά (Il1Ά) (Table 8) with SYBR Green Master PCR Mix (Applied Biosystems) and
real-time quantitative PCR (7500 Fast Real Time PCR System, Applied Biosystems). All target
mRNA levels were normalized to those of Gapdh from the same samples.
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Table 8. Primers and target sequences
Target Primer sequence 5’-3’
Forward Reverse
MAPT
4R/3R
FAM6-TAAGACTCCTCCAGGGTCAG ACTTGGAGGTCACTTTGCTC
MAPT-Seq TAAGTCACCATCAGCTAGTA AGGTCACTTTGCTCAGGTCC
Tra2ǃ TACTCGAAGGCGTCATGTTG ATTCCATTGGCACGTTCTTT
Srsf9
(Srp30c)
TGCTCTGCGTAAACTGGATG AGGGCCTGAAAGGAGAGAAG
Srsf2
(Sc35)
CGAAGCGAGAGTCCAAGTCT GCCACCTGAGGCAGATTAAA
Srsf1
(Sf2/Asf)
CCTTCGTTGAGTTCGAGGAC TTTAAGTCCTGCCAGCTTCC
TnfĮ CGAGTGACAAGCCTGTAGCC GTGGGTGAGGAGCACGTAGT
Il1ǃ TGAGCACCTTCTTTTCCTTCA CGTTGCTTGGTTCTCCTTGT
Gapdh AACTTTGGCATTGTGGAAGG ACACATTGGGGGTAGGAACA
4.6.3 Phospholipid, sterol and hyperoxide (FOX1) assays
Lipid  profiling  of  the  samples  in  study  IV  was  performed  by  our  collaborators  at  the
University of Szeged, Hungary, and the FOX1 assay were done by prof. Rashid Giniatullin’s
group at A.I.V. Institute of University of Eastern Finland, and are described in detail in the
original publication (Koivisto et al., 2014). Briefly, the levels of phosphatidylcholine (PC) and
phosphatidylethanolamine (PE) and their derivatives were determined from the cortices of
saline-perfused mice using reversed-phase contrast liquid chromatography (Kinetex C18)
and mass spectrometry (Waters Q-TOF Premier). Sterols and oxysterols were measured from
both the liver and temporal cortex of non-perfused mice with gas-liquid chromatographic
and mass spectrometric (GC-MS; HP5890 Series II plus gas chromatograph and HP5971 mass
selective detector) analysis. The concentrations of lipid hydroperoxides in the cerebellum and
hippocampus were determined using ferrous ion oxidation in an xylenol orange assay and
by reading sample absorbance at 560 nm (FOX1) (Banerjee et al., 2003, Jiang et al., 1992).
4.6.4 Protein extraction and Western blot
Protein  extraction  from  the  frozen  human  brain  tissue  samples  used  in  study  II  was
conducted previously and described in detail in Natunen et al., 2013b (Natunen et al., 2013b).
Briefly, total proteins were extracted from the organic phase (phenol-ethanol supernatant)
obtained after extraction of DNA (Natunen et al., 2013a, Natunen et al., 2013b). The organic
phase  was incubated with three  volumes of  acetone at  room temperature  for  10  min.  The
protein fraction was then separated by centrifugation at 10000 x g for 10 min. The pellet was
re-suspended for 20 min before being washed two times with wash buffer (0.3 M guanidine
hydrochloride in 1:1 mixture of 95% ethanol and 2.5% glycerol) at room temperature. The
final wash was performed with ethanol, supplemented with 2.5% glycerol. The samples were
centrifuged at 8000 x g for 5 min and the protein pellets were air-dried for 10 min at room
temperature.  Pellets  were  dissolved  in  UREA-CHAPS  [9.5  M  urea  and  2%  3-[(3-
cholamidopropyl)-dimethylammonio]propanesulfonate, pH9.1] by shaking for 15 min.
Total proteins from mouse temporal cortex homogenates (in PBS supplemented with
EDTA-free  protease  and  HALT™  phosphatase  inhibitor  cocktails)  or  cultured  cells  were
extracted by using tissue protein extraction buffer (TPER; Pierce) supplemented with EDTA-
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(Agilent, Product number 5188-5242). The custom probes used in the analysis were designed
and validated with Agilent’s eArray application (Martiskainen et al., 2015). The chips were
washed with Gene Expression Wash Pack (Agilent Product number 5188-5327) washing
buffer and scanned with Agilent Technologies Scanner (model G2565CA). The numerical
data were obtained with Agilent Feature Extraction software (version 10.7.3). The expression
levels of UBQLN1 exons were normalized to the global expression of Ά-actin gene (ACTBL2).
The ACTBL2-normalized UBQLN1 expression in Braak stage 0-II was set to 100%.
4.6.2 mRNA analysis of mouse brain tissue samples
In study III,  RNA was extracted from mouse temporal cortex homogenates (in PBS) using
TRIzol®-Reagent (Invitrogen). One millilitre of TRIzol® was added per 50-100 mg of tissue
homogenate and incubated at room temperature for 5 min. Chloroform was then added in a
one-to-five ratio to tissue homogenate and tubes were shaken vigorously. The mixture was
further incubated at room temperature for 5 min and separated by centrifugation at 12000 x
g for 15 min at +4ɃC. The RNA was precipitated from the aqueous phase using 0.5 ml 2-
propanol per 1 ml of TRIzol®at room temperature for 10 min. The samples were then
centrifuged at 12000 x g for 10 min at +4ɃC and washed twice with 75% ethanol. RNA pellets
were then air-dried, dissolved in RNase-free water and stored at -80ɃC until needed or used
directly.
Complementary DNA was synthesized from equal amount of total RNA each sample
(200ng)  in  a  reaction mixture  including 10  mM dNTP,  1µl  random hexamers,  4µl  1x  First
Strand Buffer, 0.1 M DTT, 40 U/µl Rnase out and 10000 U SuperScript™ III reverse
transcriptase (Invitrogen) in a total volume of 11 µl. One µl of cDNA was used as a template
for 6FAM-fluorescent labeled forward primer (10 pmol/µl) and unlabeled reverse primer (10
pmol/µl; tau 4R/3R, Table 8) (Suh et al., 2010) in a master mix containing 1µl 1x Buffer, 15
mM MgCl2, 10 mM dNTP, 5 U/µl Hot Star Tag (Qiagen) in 10 µl final volume. Samples were
PCR-amplified in two separate runs; 31 PCR cycles were used to amplify 3R-tau and 23 cycles
were used to amplify 4R-tau at the 58ɃC annealing temperature. 3R-tau- and 4R-tau-specific
PCR products were separated with capillary electrophoresis by using a POP-6 denaturing
polymerase and 3100 Genetic Analyzer apparatus (Applied Biosystems). The peak heights
were determined with GeneScan analysis program (Applied Biosystems) and normalized to
the levels of glyceraldehyde 3-phosphatedehydrogenase (Gapdh) from the same samples. To
validate the specificity of PCR products, 3R-tau and 4R-tau fragments were detected with
agarose gel electrophoresis (1.5%). Subsequently, fragments were extracted from agarose gel
using QIAquick Gel Extraction kit (Qiagen). Extracted fragments were re-amplified with tau-
specific primers flanking exon 10 (tau-Seq, Table 8)  and  sequenced  with  3100  Genetic
Analyzer. The data was then analyzed with the Sequence Analyzer program (Applied
Biosystems). RNA extracted from the cortex of E18 mouse was used as a positive control for
3R-tau  fragment  in  the  analysis.  Specific  primers  were  designed  to  analyze  the  levels  of
housekeeping gene Gapdh, serine/arginine-rich splicing factors, Srsf10/Tra2Ά, Srsf9 (SRp30c),
Srsf2 (SC35), Srsf1 (SF2/ASF), and inflammatory cytokines, tumor necrosis factor ΅  (Tnf΅) and
interleukin 1Ά (Il1Ά) (Table 8) with SYBR Green Master PCR Mix (Applied Biosystems) and
real-time quantitative PCR (7500 Fast Real Time PCR System, Applied Biosystems). All target
mRNA levels were normalized to those of Gapdh from the same samples.
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and centrifuged at 10000 x g for 10 s. AΆ x-40 and AΆ x-42 levels were measured from soluble
and insoluble fractions by using Human/Rat Ά Amyloid x-40 and Human/Rat Ά Amyloid x-
42 ELISA kits (Wako or Biosource International). Reactions were terminated after a 30-min
incubation at room temperature and absorbance was measured at wavelength 450 nm using
an ELISA microplate reader (BioRad). AΆ levels were normalized to total protein
concentrations and APP levels in the same samples.
4.6.7 Ά- and ·-secretase activity assays
In study IV, Ά- and ·-secretase activities were determined from the left cortex homogenates
by the collaborators at the University of Saarland, Germany, with a protocol described in the
original publication (Koivisto et al., 2014). In study II, 1.5 µg of hippocampal homogenates in
PBS were incubated with 150 mM Ά-secretase-specific substrate conjugated to fluorescent
reporter  molecules  EDANS  and  DABCYL,  for  1  h  at  +37ɃC.  The  Ά-secretase  activity  was
inhibited from randomly selected samples with 150 mM GL186 (H-VENstatineVAEF_NH2,
Calbiochem) to control the specificity of the assay. Emitted light was detected at the
wavelength,  510  nm  after  excitation  at  355  nm  with  a  fluorescence  microplate  reader.
Readings obtained from substrate alone (no secretases) were subtracted from the sample
values.
4.6.8 Extracellular tau measurement
Extracellular  tau  levels  were  measured  from  mouse  primary  neuron  –  microglial  cell  co-
culture  medium  by  using  the  mouse  tau  ELISA  kit  (Invitrogen)  performed  according  to
manufacturer’s  instructions.  The  reactions  were  terminated  after  30  min  incubation  and
absorbance was measured at the 450 nm wavelength with ELISA microplate reader (BioRad).
Extracellular tau levels were normalized to the total protein concentration and neuronal
viability in each sample.
4.6.9 TNF΅ and IL1Ά measurements
Mouse temporal cortical tissue homogenates without inhibitors (Study III) were centrifuged
at 100000 x g for 45 min at +4ɃC (Optima L-90K Ultracentrifuge, Beckman) to separate soluble
and  insoluble  proteins.  TNF΅ and  IL1Ά levels  were  measured  from  soluble  supernatant
fraction by using mouse TNF΅ (Ready-Set-Go!, eBioscience) and mouse IL1Ά (Abcam) ELISA
kits. Reactions were terminated after a 30 min incubation and absorbance was measured at
wavelength 450 nm with an ELISA microplate reader. TNF΅ levels were measured from the
medium (150 µl) of mouse primary neuron and BV2 microglial cell co-cultures, as described
above (study II). TNF΅ and IL1Ά levels were normalized to the total protein concentrations
from the same samples.
4.6.10 Neuronal viability
Mouse primary cortical neuron and BV2 microglial cell co-cultures were fixed in 4%
paraformaldehyde (PFA) solution for 20 min at room temperature, rinsed twice with PBS and
permeabilized with a solution containing methanol as well as 0.3% H2O2 for  10  min.  Non-
specific  antibody  staining  was  prevented  with  immersing  the  samples  in  blocking  buffer
(PBS, 1% BSA, 10% horse serum) for 20 min at room temperature. Cells were then incubated
with neuron-specific MAP2 primary antibody (1:2000 in blocking buffer, Table 8) overnight
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free protease and HALT™ phosphatase inhibitor cocktails, as follows. One volume of TPER
was added to mouse tissue homogenates and incubated on ice for 30 min to allow cell lysis.
Cells in culture were washed twice with PBS on ice and scraped into TPER. After a 30-min
incubation, mouse brain tissue samples and cells were centrifuged at 10000 x g, for 10 min, at
+4ɃC to separate the total protein fraction.
Total protein concentrations were measured with the BCA protein assay kit (Pierce),
according to manufacturer’s instructions. Ten to fifty µg of denatured protein lysates in
NuPAGE  LDS  sample  buffer  (Invitrogen)  containing  20%  Ά-mercapto-ethanol,  were
subjected to 4-12% Bis-Tris polyacrylamide gel electrophoresis (Invitrogen) and transferred
onto polyvinylidene difluoride membranes (Amersham Hybond-P, GE Healthcare). Non-
specific antibody staining was prevented with preincubation of the membranes with
solutions containing 5% of either non-fat milk powder or BSA. Membranes were incubated
with primary antibodies overnight at +4ɃC (Table 7). Next day, membranes were washed and
incubated with anti-mouse, anti-rabbit or goat anti-rabbit horseradish peroxidase (HRP)-
conjugated secondary antibody for 1 h at room temperature. Protein bands were detected
using enhanced chemiluminescence substrates (ECL, Amersham, GE Healthcare) and an
ImageQuant RT ECL camera (GE Healthcare).  Protein band intensities were quantified by
using Quantity One (BioRad) software and normalized to those of GAPDH or Ά-actin in the
same samples.
4.6.5 Immunoprecipitation
Tissue homogenates of UBQLN1 TV1- and GFP-injected mouse hippocampi were adjusted to
20 µg with immunoprecipitation (IP) buffer (50 mM Tris pH 8.0, 150 mM NaCl, 2 mM EDTA,
0.5%  Igepal)  containing  Complete  Mini  EDTA-free  protease  inhibitor  (Roche)  in  a  final
volume of 500 µl. Protein samples were incubated with Protein A/G Agarose beads (Pierce)
without  antibody  for  1  h  on  a  rotating  wheel  to  remove  unspecifically  binding  proteins.
Samples were centrifuged at 8000 x  g for  1  min  at  4ɃC.  Pre-cleared  supernatants  were
immunoprecipitated with 2.5 µl of anti-APP (A8717) antibody for 1 h at +4°C on a rotating
wheel. Fresh A/G Agarose beads were added to the samples and rotated overnight at +4ɃC,
to pull down the protein-antibody complexes. The beads were harvested by centrifugation
for 1 min at 8000 x g at 4ɃC, and washed four times with IP buffer. Precipitated proteins were
detached  by  heating  at  55ɃC  for  10  min  in  NuPAGE  LDS  sample  buffer  containing  5%  Ά-
mercaptoethanol. The samples were then centrifuged at 13000 x  g for  15  min  and  the
supernatants were analysed with Western blot. Samples without antibody (beads only) were
used  as  a  negative  control  and  a  sample  with  a  rabbit  polyclonal  antibody  known  not  to
interact with APP was used as a control for specificity of the assay.
4.6.6 AΆ measurement
Mouse brain homogenates from the hippocampus (study II) or temporal cortex (study IV),
were used for AΆ measurements.  In study IV, AΆ levels were determined by Prof. Heikki
Tanila’s  group  at  the  A.I.V.  Institute  at  the  University  of  Eastern  Finland  with  a  protocol
described in detail in the original publication (Koivisto et al., 2014). In study II, omogenates
in PBS were centrifuged at 100000 x  g for 2 h at +4ɃC (Optima L-90K Ultracentrifuge,
Beckman) to obtain soluble and insoluble fractions. Insoluble pellets were solubilized in 5M
guanidine-HCl, including 50 mM Tris-HCl, pH 8.0 by vortexing for 3 h at room temperature
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and centrifuged at 10000 x g for 10 s. AΆ x-40 and AΆ x-42 levels were measured from soluble
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incubation at room temperature and absorbance was measured at wavelength 450 nm using
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concentrations and APP levels in the same samples.
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In study IV, Ά- and ·-secretase activities were determined from the left cortex homogenates
by the collaborators at the University of Saarland, Germany, with a protocol described in the
original publication (Koivisto et al., 2014). In study II, 1.5 µg of hippocampal homogenates in
PBS were incubated with 150 mM Ά-secretase-specific substrate conjugated to fluorescent
reporter  molecules  EDANS  and  DABCYL,  for  1  h  at  +37ɃC.  The  Ά-secretase  activity  was
inhibited from randomly selected samples with 150 mM GL186 (H-VENstatineVAEF_NH2,
Calbiochem) to control the specificity of the assay. Emitted light was detected at the
wavelength,  510  nm  after  excitation  at  355  nm  with  a  fluorescence  microplate  reader.
Readings obtained from substrate alone (no secretases) were subtracted from the sample
values.
4.6.8 Extracellular tau measurement
Extracellular  tau  levels  were  measured  from  mouse  primary  neuron  –  microglial  cell  co-
culture  medium  by  using  the  mouse  tau  ELISA  kit  (Invitrogen)  performed  according  to
manufacturer’s  instructions.  The  reactions  were  terminated  after  30  min  incubation  and
absorbance was measured at the 450 nm wavelength with ELISA microplate reader (BioRad).
Extracellular tau levels were normalized to the total protein concentration and neuronal
viability in each sample.
4.6.9 TNF΅ and IL1Ά measurements
Mouse temporal cortical tissue homogenates without inhibitors (Study III) were centrifuged
at 100000 x g for 45 min at +4ɃC (Optima L-90K Ultracentrifuge, Beckman) to separate soluble
and  insoluble  proteins.  TNF΅ and  IL1Ά levels  were  measured  from  soluble  supernatant
fraction by using mouse TNF΅ (Ready-Set-Go!, eBioscience) and mouse IL1Ά (Abcam) ELISA
kits. Reactions were terminated after a 30 min incubation and absorbance was measured at
wavelength 450 nm with an ELISA microplate reader. TNF΅ levels were measured from the
medium (150 µl) of mouse primary neuron and BV2 microglial cell co-cultures, as described
above (study II). TNF΅ and IL1Ά levels were normalized to the total protein concentrations
from the same samples.
4.6.10 Neuronal viability
Mouse primary cortical neuron and BV2 microglial cell co-cultures were fixed in 4%
paraformaldehyde (PFA) solution for 20 min at room temperature, rinsed twice with PBS and
permeabilized with a solution containing methanol as well as 0.3% H2O2 for  10  min.  Non-
specific  antibody  staining  was  prevented  with  immersing  the  samples  in  blocking  buffer
(PBS, 1% BSA, 10% horse serum) for 20 min at room temperature. Cells were then incubated
with neuron-specific MAP2 primary antibody (1:2000 in blocking buffer, Table 8) overnight
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free protease and HALT™ phosphatase inhibitor cocktails, as follows. One volume of TPER
was added to mouse tissue homogenates and incubated on ice for 30 min to allow cell lysis.
Cells in culture were washed twice with PBS on ice and scraped into TPER. After a 30-min
incubation, mouse brain tissue samples and cells were centrifuged at 10000 x g, for 10 min, at
+4ɃC to separate the total protein fraction.
Total protein concentrations were measured with the BCA protein assay kit (Pierce),
according to manufacturer’s instructions. Ten to fifty µg of denatured protein lysates in
NuPAGE  LDS  sample  buffer  (Invitrogen)  containing  20%  Ά-mercapto-ethanol,  were
subjected to 4-12% Bis-Tris polyacrylamide gel electrophoresis (Invitrogen) and transferred
onto polyvinylidene difluoride membranes (Amersham Hybond-P, GE Healthcare). Non-
specific antibody staining was prevented with preincubation of the membranes with
solutions containing 5% of either non-fat milk powder or BSA. Membranes were incubated
with primary antibodies overnight at +4ɃC (Table 7). Next day, membranes were washed and
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conjugated secondary antibody for 1 h at room temperature. Protein bands were detected
using enhanced chemiluminescence substrates (ECL, Amersham, GE Healthcare) and an
ImageQuant RT ECL camera (GE Healthcare).  Protein band intensities were quantified by
using Quantity One (BioRad) software and normalized to those of GAPDH or Ά-actin in the
same samples.
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Tissue homogenates of UBQLN1 TV1- and GFP-injected mouse hippocampi were adjusted to
20 µg with immunoprecipitation (IP) buffer (50 mM Tris pH 8.0, 150 mM NaCl, 2 mM EDTA,
0.5%  Igepal)  containing  Complete  Mini  EDTA-free  protease  inhibitor  (Roche)  in  a  final
volume of 500 µl. Protein samples were incubated with Protein A/G Agarose beads (Pierce)
without  antibody  for  1  h  on  a  rotating  wheel  to  remove  unspecifically  binding  proteins.
Samples were centrifuged at 8000 x  g for  1  min  at  4ɃC.  Pre-cleared  supernatants  were
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to pull down the protein-antibody complexes. The beads were harvested by centrifugation
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interact with APP was used as a control for specificity of the assay.
4.6.6 AΆ measurement
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were used for AΆ measurements.  In study IV, AΆ levels were determined by Prof. Heikki
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described in detail in the original publication (Koivisto et al., 2014). In study II, omogenates
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5 Results
5.1  INFLUENCE  OF  UBIQUILIN-1  ON  DIFFERENT  ASPECTS  OF
ALZHEIMER’S DISEASE PATHOGENESIS: STUDIES I AND II
Cell stress and impairment of certain basic cellular functions, such as protein trafficking and
quality control systems, have been implicated to play a role in early AD pathogenesis (Ross
and Poirier, 2004) (Wang et al., 2014). Ubiquilin-1 is a protein which has been shown to regulate
the trafficking, accumulation and clearance of several AD-associated proteins as well as
alleviate cellular stress conditions (Haapasalo et al., 2010) (El Ayadi et al., 2012b) (Hiltunen et al.,
2006, Ko et al., 2002, Liu et al., 2014, Lu et al., 2009). Study I aimed to review the function of
ubiquilin-1 and discuss its potential as a therapeutic target in AD. In study II, the goal was
to investigate how ubiquilin-1 affects different aspects of AD-related pathological pathways
in human brain and in experimental cell and mouse models of AD.
5.1.1. Ubiquilin-1 expression is decreased, with respect to the severity of neurofibrillary
pathology, in the human brain.
Data regarding ubiquilin-1 in human brain and in mammalian animal models is scarce. In
study II, the expression of ubiquilin-1 was first investigated in post mortem human  brain
samples, in relation to AD-related neurofibrillary tangle pathology (Braak et al., 2006). For
expression analysis, sixty previously characterized (Martiskainen et al., 2015, Natunen et al.,
2013a, Natunen et al., 2013b) human temporal cortex samples were divided into three groups:
Braak stage 0-II (n=28), Braak stage II-IV (n=13), and Braak stage V-VI (n=19). Expression of
individual UBQLN1 exons (exons 4, 6, 9, and 11) was assessed, after being normalized to the
global expression of the ACTBL2 gene. The analysis revealed a global decrease in UBQLN1
mRNA expression in relation to advancing neurofibrillary pathology. Overall, the highest
UBQLN1 expression was observed in Braak stage 0.  The expression of exons 4, 6, and 9 were
significantly (p<0.05) lower in Braak stage III-IV, as compared to Braak stage 0-II, whereas
expression of exon 11 was significantly (p<0.05) lower in Braak stage V-VI than in Braak stage
0-II. Furthermore, a similar, although not statistically significant, decrease in ubiquilin-1
protein levels was observed in Braak stages III-IV (n=7) and V-VI (n=7), as compared to Braak
stage 0-II (n=10). These data are in line with a previous study showing that ubiquilin-1 levels
are decreased in AD brain as compared to age-matched controls (Stieren et al., 2011). Since
previous reports suggest that ubiquilin-1 may modulate APP processing in vitro and in vivo
(Hiltunen et al., 2006, Stieren et al., 2011, Zhang et al., 2007) (El  Ayadi  et  al.,  2012b), the
association between ubiquilin-1 levels and the levels of key proteins in APP processing was
next assessed. As a result, a trend of positive correlation between the protein levels of
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at +4ɃC (Gresa-Arribas et al., 2012). The next day, cells were washed three times with PBS and
stained with biotinylated horse anti-mouse secondary antibody (1:500 in blocking buffer;
Vector Labs) for 1 h at room temperature. This was followed by three washes with PBS and
incubation  with  ExtrAvidin-HRP  (1:500  in  blocking  buffer;  Sigma)  for  1  h  at  room
temperature. To develop the color, cells were incubated with ABTS peroxidase substrate
(Vector Labs) in the dark, for 30 min. Wavelength 405 nM absorbances were measured on a
fresh 96-well plate with an ELISA microplate reader (BioRad).
4.7 STATISTICAL ANALYSES
Microarray analysis of the neuropathological sample cohort was carried out with R statistical
software  (version  3.0.1)  and  Bioconductor  (version  2.13),  and  is  described,  at  length,  in
Martiskainen et al., 2015 (Martiskainen et al., 2015). The expression analysis of UBQLN1 was
performed using a Kruskal-Wallis test (for data which is not normally distributed). Statistical
analysis of functional studies were carried out using specific tests contained within either
GraphPad Prism or SPSS software (version 21.0). Analysis of variance (ANOVA), followed
by the appropriate post-hoc test, was used in experiments with more than one variable. In
experiments with only one variable, an independent sample’s t-test (equal variance assumed)
or Mann-Whitney U test (equal variance not assumed) was used to test the statistical
significance between sample groups. Pearson’s two-tailed correlation analysis or Spearman’s
correlation coefficient’s were used to analyze bivariate correlations between parameters of
interest.  All  results  are  reported  as  means  ±  standard  deviation  (SD)  or  standard  error  of
mean (SEM). The level of statistical significance was defined as p<0.05.
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5 Results
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Ubiquilin-1 has previously been shown to co-localize in NFTs in AD brain (Mah et al., 2000),
but the interrelationship tau and ubiquilin-1 has not been further investigated. Therefore the
effect of ubiquilin-1 overexpression under neuroinflammation on tau phosphorylation, total
tau protein levels, and tau secretion was also assessed. Ubiquilin-1 overexpression, per se, did
not exert major effects on tau phosphorylation, protein levels or secretion in this in vitro
model. However, total protein levels of the 0N3R-tau isoform were significantly increased by
the  LPS  +  IFN-· treatment  in  ubiquilin-1  overexpressing  cells,  but  not  in  control  cells,
suggesting that ubiquilin-1 may modulate tau levels under inflammatory conditions (p<0.01,
n>9). Tau phosphorylation has previously been shown to be increased after LPS treatment in
vivo (Kitazawa  et  al.,  2005,  Nikkel  et  al.,  2012),  but,  here,  no  significant  alterations  in  tau
phosphorylation were detected at AD-related epitopes (AT8) in co-cultures by LPS + IFN-·-
treatment or ubiquilin-1 overexpression. Despite this, since the results implied that there
might  exist  a  relationship  between  ubiquilin-1  and  tau,  the  effect  of  ubiquilin-1
overexpression on the predominant adult 0N4R-tau isoform was evaluated in the HEK293-
AP-APP cell line. In these cells, myc-TV1-mRFP overexpression induced a significant
increase in the phosphorylation (AT8, p<0.01, n=8) and total protein levels (p<0.05, n=8) of
co-overexpressed 0N4R-tau as compared to cells co-overexpressing control plasmid (mRFP)
and 0N4R-tau. Therefore, further studies are needed to assess the detailed mechanism of the
potential interaction between tau and ubiquilin-1.
5.1.3 Ubiquilin-1 overexpression moderately increases BACE1 levels and activity in adult
APdE9 mice hippocampi
Next, human UBQLN1 TV1-containing lentiviruses were bilaterally injected into hippocampi
of five-month old male mice (n=7) to study the effect of ubiquilin-1 overexpression in vivo in
the  APdE9  mouse  model  of  AD.  Sham-operated  mice  (n=8)  and  mice  injected  with  GFP-
containing  lentiviruses  (n=8)  were  used  as  controls.  Western  blot  analysis  and  IHC
assessment showed cleared ubiquilin-1 protein expression in the granular cells of the dentate
gyrus of hippocampus of TV1-injected mice eight weeks (a pilot study) and 4.5 months after
the injection. In contrast, ubiquilin-1 staining was detected neither in GFP-injected mice nor
in the cortex of ubiquilin-1 TV1-lentiviral injected mice, suggesting that ubiquilin-1
overexpression was successfully induced and that its expression was restricted to
hippocampal area.
The effect of ubiquilin-1 overexpression on BACE1 levels and activity in APdE9 mice
brain was next addressed. Here, BACE1 protein levels and Ά-secretase activity were mildly,
but  consistently  increased  in  the  hippocampi  of  TV1-injected  mice  as  compared  to  GFP-
injected mice. This did not, however, reach statistical significance. BACE1 and ubiquilin-1
were  partially  co-localized  in  the  cells  of  dentate  gyrus,  although  their  subcellular
localization was different as BACE1 was mostly localized in puncate structures, which did
not include ubiquilin-1. Strong BACE1 staining was also observed around AΆ plaques and
this  was  not  changed  due  to  ubiquilin-1  overexpression.  The  Ά-secretase  activity  was
significantly correlated with soluble AΆ40 and AΆ42 levels in the hippocampi of APdE9 mice
(p<0.001). Ubiquilin-1 has previously been shown to alter APP maturation, trafficking,
processing, and degradation in cultured cells (El Ayadi et al., 2012a, Hiltunen et al., 2006,
Stieren et al., 2011, Viswanathan et al., 2011, Viswanathan et al., 2013, Zhang et al., 2007). In
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role of ubiquilin-1 during AD-associated neuroinflammation has not been investigated
(Heneka et al., 2015). To delineate the effect of ubiquilin-1 overexpression on different aspects
of AD-pathology under neuroinflammation, primary neuron cultures from embryonic stage
18 mouse cortices were prepared. Lentivirus-mediated transductions with the full-length
human UBQLN1 TV1  cDNA  or  control  lentivirus,  which  lacks  the  coding  insert,  were
performed on DIV4. A day later, BV2 microglial cells were added to the neuronal cultures
and  co-cultures  were  treated  with  LPS  (200ng/ml)  +  IFN-· (5ng/ml)  for  48  h  to  induce
neuroinflammation (Figure 10A). First, the amount of secreted TNF΅ was analyzed from the
medium, to evaluate the extent of neuroinflammation. TNF΅ levels were significantly
increased after LPS + IFN-·-treatment as compared to vehicle treated samples (p<0.0001,
n=15).  In  spite  of  an  evident  inflammatory  response,  neuronal  viability  was  only  slightly
compromised after LPS + IFN-· treatment. Western blot analysis revealed that protein levels
of human ubiquilin-1 were approximately ~3.5 (in vehicle treated samples, p<0.01, n=3-4) to
5 (in LPS + IFN-· treated samples, p<0.01, n=3-4) fold increased in cell transduced with the
TV1 of human UBQLN1 gene as compared cells transduced with control virus. Interestingly,
overexpressed human ubiquilin-1 levels were also significantly higher in LPS + IFN-·-treated
samples than in vehicle-treated samples, suggesting that UBQLN1 expression  might  be
upregulated during neuroinflammation (p<0.05). However, a similar increase in ubiquilin-1
protein levels was not observed in endogenously expressed mouse Ubqln1 gene.  A slight,
approximately 30%, increase in TNF΅ levels in the medium of LPS + IFN-· treated samples
was observed upon ubiquilin-1 overexpression, although the difference to control virus was
not statistically significant. Surprisingly, ubiquilin-1 overexpression significantly decreased
neuronal viability in both vehicle-treated and LPS + IFN-·-treated cultures as compared to
control virus (LPS + IFN-·-treated, p<0.05; vehicle-treated, p<0.0001, n>10). To address the
possible mechanism, by which ubiquilin-1 might affect neuronal survival, the activation of
Akt signaling pathway, which is known to affect neuronal survival, was next assessed in co-
cultures. Akt phosphorylation (p-Ser473) was significantly increased after LPS + IFN-·-
treatment regardless of the transduction (p<0.05, n=3-4), suggesting that LPS + IFN-·-induced
neuroinflammation increases Akt signaling. However, there were no significant differences
upon ubiquilin-1 overexpression in the phosphorylation status of Akt, suggesting that
compromised neuronal viability is not mediated by altered activity of the Akt signaling
pathway. Together, the data suggest that ubiquilin-1 does not have a major influence on the
level of neuroinflammation, but ubiquilin-1 overexpression itself appears to be detrimental
for mouse cortical neurons. The augmented neuronal death upon ubiquilin-1 overexpression
is not likely to be mediated via changes in the Akt signaling pathway in this case.
Driven by the  possible  interrelationship between ubiquilin-1  and BACE1 in  the  aged
human  brain,  the  effect  of  ubiquilin-1  overexpression  on  the  levels  of  endogenously
expressed BACE1 was next investigated. Interestingly, ubiquilin-1 overexpression induced a
significant increase in BACE1 levels as compared to control (p<0.05, n>10). Previous studies
have shown that BACE1 expression is promoted under inflammation after treatment with
proinflammatory compounds, such as LPS and IFN- (Cho et al., 2007, Wang et al., 2015).  In line
with this, a trend of increased BACE1 protein levels after LPS + IFN-·-treatment was detected
in study II, although it was not statistically significant.
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ubiquilin-1 overexpression did not exert a similar increase in the levels of co-overexpressed
EGFP-F, or endogenously expressed ERK1/2 protein, suggesting a specific interrelationship
between ubiquilin-1 and BACE1. These data collectively indicate that both transient and
stable co-overexpression of ubiquilin-1 with BACE1 significantly and specifically increases
BACE1 protein levels in different neuronal cell lines.
The next aim was to investigate potential molecular mechanism(s) that may account for
the observed interrelationship between ubiquilin-1 and BACE1. First of all, a cycloheximide
time-course assay was performed to study whether ubiquilin-1 affects the half-life of BACE1.
This assay revealed significantly (p<0.001, n=3) prolonged half-life of 5’3’UTR-BACE1 in H4-
TV1 (t1/2 ~7.5h) cells as compared to H4-pcDNA cells (t1/2 ~5h). These findings suggest that
overexpression of ubiquilin-1 increases BACE1 levels by slowing down the degradation of
BACE1. To investigate further how the decelerated degradation could be explained, SH-
SY5Y-APP751 cells were co-transfected with 5’3’UTR-BACE1 and myc-TV1 or 5’3’UTR-
BACE1 and control plasmid (pcDNA) and investigated by microscopy. Myc-TV1 localization
was mainly cytoplasmic and it partially resided inside large cytoplasmic structures that may
contain ubiquitinated proteins, as shown previously in these cells (Viswanathan et al., 2011).
BACE1  did  not  co-localize  with  myc-TV1  in  these  structures.  Similar  to  the in vivo data,
BACE1 was localized inside small vesicles in the soma and processes of the cells as indicated
by  punctate  staining.  BACE1  has  previously  been  shown  to  localize  in  endosomes  and
lysosomes (Cole and Vassar, 2007). In accordance with this information, BACE1 prominently
co-localized with Rab7, a marker for LEL, in these cells. BACE1 displayed co-localization as
well with transferrin receptor (TfR), a marker for early and recycling endosome and EEA1, a
marker for early endosomes. Myc-TV1 overexpression significantly decreased BACE1 co-
localization with Rab7 when compared to control cells (pcDNA) (p<0.05, n>45). A
concominant  increase  in  BACE1  co-localization  with  TfR  was  observed  in  cells
overexpressing myc-TV1 as compared to control cells, but this increase did not reach
statistical significance (n>13). Similarly, BACE1 co-localization with EEA1 in cells
overexpressing myc-TV1 showed an increasing, but statistically non-significant, trend. No
evidence  for  altered  protein  levels  of  several  different  factors  known  to  affect  BACE1
subcellular trafficking or sorting, such as GGA1, GGA3, ARF6, seladin-1, or BACE1 Lys-48
or Lys-63-linked ubiquitination, were detected. Despite this, the data suggest that
overexpression of ubiquilin-1 leads to decreased localization of BACE1 in the lysosomal
compartment, where BACE1 degradation normally takes place.
5.2 MOLECULAR AND BEHAVIORAL EFFECTS OF DIETARY MANIPULATION
IN MICE: STUDIES III AND IV
Several lines of evidence suggest that dietary fatty acid composition may play a role in AD
risk  and  several  aspects  of  AD  pathogenesis  (Morris  and  Tangney,  2013).  It  has  been
suggested that ‘typical Western-type’ HFD, containing considerable amount of SFAs, may
increase the risk and/or progression of the AD pathology (Ho et al., 2004, Julien et al., 2010,
Kohjima et al., 2010, Laitinen et al., 2006, Leboucher et al., 2013, Morris et al., 2003a, Oksman
et al., 2006). On the other hand, a growing body of evidence implies that diets rich in PUFAs
and n-3 sources,  such  as  fish  oil,  may  alleviate  amyloid  pathology  and  reduce  the  risk  of
dementia (Laitinen et al., 2006, Morris et al., 2003b, Morris et al., 2015, Oksman et al., 2006).
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study  II,  no  significant  changes  were  observed  in  the  APP  maturation,  levels  of  APP
metabolites (CTFs and AΆ), plaque load, or APP ubiquitination status in the hippocampi of
TV1-injected mice as compared to GFP-injected mice. However, plaque load was modestly
decreased, while soluble and insoluble AΆ40, as well as soluble AΆ42 levels, were increased in
the hippocampi of TV1-containing lentivirus injected mice as detected with IHC and ELISA,
respectively. It is plausible, though, that this variability arises from a dynamic nature of AΆ
aggregates, in other words, by constant aggregation and dissolution of AΆ molecules from
the plaques, as described previously (Maggio et al., 1992). Finally, no significant alterations
in tau phosphorylation (AT8) or total tau protein levels were detected in TV1-injected mice
as compared to GFP-injected mice. These data altogether suggest that ubiquilin-1 does not
exert major effects on tau levels or APP processing or degradation in vivo in the APdE9 mouse
hippocampus. However, it may slightly affect BACE1 levels, Ά-secretase activity as well as
Ά levels  and  plaque  load  in  these  mice.  Moreover,  ubiquilin-1  overexpression  does  not
appear to influence neuroinflammation in vivo in  the  mouse  brain,  as  the  levels  of  glial
fibrillary acidic protein (GFAP) and the CD45 immunopositive area remained unaltered
between TV1- and GFP-injected mice.
5.1.4 Ubiquilin-1 overexpression increases BACE1 stability by diverting it from the
lysosomal pathway in cultured neuronal cells
To mechanistically characterize the observed interrelationship between ubiquilin-1 and
BACE1, H4 cells stably overexpressing human ubiquilin-1 TV1 (H4-TV1) and control cells
stably  expressing  empty  plasmid  (H4-pcDNA)  were  transiently  transfected  with  BACE1
plasmids under different promoters (5’UTR-BACE1, 5’3’UTR-BACE1 or BACE1-myc).
Transfection of the BACE1-myc plasmid containing highly potent CMV promoter, but
without endogenous 5’UTR or 3’UTR BACE1 regulatory regions, yielded the highest BACE1
overexpression in this series of experiments. Expression of BACE1 plasmids containing the
endogenous promoter and 5’3’UTR or 5’UTR regulatory regions resulted in a more moderate
BACE1 overexpression. Cells transfected with the control plasmid (pcDNA) did not show
BACE1  protein  in  Western  blots,  indicating  that  H4  cells  do  not  endogenously  express
detectable amounts of BACE1. Ubiquilin-1 overexpression significantly increased BACE1
expression levels in all cells transfected with the three different BACE1 constructs:  BACE1-
myc, 5’UTR-BACE1 and 5’3’UTR-BACE1 levels were ~1.7 fold (p<0.05), ~3.3 (p<0.01) fold and
~4.0 fold (p<0.01) increased, respectively, in H4-TV1 cells as compared to H4-pcDNA cells
(n=7). This finding was further corroborated by the fact that ubiquilin-1-mediated increase in
BACE1 levels was reversed by siRNA-mediated downregulation of overexpressed ubiquilin-
1 in H4-TV1 cells. Here approximately a ~20% reduction in UBQLN1 TV1 levels (p<0.05) by
RNAi resulted in approximately ~15% decrease in 5’3’UTR-BACE1 levels (p<0.05, n=4).
Furthermore, correlation analysis revealed a statistically significant positive correlation
between protein levels of ubiquilin-1 and BACE1, both before and after ubiquilin-1
downregulation, suggesting a strong association between these proteins (p<0.01, n=6-8). A
similar significant increase in BACE1 levels was also observed in two additional cell lines
transiently transfected with ubiquilin-1 TV1 and 5’3’UTR-BACE1 (p<0.001 and p<0.01 in H4-
APP751 and SH-SY5Y-APP751, respectively). This confirmed that ubiquilin-1 induced an
increase  in  BACE1  levels  that  was  not  restricted  to  particular  cell  types.  Furthermore,
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ubiquilin-1 overexpression did not exert a similar increase in the levels of co-overexpressed
EGFP-F, or endogenously expressed ERK1/2 protein, suggesting a specific interrelationship
between ubiquilin-1 and BACE1. These data collectively indicate that both transient and
stable co-overexpression of ubiquilin-1 with BACE1 significantly and specifically increases
BACE1 protein levels in different neuronal cell lines.
The next aim was to investigate potential molecular mechanism(s) that may account for
the observed interrelationship between ubiquilin-1 and BACE1. First of all, a cycloheximide
time-course assay was performed to study whether ubiquilin-1 affects the half-life of BACE1.
This assay revealed significantly (p<0.001, n=3) prolonged half-life of 5’3’UTR-BACE1 in H4-
TV1 (t1/2 ~7.5h) cells as compared to H4-pcDNA cells (t1/2 ~5h). These findings suggest that
overexpression of ubiquilin-1 increases BACE1 levels by slowing down the degradation of
BACE1. To investigate further how the decelerated degradation could be explained, SH-
SY5Y-APP751 cells were co-transfected with 5’3’UTR-BACE1 and myc-TV1 or 5’3’UTR-
BACE1 and control plasmid (pcDNA) and investigated by microscopy. Myc-TV1 localization
was mainly cytoplasmic and it partially resided inside large cytoplasmic structures that may
contain ubiquitinated proteins, as shown previously in these cells (Viswanathan et al., 2011).
BACE1  did  not  co-localize  with  myc-TV1  in  these  structures.  Similar  to  the in vivo data,
BACE1 was localized inside small vesicles in the soma and processes of the cells as indicated
by  punctate  staining.  BACE1  has  previously  been  shown  to  localize  in  endosomes  and
lysosomes (Cole and Vassar, 2007). In accordance with this information, BACE1 prominently
co-localized with Rab7, a marker for LEL, in these cells. BACE1 displayed co-localization as
well with transferrin receptor (TfR), a marker for early and recycling endosome and EEA1, a
marker for early endosomes. Myc-TV1 overexpression significantly decreased BACE1 co-
localization with Rab7 when compared to control cells (pcDNA) (p<0.05, n>45). A
concominant  increase  in  BACE1  co-localization  with  TfR  was  observed  in  cells
overexpressing myc-TV1 as compared to control cells, but this increase did not reach
statistical significance (n>13). Similarly, BACE1 co-localization with EEA1 in cells
overexpressing myc-TV1 showed an increasing, but statistically non-significant, trend. No
evidence  for  altered  protein  levels  of  several  different  factors  known  to  affect  BACE1
subcellular trafficking or sorting, such as GGA1, GGA3, ARF6, seladin-1, or BACE1 Lys-48
or Lys-63-linked ubiquitination, were detected. Despite this, the data suggest that
overexpression of ubiquilin-1 leads to decreased localization of BACE1 in the lysosomal
compartment, where BACE1 degradation normally takes place.
5.2 MOLECULAR AND BEHAVIORAL EFFECTS OF DIETARY MANIPULATION
IN MICE: STUDIES III AND IV
Several lines of evidence suggest that dietary fatty acid composition may play a role in AD
risk  and  several  aspects  of  AD  pathogenesis  (Morris  and  Tangney,  2013).  It  has  been
suggested that ‘typical Western-type’ HFD, containing considerable amount of SFAs, may
increase the risk and/or progression of the AD pathology (Ho et al., 2004, Julien et al., 2010,
Kohjima et al., 2010, Laitinen et al., 2006, Leboucher et al., 2013, Morris et al., 2003a, Oksman
et al., 2006). On the other hand, a growing body of evidence implies that diets rich in PUFAs
and n-3 sources,  such  as  fish  oil,  may  alleviate  amyloid  pathology  and  reduce  the  risk  of
dementia (Laitinen et al., 2006, Morris et al., 2003b, Morris et al., 2015, Oksman et al., 2006).
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study  II,  no  significant  changes  were  observed  in  the  APP  maturation,  levels  of  APP
metabolites (CTFs and AΆ), plaque load, or APP ubiquitination status in the hippocampi of
TV1-injected mice as compared to GFP-injected mice. However, plaque load was modestly
decreased, while soluble and insoluble AΆ40, as well as soluble AΆ42 levels, were increased in
the hippocampi of TV1-containing lentivirus injected mice as detected with IHC and ELISA,
respectively. It is plausible, though, that this variability arises from a dynamic nature of AΆ
aggregates, in other words, by constant aggregation and dissolution of AΆ molecules from
the plaques, as described previously (Maggio et al., 1992). Finally, no significant alterations
in tau phosphorylation (AT8) or total tau protein levels were detected in TV1-injected mice
as compared to GFP-injected mice. These data altogether suggest that ubiquilin-1 does not
exert major effects on tau levels or APP processing or degradation in vivo in the APdE9 mouse
hippocampus. However, it may slightly affect BACE1 levels, Ά-secretase activity as well as
Ά levels  and  plaque  load  in  these  mice.  Moreover,  ubiquilin-1  overexpression  does  not
appear to influence neuroinflammation in vivo in  the  mouse  brain,  as  the  levels  of  glial
fibrillary acidic protein (GFAP) and the CD45 immunopositive area remained unaltered
between TV1- and GFP-injected mice.
5.1.4 Ubiquilin-1 overexpression increases BACE1 stability by diverting it from the
lysosomal pathway in cultured neuronal cells
To mechanistically characterize the observed interrelationship between ubiquilin-1 and
BACE1, H4 cells stably overexpressing human ubiquilin-1 TV1 (H4-TV1) and control cells
stably  expressing  empty  plasmid  (H4-pcDNA)  were  transiently  transfected  with  BACE1
plasmids under different promoters (5’UTR-BACE1, 5’3’UTR-BACE1 or BACE1-myc).
Transfection of the BACE1-myc plasmid containing highly potent CMV promoter, but
without endogenous 5’UTR or 3’UTR BACE1 regulatory regions, yielded the highest BACE1
overexpression in this series of experiments. Expression of BACE1 plasmids containing the
endogenous promoter and 5’3’UTR or 5’UTR regulatory regions resulted in a more moderate
BACE1 overexpression. Cells transfected with the control plasmid (pcDNA) did not show
BACE1  protein  in  Western  blots,  indicating  that  H4  cells  do  not  endogenously  express
detectable amounts of BACE1. Ubiquilin-1 overexpression significantly increased BACE1
expression levels in all cells transfected with the three different BACE1 constructs:  BACE1-
myc, 5’UTR-BACE1 and 5’3’UTR-BACE1 levels were ~1.7 fold (p<0.05), ~3.3 (p<0.01) fold and
~4.0 fold (p<0.01) increased, respectively, in H4-TV1 cells as compared to H4-pcDNA cells
(n=7). This finding was further corroborated by the fact that ubiquilin-1-mediated increase in
BACE1 levels was reversed by siRNA-mediated downregulation of overexpressed ubiquilin-
1 in H4-TV1 cells. Here approximately a ~20% reduction in UBQLN1 TV1 levels (p<0.05) by
RNAi resulted in approximately ~15% decrease in 5’3’UTR-BACE1 levels (p<0.05, n=4).
Furthermore, correlation analysis revealed a statistically significant positive correlation
between protein levels of ubiquilin-1 and BACE1, both before and after ubiquilin-1
downregulation, suggesting a strong association between these proteins (p<0.01, n=6-8). A
similar significant increase in BACE1 levels was also observed in two additional cell lines
transiently transfected with ubiquilin-1 TV1 and 5’3’UTR-BACE1 (p<0.001 and p<0.01 in H4-
APP751 and SH-SY5Y-APP751, respectively). This confirmed that ubiquilin-1 induced an
increase  in  BACE1  levels  that  was  not  restricted  to  particular  cell  types.  Furthermore,
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words, the mRNA levels of 4R-tau and 3R-tau significantly correlated with impaired spatial
memory (search bias) in both the swim navigation task (r=-0.38 and r=-40, respectively; p<0.05
for both) and the reduced vertical activity (rearing) measurement (r=-40 and r=-36,
respectively; p<0.05 for both).
Additionaly, 4R-tau and 3R-tau mRNA levels, as well as the 4R-tau/3R-tau mRNA ratio
correlated with diet-induced weight gain, peripheral metabolic changes, the levels of
neuroinflammatory  markers  and  the  activity  Akt/glycogen  synthase  kinase  3Ά (GSK3Ά)
signaling cascade. HFD exposure induced a significant weight gain in all genotypes except
in A+Iw (p<0.0001). The correlation analysis revealed a significant positive association
between weight gain and the mRNA levels of 4R-tau (r=0.71; p<0.01), 3R-tau (r=0.46; p<0.01)
and 4R-tau/3R-tau ratio (r=0.62; p<0.0001).  However, as the A+Iw mice did not gain weight
while put on the HFD, the weight gain is not probably the only mechanism explaining the
genotype-independent increase in tau expression after HFD. In the previous study, both the
IGF2 genotype  (I+)  and  the  HFD  induced  peripheral  hyperglycemia,  whereas  sustained
hyperinsulinaemia  and  insulin  resistance  were  only  observed  in  triple  transgenic  (A+I+)
mice,  regardless  of  the  diet  (Hiltunen et  al.,  2012).  Accordingly,  no correlation was found
between the mRNA levels of 4R-tau, 3R-tau or 4R-tau/3R-tau ratio and blood Ά-glucose or
plasma  insulin  levels  (as  determined  by  GTT  and  ITT,  respectively)  in  female  mice.  HFD
significantly affected neither the levels of astrocyte marker protein GFAP nor CD45
immunopositive area, which was determined in the previous study (Hiltunen et al., 2012). In
line with this, expression-wise tau changes were not found to correlate with the levels GFAP.
In  contrast,  HFD  significantly  decreased  the  protein  levels  of  TNF΅,  and  slightly,  but
insignificantly  decreased  the  protein  levels  of  IL1Ά,  while  the  mRNA  levels  of  both
inflammatory cytokines remained unaltered. TNF΅ and IL1Ά protein levels were negatively
correlated with mRNA levels of 4R-tau (r=-0.36, p<0.05 and r=-0.42, p<0.05, respectively) and
4R-tau/3R-tau mRNA ratio (r=-0.40, p<0.05 and r=-0.46, p<0.01, respectively). Together, these
observations imply that HFD-induced tau expression is not associated with accelerated
neuroinflammation in the temporal cortex of female mice.
Next, the effect of HFD on the activity of the Akt/GSK3Ά signaling pathway was
determined. However, the activities of these two central kinases involved in insulin signaling
and tau phosphorylation were not influenced by the diet or associated with diet-induced tau
changes. Finally, expressional changes of established tau exon 10 splicing enhancers,
SF2/ASF, C35, Tra2Ά, and Sp30c, were elucidated to address the mechanism behind increased
4R-tau to 3R-tau mRNA ratio (Liu and Gong, 2008, Qian and Liu, 2014). However, there were
no  significant  diet-related  changes  in  the  mRNA  levels  of  any  of  these  splicing  agents
examined. In summary, these results suggest that a high-fat diet increases tau expression and
exon 10 inclusion in female mice, regardless of the animal’s genotype, peripheral or central
insulin signaling, or neuroinflammation status.
5.2.2 Special fish oil based diets alleviate cognitive deficits in the APdE9 mice
independent of Ά amyloid deposition: Study IV
To investigate potential beneficial effects of dietary fish oil and specific additional nutrients
in a mouse model of AD, APdE9 female mice were fed with diets containing fish oil  (FO),
fish  oil  and  plant  sterols  (FOPS),  or  fish  oil  and  precursors  and  cofactors  for  synaptic
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Moreover, it has been proposed that additional dietary supplements, including plant sterols
and nutrients consisting of precursors and cofactors for neuronal membrane synthesis may
enhance the beneficial effects of fish oil-based diet. Studies III and IV, aimed to investigate
the effects of HFD and special fish oil-based diets on AD-related molecular and behavioral
changes in mice.
5.2.1 A high-fat diet increases tau expression and exon 10 inclusion in mouse brain
regardless of peripheral metabolic status: Study III
AD and T2DM are risk factors for each other, which both are influenced by environmental
factors, such as diet (Carlsson, 2010, Morris and Tangney, 2014, Sindi et al., 2015). Our group
has previously investigated this co-morbidity in mice concomitantly engineered to model
both of these disorders by genetic and dietary manipulation (Hiltunen et al., 2012). For that
purpose, the APdE9 mice (A+Iw) were crossbred with the T2DM mice, overexpressing IGF2
in the pancreas (AwI+), to create triple transgenic APdE9xIGF2 mice (A+I+). In addition, mice
in  each  genotype  group  (AwIw,  A+Iw,  AwI+,  A+I+)  were  fed  with  HFD  for  four  months.
AwIw,  A+Iw,  AwI+,  and A+I+  mice  fed with standard laboratory mouse food (STD) were
used as controls. In the previous study, tau protein levels and phosphorylation (at the AT8
epitopes Ser199, Ser202/Thr205) were demonstrated to be increased in the brain of female
mice after HFD, while AΆ load was unaffected by the diet or IGF2 genotype (Hiltunen et al.,
2012).  In  line  with  these  previous  data,  a  robust  increase  in  the  protein  levels  of  4R-tau
isoform was detected in the temporal cortex of female mice on HFD as compared to those on
STD in study III.  Accordingly, a similar, approximately ~4.5 fold significant increase in 4R-
tau mRNA levels was observed in the temporal cortex of female mice on HFD, as compared
to those on STD (p<0.0001). No such diet-effect was detected in 4R-tau protein or mRNA
levels  in  the  temporal  cortex  of  male  mice,  indicating  that  diet-induced  changes  in  tau
expression are dependent on gender-related factors, such as female hormones. In female
mice, both protein and mRNA levels of 4R-tau were unaltered upon the presence of AwIw,
A+Iw, AwI+, or A+I+ genotype. This suggests that a high-fat diet increases 4R-tau expression
regardless of AD or T2DM genetic background.
3R-tau protein levels in the temporal cortex of adult mice were too low for detection
with Western blot. Despite 3R-tau mRNA levels being, similarly, extremely low, a significant
increase in the 3R-tau mRNA expression was detected in the temporal cortices of HFD-fed
female mice as compared to STD-fed female mice (p<0.0001). However, as the HFD-induced
increase in the 3R-tau mRNA expression (~30%) was much less pronounced than that seen
with the 4R-tau (~400%), a significant increase in 4R-tau/3R-tau mRNA ratio was observed
in the temporal cortex of female mice fed a HFD (p<0.0001).  This suggests that a HFD not
only increases tau expression, but also may affect alternative splicing of exon 10. In contrast
to  4R-tau,  3R-tau  mRNA  expression  was  additionally  affected  by  the  genotype  to  diet
interaction in female mice. More precisely, 3R-tau mRNA expression was significantly higher
in triple transgenic A+I+ mice on STD as compared to A+Iw and AwI+ mice on STD, but this
increase was not further potentiated by HFD. The finding implies that expression of 4R-tau
and  3R-tau  isoforms  might  be  regulated  via  different  mechanisms  in  the  mouse  brain.
Notably,  the  HFD-induced  increase  in  tau  expression  was  found  to  be  associated  with  a
cognitive phenotype, as demonstrated in the previous study (Hiltunen et al., 2012). In other
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words, the mRNA levels of 4R-tau and 3R-tau significantly correlated with impaired spatial
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neuroinflammatory  markers  and  the  activity  Akt/glycogen  synthase  kinase  3Ά (GSK3Ά)
signaling cascade. HFD exposure induced a significant weight gain in all genotypes except
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between weight gain and the mRNA levels of 4R-tau (r=0.71; p<0.01), 3R-tau (r=0.46; p<0.01)
and 4R-tau/3R-tau ratio (r=0.62; p<0.0001).  However, as the A+Iw mice did not gain weight
while put on the HFD, the weight gain is not probably the only mechanism explaining the
genotype-independent increase in tau expression after HFD. In the previous study, both the
IGF2 genotype  (I+)  and  the  HFD  induced  peripheral  hyperglycemia,  whereas  sustained
hyperinsulinaemia  and  insulin  resistance  were  only  observed  in  triple  transgenic  (A+I+)
mice,  regardless  of  the  diet  (Hiltunen et  al.,  2012).  Accordingly,  no correlation was found
between the mRNA levels of 4R-tau, 3R-tau or 4R-tau/3R-tau ratio and blood Ά-glucose or
plasma  insulin  levels  (as  determined  by  GTT  and  ITT,  respectively)  in  female  mice.  HFD
significantly affected neither the levels of astrocyte marker protein GFAP nor CD45
immunopositive area, which was determined in the previous study (Hiltunen et al., 2012). In
line with this, expression-wise tau changes were not found to correlate with the levels GFAP.
In  contrast,  HFD  significantly  decreased  the  protein  levels  of  TNF΅,  and  slightly,  but
insignificantly  decreased  the  protein  levels  of  IL1Ά,  while  the  mRNA  levels  of  both
inflammatory cytokines remained unaltered. TNF΅ and IL1Ά protein levels were negatively
correlated with mRNA levels of 4R-tau (r=-0.36, p<0.05 and r=-0.42, p<0.05, respectively) and
4R-tau/3R-tau mRNA ratio (r=-0.40, p<0.05 and r=-0.46, p<0.01, respectively). Together, these
observations imply that HFD-induced tau expression is not associated with accelerated
neuroinflammation in the temporal cortex of female mice.
Next, the effect of HFD on the activity of the Akt/GSK3Ά signaling pathway was
determined. However, the activities of these two central kinases involved in insulin signaling
and tau phosphorylation were not influenced by the diet or associated with diet-induced tau
changes. Finally, expressional changes of established tau exon 10 splicing enhancers,
SF2/ASF, C35, Tra2Ά, and Sp30c, were elucidated to address the mechanism behind increased
4R-tau to 3R-tau mRNA ratio (Liu and Gong, 2008, Qian and Liu, 2014). However, there were
no  significant  diet-related  changes  in  the  mRNA  levels  of  any  of  these  splicing  agents
examined. In summary, these results suggest that a high-fat diet increases tau expression and
exon 10 inclusion in female mice, regardless of the animal’s genotype, peripheral or central
insulin signaling, or neuroinflammation status.
5.2.2 Special fish oil based diets alleviate cognitive deficits in the APdE9 mice
independent of Ά amyloid deposition: Study IV
To investigate potential beneficial effects of dietary fish oil and specific additional nutrients
in a mouse model of AD, APdE9 female mice were fed with diets containing fish oil  (FO),
fish  oil  and  plant  sterols  (FOPS),  or  fish  oil  and  precursors  and  cofactors  for  synaptic
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Moreover, it has been proposed that additional dietary supplements, including plant sterols
and nutrients consisting of precursors and cofactors for neuronal membrane synthesis may
enhance the beneficial effects of fish oil-based diet. Studies III and IV, aimed to investigate
the effects of HFD and special fish oil-based diets on AD-related molecular and behavioral
changes in mice.
5.2.1 A high-fat diet increases tau expression and exon 10 inclusion in mouse brain
regardless of peripheral metabolic status: Study III
AD and T2DM are risk factors for each other, which both are influenced by environmental
factors, such as diet (Carlsson, 2010, Morris and Tangney, 2014, Sindi et al., 2015). Our group
has previously investigated this co-morbidity in mice concomitantly engineered to model
both of these disorders by genetic and dietary manipulation (Hiltunen et al., 2012). For that
purpose, the APdE9 mice (A+Iw) were crossbred with the T2DM mice, overexpressing IGF2
in the pancreas (AwI+), to create triple transgenic APdE9xIGF2 mice (A+I+). In addition, mice
in  each  genotype  group  (AwIw,  A+Iw,  AwI+,  A+I+)  were  fed  with  HFD  for  four  months.
AwIw,  A+Iw,  AwI+,  and A+I+  mice  fed with standard laboratory mouse food (STD) were
used as controls. In the previous study, tau protein levels and phosphorylation (at the AT8
epitopes Ser199, Ser202/Thr205) were demonstrated to be increased in the brain of female
mice after HFD, while AΆ load was unaffected by the diet or IGF2 genotype (Hiltunen et al.,
2012).  In  line  with  these  previous  data,  a  robust  increase  in  the  protein  levels  of  4R-tau
isoform was detected in the temporal cortex of female mice on HFD as compared to those on
STD in study III.  Accordingly, a similar, approximately ~4.5 fold significant increase in 4R-
tau mRNA levels was observed in the temporal cortex of female mice on HFD, as compared
to those on STD (p<0.0001). No such diet-effect was detected in 4R-tau protein or mRNA
levels  in  the  temporal  cortex  of  male  mice,  indicating  that  diet-induced  changes  in  tau
expression are dependent on gender-related factors, such as female hormones. In female
mice, both protein and mRNA levels of 4R-tau were unaltered upon the presence of AwIw,
A+Iw, AwI+, or A+I+ genotype. This suggests that a high-fat diet increases 4R-tau expression
regardless of AD or T2DM genetic background.
3R-tau protein levels in the temporal cortex of adult mice were too low for detection
with Western blot. Despite 3R-tau mRNA levels being, similarly, extremely low, a significant
increase in the 3R-tau mRNA expression was detected in the temporal cortices of HFD-fed
female mice as compared to STD-fed female mice (p<0.0001). However, as the HFD-induced
increase in the 3R-tau mRNA expression (~30%) was much less pronounced than that seen
with the 4R-tau (~400%), a significant increase in 4R-tau/3R-tau mRNA ratio was observed
in the temporal cortex of female mice fed a HFD (p<0.0001).  This suggests that a HFD not
only increases tau expression, but also may affect alternative splicing of exon 10. In contrast
to  4R-tau,  3R-tau  mRNA  expression  was  additionally  affected  by  the  genotype  to  diet
interaction in female mice. More precisely, 3R-tau mRNA expression was significantly higher
in triple transgenic A+I+ mice on STD as compared to A+Iw and AwI+ mice on STD, but this
increase was not further potentiated by HFD. The finding implies that expression of 4R-tau
and  3R-tau  isoforms  might  be  regulated  via  different  mechanisms  in  the  mouse  brain.
Notably,  the  HFD-induced  increase  in  tau  expression  was  found  to  be  associated  with  a
cognitive phenotype, as demonstrated in the previous study (Hiltunen et al., 2012). In other
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no similar genotype effect was observed on the activity of ·-secretase. Previous in vitro and
in vivo studies  have  suggested  that  DHA-derived  n3  PUFAs  may  reduce  AΆ load  by
inhibiting the activities of both Ά- and ·-secretase (Grimm et al., 2011). Agreeing with this, a
significant effect of the dietary manipulation was observed on both Ά-secretase (p<0.001) and
·-secretase (p<0.01) activity. However, the previously reported DHA activity, here present
in all experimental diets, was also strongly modified by other dietary components. More
precisely, only the FO diet significantly reduced the activity of Ά-secretase in the cortex as
compared to APdE9 mice on control diet (p<0.001). A similar trend was also observed in the
cortex of Fortasyn-fed mice, although this change did not reach statistical significance. The
·-secretase activity was more uniformly reduced after all fish oil based diets, although only
FO (p<0.001) and FOPS (p<0.05) groups were significantly different from APdE9 control
group. Next,  it  was addressed whether reduced Ά-  and ·-secretase activities translate into
decreased AΆ production in the brain of APdE9 mice after fish oil-based diets. The analysis
revealed a significant overall diet effect on the soluble AΆ42 (p<0.00001), but not on soluble
Ά40 levels.   However,  a  closer  examination showed a  significant  decrease  in  soluble  AΆ42
(p<0.001) levels as  well  as  AΆ42/AΆ40 (p<0.05) ratio only after FOPS diet. Moreover, no
significant diet effects were detected on the levels insoluble AΆ40, AΆ42, the AΆ42/AΆ40 ratio, or
on  the  Ά-amyloid  plaque  load  in  the  brain  of  APdE9  mice.  These  results  imply  that  diet-
associated behavioral phenotypes observed in this study are not explained by alterations in
brain Ά-amyloid pathology.
Neuroinflammation and oxidative stress are two key mechanisms suggested to be
involved in the pathogenesis of AD (Heneka et al., 2015). Oxidative damage accompanies the
Ά-amyloid pathology in the brain of AD mouse models (Abdul et al., 2008, Du et al., 2010,
Pratico  et  al.,  2001).  Plant  sterols  and  some  other  dietary  supplements,  such  as  several
vitamins, have been implicated to possess antioxidative properties (Malar and Devi, 2014).
Therefore, the effect of fish oil based diets on neuroinflammation and oxidative stress was
next  assessed  in  the  brain  of  APdE9  mice.  IHC  analysis  showed  that  only  FOPS  diet
significantly reduced the overall amount of activated microglia and in the brain of APdE9
mice (p<0.05). Other experimental diets did not affect overall or the plaque-surrounding
CD45 immunopositive  area.  In  contrast,  mice  on the  FOPS diet  were  also  the  only  group,
which showed significantly increased production of reactive oxygen species (ROS, p<0.05)
and lysophosphatidylcholine (LPC 16:0 and LPC 18:1; p<0.05), a phospholipid with
proinflammatory properties (Sundaram et al., 2012), in the brain. Other diets did not affect
the levels of ROS or LPCs. Based on these findings, the diet-induced improvements in spatial
and olfactory memory are not likely mediated through alleviated neuroinflammation or
oxidative stress in these mice. However, in general, in APdE9 mice, higher ROS levels in the
cerebellum and hippocampus were associated with a poorer outcome in behavioral tasks,
such as reduced rearing (r=-0.39, p<0.01), increased thigmotaxis (tendency to swim near the
pool wall, r=0.29, p<0.05) and impaired search bias (r=-0.30, p<0.05). Thus, oxidative stress
may be associated with at least some of the behavioral and memory deficits found in APdE9
mice,  although  these  may  not  necessarily  be  mediated  by  dietary  factors.  Finally,  dietary
manipulation did not affect the total cortical SFA levels. In contrast, all fish oil based diets
led to a consistent increase in the brain n-3/n-6 PUFA ratio (significant in FO group, p<0.05),
suggesting that the n3/n6 PUFA ratio is modified by dietary supplementation with fish oil.
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membrane synthesis (Fortasyn)(Table 6),  for  9  months.  APdE9  mice  and  their  wild-type
littermates fed with normal laboratory mouse chow were used as controls in the study. In
line with the previous reports, 14-month-old wild-type mice performed significantly better
in the swim navigation task than age-matched APdE9 mice on the control diet (p<0.05). None
of the experimental diets (FO, FOPS, Fortasyn) improved spatial learning of the APdE9 mice,
as  was indicated by the  similar  escape latencies  between diet  groups during the  five  task
acquisition days. However, when the two last aquisition days were analyzed separately (the
learning curve had reached the plateau), the mice on Fortasyn diet performed significantly
(p<0.05) better than FO or FOPS fed mice. This suggests that fish oil, in combination with
specific nutrients targeted for retaining synaptic function, may be more efficient in improving
spatial memory than fish oil alone.
Olfactory dysfunction is one of the earliest symptoms of AD (Masurkar and Devanand,
2014) and has been reported to occur in transgenic mouse models of AD as well (Cassano et
al., 2011, Wesson et al., 2011). Therefore, the ability to distinguish species-specific odors was
tested next. Odor recognition ability of the mice was determined as the relative time, which
each mouse spent exploring two wooden balls, one odorized with the scent of an unfamiliar
mouse (novel odor) and the other one with the mouse’s own odor (familiar odor). Wild-type
mice were significantly more interested in exploring the wooden balls than APdE9 mice on
control diet (p<0.05). Wild-type mice were also clearly more interested in the novel odor than
of the familiar one as they spent approximately 70% of the total time exploring the novel
odor. In contrast,  APdE9 mice on control diet did not show an odor preference at all  and,
thus, their behavior was significantly different from that seen in the wild-type litter-mate
mice (p<0.05). Importantly, each of the experimental diets fully restored the odor recognition
ability in APdE9 mice. The mice on FO, FOPS and Fortasyn diets showed a strong preference
towards the novel odor and each group spent more than 70% of total time exploring the ball
with the scent of unfamiliar mouse (FO p<0.01, FOPS p<0.05, Fortasyn p<0.01, as compared
to  control  group).  This  indicates  that  AD-associated  olfactory  deficit  in  mice  may  be
alleviated by long-term fish oil consumption.
Fear and anxiety-related hyperactivity and decreased explorative behavior are
characteristics  of  the  APdE9  model  genotype  when  these  animals  are  placed  in  a  novel
environment (Jansen et al., 2013) (Kemppainen et al., 2012). Accordingly, significantly
(p<0.01) increased activity (ambulatory distance) among APdE9 mice on control diet as
compared to wild-type mice was observed in study IV. However, none of the experimental
diets was found to reduce the hyperactive behavior of APdE9 mice. Habituation to the novel
environment was determined by comparing the time that the mouse spent exploring the test
cage  (rearing  time)  on  day  3  versus  on  the  first  trial  day.  APdE9  mice  on  control  diet
habituated poorly and were the least similar with the wild-type mice in their behavior. FOPS-
fed  mice,  on  the  contrary,  showed  good  habituation,  as  they  spent  significantly  less  time
rearing on the third trial day than on the first trial day (p<0.05).  However, FOPS-fed mice
were  also  significantly  heavier  than APdE9 mice  on control  diet  (p<0.0001).  It  is  therefore
possible that increased body weight affected the rearing activity of FOPS-fed mice.
The Ά-secretase activity has been shown to increase in the AD brain (Vassar et al., 2014).
In  line  with  this,  Ά-secretase  activity  proved  to  be  significantly  increased  in  the  brain  of
APdE9 mice on control diet as compared to wild-type mice on control diet (p<0.01). However,
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no similar genotype effect was observed on the activity of ·-secretase. Previous in vitro and
in vivo studies  have  suggested  that  DHA-derived  n3  PUFAs  may  reduce  AΆ load  by
inhibiting the activities of both Ά- and ·-secretase (Grimm et al., 2011). Agreeing with this, a
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·-secretase (p<0.01) activity. However, the previously reported DHA activity, here present
in all experimental diets, was also strongly modified by other dietary components. More
precisely, only the FO diet significantly reduced the activity of Ά-secretase in the cortex as
compared to APdE9 mice on control diet (p<0.001). A similar trend was also observed in the
cortex of Fortasyn-fed mice, although this change did not reach statistical significance. The
·-secretase activity was more uniformly reduced after all fish oil based diets, although only
FO (p<0.001) and FOPS (p<0.05) groups were significantly different from APdE9 control
group. Next,  it  was addressed whether reduced Ά-  and ·-secretase activities translate into
decreased AΆ production in the brain of APdE9 mice after fish oil-based diets. The analysis
revealed a significant overall diet effect on the soluble AΆ42 (p<0.00001), but not on soluble
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(p<0.001) levels as  well  as  AΆ42/AΆ40 (p<0.05) ratio only after FOPS diet. Moreover, no
significant diet effects were detected on the levels insoluble AΆ40, AΆ42, the AΆ42/AΆ40 ratio, or
on  the  Ά-amyloid  plaque  load  in  the  brain  of  APdE9  mice.  These  results  imply  that  diet-
associated behavioral phenotypes observed in this study are not explained by alterations in
brain Ά-amyloid pathology.
Neuroinflammation and oxidative stress are two key mechanisms suggested to be
involved in the pathogenesis of AD (Heneka et al., 2015). Oxidative damage accompanies the
Ά-amyloid pathology in the brain of AD mouse models (Abdul et al., 2008, Du et al., 2010,
Pratico  et  al.,  2001).  Plant  sterols  and  some  other  dietary  supplements,  such  as  several
vitamins, have been implicated to possess antioxidative properties (Malar and Devi, 2014).
Therefore, the effect of fish oil based diets on neuroinflammation and oxidative stress was
next  assessed  in  the  brain  of  APdE9  mice.  IHC  analysis  showed  that  only  FOPS  diet
significantly reduced the overall amount of activated microglia and in the brain of APdE9
mice (p<0.05). Other experimental diets did not affect overall or the plaque-surrounding
CD45 immunopositive  area.  In  contrast,  mice  on the  FOPS diet  were  also  the  only  group,
which showed significantly increased production of reactive oxygen species (ROS, p<0.05)
and lysophosphatidylcholine (LPC 16:0 and LPC 18:1; p<0.05), a phospholipid with
proinflammatory properties (Sundaram et al., 2012), in the brain. Other diets did not affect
the levels of ROS or LPCs. Based on these findings, the diet-induced improvements in spatial
and olfactory memory are not likely mediated through alleviated neuroinflammation or
oxidative stress in these mice. However, in general, in APdE9 mice, higher ROS levels in the
cerebellum and hippocampus were associated with a poorer outcome in behavioral tasks,
such as reduced rearing (r=-0.39, p<0.01), increased thigmotaxis (tendency to swim near the
pool wall, r=0.29, p<0.05) and impaired search bias (r=-0.30, p<0.05). Thus, oxidative stress
may be associated with at least some of the behavioral and memory deficits found in APdE9
mice,  although  these  may  not  necessarily  be  mediated  by  dietary  factors.  Finally,  dietary
manipulation did not affect the total cortical SFA levels. In contrast, all fish oil based diets
led to a consistent increase in the brain n-3/n-6 PUFA ratio (significant in FO group, p<0.05),
suggesting that the n3/n6 PUFA ratio is modified by dietary supplementation with fish oil.
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(n=7-8 mice/group) in the in vivo experiment, may partially explain the lack of significance in
this study. Experiments  in  different  cultured  neuronal  cells  using  co-overexpression  of
ubiquilin-1 and different BACE1 constructs (with or without the endogenous 5’ and 3’ UTRs)
further  corroborated  this  increase  in  BACE1  levels.  In  these  cells,  stable  or  transient
overexpression of ubiquilin-1 significantly increased the protein levels of all three BACE1
constructs and this increase was reversed by ubiquilin-1 downregulation by RNAi. A similar
increase was not observed in endogenously expressed ERK1/2 or overexpressed GFP,
suggesting that human ubiquilin-1 might specifically interact with BACE1. Finally, the levels
of  ubiquilin-1  and  BACE1  were  significantly  correlated  in  these  cells,  suggesting  a  strong
association between these proteins. Altogether, these data indicate an interrelationship
between ubiquilin-1 and BACE1 in the human brain, in vivo in the mouse brain and in vitro
in primary neurons and cultured neuronal cells.
The increase in BACE1 protein levels in ubiquilin-1-overexpressing cells may involve
several alternative underlying molecular mechanisms. Increased BACE1 levels upon
ubiquilin-1 overexpression in cells transfected with the BACE1-myc construct, which
contains the very potent CMV-promoter (Choi et al., 2005) but lacks the endogenous UTRs,
suggests that ubiquilin-1 increases BACE1 levels by a post-translational mechanism(s). The
following studies indicated that overexpression of ubiquilin-1 significantly increased the
half-life of BACE1 protein, suggesting that BACE1 levels are stabilized in cells
overexpressing ubiquilin-1. At the same time, BACE1 localization in Rab7-positive LELs was
decreased, while it was modestly increased in TfR-positive early endosomal compartments
in  cells  overexpressing  ubiquilin-1.  Although  there  was  no  evidence  for  altered  levels  of
GGA1, GGA3, ARF6, seladin-1, or BACE1 ubiquitination, factors known to regulate BACE1
trafficking (Kang et al., 2010, Kang et al., 2012, Sannerud et al., 2011, Sarajarvi et al., 2009,
Tesco  et  al.,  2007),  it  is  possible  to  suggest  that  less  BACE1  is  targeted  to  the  lysosomal
degradation pathway in cells overexpressing ubiquilin-1. As has been reviewed in study I,
this  finding  agrees  with  the  previously  indicated  role  for  ubiquilin-1  in  the  regulation  of
intracellular trafficking of several different proteins (Hiltunen et al., 2006, Lu et al., 2009,
Massey et al., 2004, Thomas et al., 2006, Viswanathan et al., 2011, Viswanathan et al., 2013).
Collectively, these data suggest that ubiquilin-1 affects BACE1 levels at the post-translational
level and stabilizes BACE1 by diverting it from the lysosomal degradation pathway.
However, unraveling the exact molecular mechanisms by which ubiquilin-1 mediates BACE1
subcellular trafficking still requires further investigations.
BACE1 is a rate-limiting enzyme in AΆ production (Cole and Vassar, 2007). Therefore,
the  finding  that  ubiquilin-1  overexpression  increases  BACE1  levels  is  partially  in  contrast
with previous studies showing that downregulation of ubiquilin-1 increases APP processing
and AΆ production (El Ayadi et al., 2012a, Hiltunen et al., 2006, Stieren et al., 2011). On the
other hand, another study conducted in a different cell line has suggested an opposite effect
on APP by ubiquilin-1 knockdown (Zhang et al., 2007). Based on these studies, it is possible
that  ubiquilin-1-mediated regulation of  APP is  cell  type-specific.  In  study II,  the  effects  of
ubiquilin-1 on APP processing and AΆ pathology have been investigated for the first time in
vivo in  the  brain  of  APdE9  transgenic  AD  mice.  In  this  study,  there  were  no  significant
changes in APP ubiquitination, maturation, levels of APP metabolites or plaque load
associated with ubiquilin-1  overexpression in  the  brain  of  APdE9 mice.  However,  a  trend
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6 Discussion
6.1 COMPLEX ROLE OF UBIQUILIN-1 IN ALZHEIMER’S DISEASE
PATHOGENESIS: STUDIES I AND II
AD  is  the  most  common  cause  of  dementia  in  the  elderly,  and  is  soon  expected  to  reach
epidemic proportions. Currently, there are no drugs or treatments available for AD that
could prevent or halt the disease progression. Furthermore, traditional therapeutic
approaches have recently ended up with inconclusive or adverse results in phase III clinical
trials (Kumar et al., 2015). Accumulating evidence indicates that deficits in protein
trafficking, protein quality control and clearance systems (collectively called proteostasis) in
combination with disease-associated genetic and environmental alterations may play a
pivotal role in protein aggregation and subsequent neurodegeneration due to their improper
clearance (Haapasalo et al., 2010) (Ross and Poirier, 2004) (Wang et al., 2014). Therefore,
careful characterization of pathways involved in trafficking, processing and degradation of
AD-related  proteins  is  of  great  importance.  As  reviewed  in  study  I,  ubiquilin-1  has  been
consistently found to associate with AD pathogenesis at both the genetic and functional
points of view, and to specifically regulate trafficking, the levels, and accumulation of several
AD-associated proteins (El Ayadi et al., 2012a, Hiltunen et al., 2006, Kleijnen et al., 2003, Liu
et al., 2014, Lu et al., 2009, Mah et al., 2000, Massey et al., 2004, Stieren et al., 2011,
Viswanathan et al., 2011). However, the data regarding ubiquilin-1 in the brain of humans
and other vertebrate animals is scarce and the contribution of ubiquilin-1 to the development
and progression of AD pathology still largely remains an open question. In study II, the goal
was to investigate the relationship between ubiquilin-1 and key pathological aspects of AD
in human brain and in experimental in vitro and in vivo AD models overexpressing ubiquilin-
1. In this study, ubiquilin-1 mRNA and protein levels were found both to be decreased, in
relation to advancing AD-related neurofibrillary pathology, in the post mortem human
temporal cortex. This finding is in line with a previous study showing that ubiquilin-1 protein
levels are significantly decreased in late onset AD patient brains ((Stieren et al., 2011)). When
ubiquilin-1 protein levels were correlated with other central AD-associated proteins, a trend
towards positive correlation between ubiquilin-1 and BACE1 protein levels was observed in
human  brain.  Although  this  piece  of  data  is  partially  inconsistent  with  previous  reports
demonstrating  that  BACE1  protein  levels  are  increased  in  human  AD  brains  (Cole  and
Vassar, 2007), it suggests that there might exist an interrelationship between ubiquilin-1 and
BACE1 levels.
The suggested interrelationship between BACE1 and ubiquilin-1 was supported by the
findings in mouse embryonic primary cortical neuron-microglial co-cultures and APdE9
mouse hippocampus in vivo. In co-cultures, overexpression of ubiquilin-1 resulted in
significantly increased levels of endogenously expressed BACE1, whereas in the mouse brain
samples the increase in BACE1 protein levels and activity upon ubiquilin-1 overexpression
was highly consistent, but more modest and not statistically significant. However, the milder
in vivo effect could arise from the fact that the infection efficacy of lentivirus is much higher
in cells (~60% neurons were infected) than in vivo in mouse brain (~20% of the neurons of the
dentate  gyrus  of  hippocampus  were  infected).  Furthermore,  a  relatively  small  group  size
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brain, suggesting that there may exist a relationship between ubiquilin-1 and tau (Mah et al.,
2000, Mizukami et al., 2014). In cultured non-neuronal cells, ubiquilin-1 overexpression led
to a significant increase in the levels of the predominant adult 0N4R-tau protein isoform and
its phosphorylation at the AD-specific AT8 epitopes. However, a similar effect on tau was
not observed in co-cultures of mouse embryonic primary cortical neurons and BV2 microglial
cells, although ubiquilin-1 slightly augmented LPS + IFN-·-induced increase in total 0N3R-
tau protein levels. As the 0N3R-isoform is the predominant form of tau expressed in neurons
during embryogenesis and possess a completely different role than adult tau (Lee et al., 2001),
it is plausible that ubiquilin-1 differentially regulates divergent tau isoforms during different
developmental stages. In contrast to this prediction, no major alterations were detected in
endogenously expressed 0N4R-tau isoform levels or phosphorylation in vivo in the
hippocampus of APdE9 mice after ubiquilin-1 overexpression. However, it should be noted
that APdE9 mice do not develop tau aggregates, and ubiquilin-1 has been shown to associate
especially with NFTs in human brain (Mah et al., 2000, Mizukami et al., 2014). Probably, it
would  be  more  relevant  to  elucidate  the  interaction  between  tau  and  ubiquilin-1  in  mice
overexpressing human tau. Future studies will allow a better understanding of the potential
interaction of ubiquilin-1 and tau and the underlying molecular mechanisms leading to
increased tau levels under cellular stress.
6.2 THE EFFECT OF DIETARY LIPID COMPOSITION ON ALZHEIMER’S
DISEASE-RELATED PATHOGENESIS AND COGNITIVE DECLINE: STUDIES
III AND IV
6.2.1 High-fat diet increases tau expression and exon 10 inclusion in the brain of female
mice independently of genotype, peripheral or central insulin signaling or
neuroinflammation status: Study III
Due to the anticipated increase in the numbers of people suffering from AD and the fact that
there is currently no cure for this affliction, it is of great importance to identify efficient
strategies for reducing the risk of developing or preventing the progression of this disease.
Accumulating evidence indicates that one plausible approach to intervene with disease
development might be dietary manipulation. AD by itself as well as several AD risk factors,
including  obesity  and  T2DM,  are  directly  associated  with  dietary  choices  (Morris  and
Tangney,  2014,  Sindi  et  al.,  2015).  HFD,  which contains  considerable  amount  of  SFAs,  is  a
common way to induce obesity and/or T2DM in rodents and several lines of evidence suggest
that  HFD accelerates  cognitive  decline  and AD-related pathology in  mouse models  of  AD
(Ho et al., 2004, Julien et al., 2010, Kohjima et al., 2010, Oksman et al., 2006, Takeda et al.,
2010, Vandal et al., 2014). In particular, several recent studies have demonstrated that a HFD
and  high  calorie  surplus  over  energetic  expenditure  induce  the  expression  and/or
phosphorylation of tau in mice, although the functional significance of these observations
have remained unclear (Bhat and Thirumangalakudi, 2013, Jeon et al., 2012, Koga et al., 2014,
Leboucher  et  al.,  2013,  Moroz  et  al.,  2008).  In  the  study  III,  HFD  was  found  to  elicit  a
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towards an increase in the levels of soluble AΆ40 and AΆ42 as well as insoluble AΆ40 were found
in the hippocampi of lentiviral expressing ubiquilin-1-injected mice as compared to controls.
At the same time, AΆ plaque load was contrastingly found to be moderately decreased in the
brain upon ubiquilin-1 overexpression. This inconsistency between plaque load and AΆ
levels could be due to the fact that the AΆ molecules continuously aggregate into and dissolve
from the plaques, which have been suggested to be dynamic structures (Maggio et al., 1992).
Based on this, it is possible that overexpression of ubiquilin-1 could somehow modulate the
balance between aggregated and soluble forms of AΆ.  All  in all,  together with previous in
vitro data reviewed in detail  in study I,  it  appears plausible that ubiquilin-1 influences AΆ
pathology at multiple levels,  by regulating both APP and BACE1 and by possibly the flux
state  of  AΆ aggregation.  A  recent,  and  currently  the  only  study,  which  has  previously
elucidated the role of ubiquilin-1 in mouse brain, found that knockdown of ubiquilin-1 leads
to the accumulation of ubiquitinated proteins and an aggravation of neuronal damage, while
lifelong ubiquilin-1 overexpression protects the mice from neuronal insults and the
prolonged motor defects that occur after ischemic insult or oxidative stress (Liu et al., 2014).
Thus, it  is possible that,  if  induced earlier,  the effects of ubiquilin-1 overexpression on AΆ
pathology  might  be  stronger  than  those  observed  in  the  present  study.  In  any  follow  up
studies, it would also be interesting to determine how ubiquilin-1 knockdown would
influence  APP  processing  or  AΆ pathology  in  the  brain  of  APP  transgenic  mice  under
excessive AD-associated stress.
Accumulating  evidence  indicates  that  neuroinflammation  plays  a  role  in  the  AD
pathogenesis  (Heneka  et  al.,  2015).  Ubiquilin-1,  on  the  other  hand,  has  been  suggested  to
alleviate different stress effects in vitro and in vivo, but its role in neuroinflammation had not
been characterized previously ((Ko et al., 2002, Lim et al., 2009, Liu et al., 2014, Lu et al.,
2009)). In study II, ubiquilin-1 overexpression was not observed to significantly influence the
inflammatory response during LPS + IFN-· –induced neuroinflammation in co-cultures of
mouse embryonic primary cortical neurons and BV2 microglial cells. Conversely,
overexpressed ubiquilin-1 was upregulated by the LPS + IFN-· treatment, suggesting that
ubiquilin-1 somehow responds to neuroinflammatory stress.  These results altogether
suggest that under this type of acute inflammatory stress, the up-regulation of ubiquilin-1
levels does not lead to an alleviation of neuroinflammation in a similar manner to the case of
ER  stress  (Ko  et  al.,  2002,  Lu  et  al.,  2009),  but  instead  it  may  aggravate  the  subsequent
neurodegeneration. There were no ubiquilin-1-associated alterations in the activity of Akt,
which  is  a  kinase  mediating  neuronal  survival  via  activation  of  a  prosurvival  signaling
cascade (Ghosh and Greenberg, 1995). Therefore, the mechanism of compromised neuronal
survival  upon  ubiquilin-1  overexpression  will  remain  a  matter  of  investigation  in  future
studies. All in all, together with the previous data, these findings suggest that ubiquilin-1
may  have  divergent  roles  depending  on  the  prevailing  stress  conditions.  According  to
previous data showing that BACE1 expression is increased by both LPS and IFN-·-induced
inflammation, here BACE1 levels were also modestly, although not significantly,
upregulated under inflammation.
The  final  aim  of  the  study  II  was  to  investigate  the  previously  uncharacterized
relationship of ubiquilin-1 and tau in vitro and in vivo.  Ubiquilin-1  has  been  shown  to  be
detectable  in  NFTs,  which  primarily  contain  aggregated,  hyperphosphorylated  tau  in  AD
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brain, suggesting that there may exist a relationship between ubiquilin-1 and tau (Mah et al.,
2000, Mizukami et al., 2014). In cultured non-neuronal cells, ubiquilin-1 overexpression led
to a significant increase in the levels of the predominant adult 0N4R-tau protein isoform and
its phosphorylation at the AD-specific AT8 epitopes. However, a similar effect on tau was
not observed in co-cultures of mouse embryonic primary cortical neurons and BV2 microglial
cells, although ubiquilin-1 slightly augmented LPS + IFN-·-induced increase in total 0N3R-
tau protein levels. As the 0N3R-isoform is the predominant form of tau expressed in neurons
during embryogenesis and possess a completely different role than adult tau (Lee et al., 2001),
it is plausible that ubiquilin-1 differentially regulates divergent tau isoforms during different
developmental stages. In contrast to this prediction, no major alterations were detected in
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would  be  more  relevant  to  elucidate  the  interaction  between  tau  and  ubiquilin-1  in  mice
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interaction of ubiquilin-1 and tau and the underlying molecular mechanisms leading to
increased tau levels under cellular stress.
6.2 THE EFFECT OF DIETARY LIPID COMPOSITION ON ALZHEIMER’S
DISEASE-RELATED PATHOGENESIS AND COGNITIVE DECLINE: STUDIES
III AND IV
6.2.1 High-fat diet increases tau expression and exon 10 inclusion in the brain of female
mice independently of genotype, peripheral or central insulin signaling or
neuroinflammation status: Study III
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(Hiltunen et al., 2012), it is thus likely that the expression and/or splicing of individual tau
isoforms are mechanistically differentially regulated by the diabetic phenotype and the HFD.
This  idea agrees  with  the  recent  study,  which similarly  reported a  specific  increase  in  the
levels  of  3R-tau,  accompanied  by  the  increased  expression  of  exon  10  splicing  silencer,
Srp55c,  in  the  rat  model  of  T2DM  (Jung  et  al.,  2011).  Notably,  another  study  recently
demonstrated that  AΆ may modulate  tau exon 10  splicing via  activating GSK3Ά,  which in
turn phosphorylates exon 10 splicing factor, SC35, and thus reduces the relative amount of
4R-tau (Chen et al., 2010). It is interesting to note, that the expression of SC35, Srp30c and
SF2/ASF were slightly, although not significantly increased in A+, but not in Aw mice after
HFD  in  the  current  study.  Since  a  similar  trend  of  modest  reduction  in  the  inhibitory
phosphorylation of GSK3Ά was detected in A+ mice after HFD, it is plausible that increased
Ά levels  may  contribute  to  increased  3R-tau  expression  in  A+  mice.  However,  this  idea
needs to be investigated in the future studies by determining the phosphorylation of SC35,
Srp33c, and SF2/ASF. All in all, these findings suggest that the delicate balance between the
expression of different tau isoforms is compromised by the HFD regime, although further
investigations are needed to comprehensively assess the exact underlying mechanisms of this
derangement.
It has been suggested that diet-induced obesity and related dyslipidemia, abnormal
peripheral and/or central insulin signaling may underlie tau-related changes in mice (Bhat
and Thirumangalakudi, 2013, Jeon et al., 2012, Koga et al., 2014, Leboucher et al., 2013, Moroz
et  al.,  2008).  Thus,  association  between  tau  levels  and  weight  gain,  peripheral  glucose
metabolism,  and  brain  insulin  signaling  was  elucidated  order  to  address  whether  these
factors influence the diet-related tau changes. Interestingly, increased phosphorylation of tau
has  been  demonstrated  in  the  brain  of  cognitively  intact  morbidly  obese  individuals,
suggesting that obesity may in fact predispose animals to tau-related changes (Mrak, 2009).
In the current study, the weight gain observed in the female HFD mice positively correlated
with 4R-tau and 3R-tau expression as well as increased 4R-tau to 3R-tau ratio. However, since
the weight gain in the female A+Iw mice on the HFD did not reach statistical significance, it
cannot exclusively explain the tau-related changes. Furthermore, neither 4R-tau, nor 3R-tau
expression,  nor  exon  10  splicing  were  associated  with  peripheral  changes  in  glucose
metabolism. This agrees with the previous study, where sustained hyperglycemia as well as
insulin resistance and hyperinsulinemia were observed only in the A+I+ mice (Hiltunen et
al., 2012). The relationship between central insulin signaling and tau-related pathology after
HFD  have  yielded  conflicting  results  in  animals  (Becker  et  al.,  2012,  Jeon  et  al.,  2012,
Leboucher et al., 2013, Moroz et al., 2008). It is well-established that the Akt/GSK3Ά signaling
pathway has a pivotal role in the central insulin resistance and molecular mechanisms of AD
(Jope and Johnson, 2004). Here, the HFD did not affect the activity of Akt or GSK3Ά in the
temporal cortex, implying that diet-related tau changes are not mediated by impaired central
insulin signaling via Akt/GSK3Ά signaling pathway. The findings regarding the association
between  peripheral  and  central  insulin  signaling  and  diet-induced  tau  changes  are  in
accordance with a recent study, which reported that HFD-induced obesity worsens tau
pathology independently of peripheral or central insulin resistance in THY-tau22 transgenic
and wild-type mice (Leboucher et al., 2013).
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extracted from the temporal cortex of these mice after HFD (Hiltunen et al., 2012). In contrast,
male  mice  on  HFD  did  not  show  similar  increase  in  the  expression,  splicing  or
phosphorylation of tau. Related to this, it has previously been shown that the AΆ pathology
in APdE9 mice  progress  faster  in  females  compared to  males  (Wang et  al.,  2003)  and that
dietary  supplementation  with  DHA  protects  female,  but  not  male,  mice  from  amyloid
pathology (Perez et al., 2010). The reason of this difference between the genders remains thus
far unclear and further studies are required for instance in ovariectomized mice combined
with dietary manipulation. Importantly, the diet-induced increase in tau mRNA expression
in female mice was correlated with poorer performance in spatial memory test and reduced
explorative activity in the novel environment. However, as the most significant impairment
of spatial memory was strongly associated with A+I+ genotype (Hiltunen et al., 2012), it
seems plausible that increased tau expression contributes to, but is insufficient on its own, to
cause severe cognitive impairment (Hiltunen et al., 2012). Taken together, it is likely that in
addition to diet, gender-specific factors contribute to the tau pathology and cognitive decline.
Although  3R-tau  levels  are  generally  low  in  the  brain  of  adult  mice,  a  recent  study
demonstrated  that  3R-tau  is  abundantly  expressed  at  least  in  certain  brain  areas  of  three-
month-old  wild-type  mice  (McMillan  et  al.,  2008).  In  the  present  study  III,  3R-tau  protein
levels were below the detection level in the temporal cortex of aged female mice. However,
optimization of the PCR conditions separately for 3R- and 4R-tau allowed the quantification
of mRNA levels of 3R-tau and to addressing the effects of genotype and diet on the 3R-tau
expression and alternative splicing of exon 10. Although the pathogenic role of aberrant tau
splicing is a matter of debate in AD, it has been demonstrated that increased levels of 3R tau
may play a role in the progression of tau pathology during AD (Connell et al., 2005, Espinoza
et al., 2008, Glatz et al., 2006, Ingelsson et al., 2006). In contrast, most of the familial tau
mutations associated with neurodegenerative tauopathies lead to the imbalanced splicing of
the tau exon 10, so that the 4R-tau isoforms become over-represented (Lee et al., 2001). In the
current  study,  a  significant  diet-induced  increase  in  4R-tau  to  3R-tau  mRNA  ratio  was
detected in the brain of female mice regardless of the genotype. This suggests that HFD does
not only promote tau expression, but may also alter tau exon 10 alternative splicing. Recently,
it was demonstrated that the expression levels of tau splicing factors, such as Tra2Ά, may be
altered during obesity and abnormal peripheral insulin signaling in humans and animal
models (Jung et al., 2011, Pihlajamaki et al., 2011). Therefore, the involvement of expressional
changes in the tau exon 10 splicing enhancers was elucidated in the brain of HFD mice. Even
though HFD significantly increased the ratio of 4R-tau to 3R-tau in this study, there were no
diet-related effects on the expression of tau exon 10 splicing enhancers, TraΆ, SC35, SRp30c
and SF2/ASF (Liu and Gong, 2008, Qian and Liu, 2014). This does not, however, rule out the
possibility  that  the  expression of  tau exon 10  splicing silencers  were  affected by the  HFD.
Furthermore, it should be noted that the activity of tau splicing factors are primarily
regulated through changes in their phosphorylation status, which was not assessed here
(Hartmann et al., 2001, Qian and Liu, 2014). In contrast to the 4R-tau expression, which was
exclusively influenced by the diet, the mRNA levels of 3R-tau were also significantly altered
by the genotype. More precisely, the mRNA levels of 3R-tau were increased in A+I+ mice on
standard diet as compared to A+Iw or AwI+ mice, and this was not further augmented by
the  HFD.  Since  the  accelerated  T2DM  phenotype  was  observed  only  in  the  A+I+  mice
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6.2.2 Additional dietary supplements modulate beneficial effects of fish oil based diets:
Study IV
The data from epidemiologic and experimental studies suggest that dietary supplementation
with  a n-3 PUFA,  DHA,  may  decrease  AD  risk  and  protect  from  AD-related  pathological
changes, whereas DHA depletion and increased n-6/n-3 ratio may have the opposite effect
(Calon et al., 2004, Calon et al., 2005, Grimm et al., 2011, Julien et al., 2010, Laitinen et al.,
2006, Ma et al., 2009, Morris et al., 2003b, Oksman et al., 2006, Teng et al., 2015). Despite the
evident beneficial effect of fish oil and other n-3 PUFA sources in these studies, it has been
suggested that the protective effects cannot be attributed to individual nutrients and that
DHA alone might be insufficient in providing protection from AD-related pathological
changes  (Lim  et  al.,  2006).  Presumably,  the  combined  intake  of  selected  nutritional
components,  such as plant sterols or UMP, choline, phospholipids, folic acid, vitamins B6,
B12,  C,  E,  and  selenium,  which  are  precursors  and  cofactors  for  synaptic  membrane
synthesis, may be required in order to reach true efficacy (Broersen et al., 2013, Cansev et al.,
2015, de Waal et al., 2014, de Wilde et al., 2011, Jansen et al., 2013, Jansen et al., 2014, Malar
and Devi, 2014, Scheltens et al., 2010, Scheltens et al., 2012, van Wijk et al., 2014). Study IV
demonstrates that the effects of fish oil based diet on cognition and amyloid pathology can
be modified by additional nutrients in the APdE9, AD, mouse model. Whereas all fish oil-
containing  experimental  diets  (FO,  FOPS  and  Fortasyn)  were  found  to  fully  restore  the
impaired olfactory recognition in APdE9 mice, only additional specific multinutrient
supplementation found in Fortasyn alleviated their deficit in spatial memory. This is
consistent with the previous studies, where DHA-containing diets were reported to improve
the performance of AD mice in object recognition tests (Arsenault et al., 2011, Kariv-Inbal et
al.,  2012),  but not in Morris swim navigation task measuring spatial memory and learning
(Arendash et al., 2007, Oksman et al., 2006). Divergent behavioral benefits of different dietary
supplements  might  arise  from  the  fact  that  memory  tasks  used  in  the  study  require  the
function of different brain circuits and different plasticity mechanisms. In other words, it has
been shown that recognition memory is mainly dependent on long-term synaptic depression
(Griffiths et al., 2008), while hippocampal dependent spatial memory requires long-term
synaptic potentiation (Morris et al., 2003b). Cholinergic signaling, on the other hand, may be
central  for  function  of  both  memory  types  (Cansev  et  al.,  2015,  Miranda  et  al.,  2009,
Warburton et al., 2003). Agreeing with the idea that Fortasyn may specifically modulate
memory functions associated with cholinergic neurotransmission, a recent study reported
that this multinutrient composition efficiently enhanced hippocampal cholinergic signaling
in aged rats (Cansev et al.,  2015).  In addition to this finding, mice receiving the FOPS diet
were  found  to  be  the  poorest  learners  in  the  Morris  swim  task  but  showed  the  fastest
habituation to the novel test cage in the current study. Although both are related to synaptic
spatial memory, it is possible that the confounding results are influenced by significantly
increased body weight observed in the FOPS group. Besides memory defects, anxiety,
restlessness  and  depression  are  common  features  in  AD  (Ferretti  et  al.,  2001).  Previous
experimental studies have suggested that dietary supplementation with the Fortasyn, but not
fish oil alone, may alleviate anxiety-related behavior in AD mouse models (Jansen et al., 2013,
Jansen et al.,  2014).  In contrast to these observations, none of the experimental diets in the
current study were able to reduce the anxiety-related hyperactivity or increase the reduced
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Finally, neuroinflammation is a potential mechanism that could link neurodegenerative
diseases,  T2DM  (Jope  and  Johnson,  2004)  and  tau-related  changes  during  diet-induced
obesity (Julien et al., 2010, Koga et al., 2014, Moroz et al., 2008). Based on this idea, the effects
of HFD on astrogliosis and the expression of proinflammatory cytokines, TNF΅ and IL1Ά,
were  investigated.  As  was  previously  shown,  HFD  exposure  does  not  affect  microglial
activation in these mice (Hiltunen et al., 2012). Consistent with that, there were no diet-
related  effects  on  astrogliosis  in  the  brain  of  female  mice.  These  findings  are  partially  in
contrast with other studies, where HFD and genetically-induced diabetes promoted cerebral
inflammation in mice (Jeon et al., 2012, Julien et al., 2010, Koga et al., 2014, Moroz et al., 2008,
Takeda  et  al.,  2010).  On  the  other  hand,  the  mRNA,  but  not  protein  levels  of  TNF΅ were
significantly decreased after HFD and negatively associated with tau-related changes,
suggesting that diet-induced expression and splicing of exon 10 of tau are not mediated by
exacerbated neuroinflammation. However, given that TNF΅ is a protein that is secreted from
the cells into the interstitial space, it is plausible that the mRNA levels of TNF΅ may in fact
reflect local inflammation status better than the protein levels in the temporal cortex. Thus,
it cannot conclusively ruled out that some other parts of the brain outside of the temporal
cortex could show aggravated cerebral inflammation due to the HFD.
Altogether, the present data in conjunction with previous results from these mice lend
support to the notion that the changes in tau expression and tau exon 10 inclusion are
influenced by dietary lipids and altered lipid profile rather than diabetes-related changes
(both  central  and  peripheral)  or  neuroinflammation.  In  line  with  this  hypothesis,  it  was
recently reported that certain lipids may play a role in triggering neuroinflammation and
neurodegeneration, suggesting that diet-induced dyslipidemia may influence cerebral
conditions (Sundaram et al., 2012). In addition, previous reports indicate that cholesterol
dyshomeostasis increase tau phosphorylation and cholesterol-lowering compounds are
protective in tau transgenic animals (Boimel et al., 2009, Glockner et al., 2011) (Grimm et al.,
2013). Furthermore, accumulating evidence from experimental studies suggest that the levels
of DHA and plan sterols directly modulate AD-type pathology in the brain (Calon et al., 2005,
Grimm et al., 2011, Julien et al., 2010, Morris et al., 2003b, Oksman et al., 2006). However, it
remains to be determined in future studies whether these mice suffer from dyslipidemia after
HFD.
Another plausible mechanism for possible diet-induced tau pathology, which was not
addressed here, is oxidative stress. Oxidative stress is thought to be centrally involved in the
pathogenesis  of  both  AD  and  T2DM  (Rosales-Corral  et  al.,  2015)  and  has  been  shown  to
precede amyloid pathology in the brain of AD mouse models (Abdul et al., 2008, Du et al.,
2010, Pratico et al., 2001). In support of this idea, a recent study reported that long-term HFD
consumption leads to hippocampal-dependent memory defects, which were associated with
mitochondrial dysfunction in the transgenic mouse model of AD (Petrov et al., 2015). On the
other hand, mitochondrial dysfunction and oxidative stress were directly linked to tau-
related pathology in situ in human hippocampal neurons during AD and in vitro model of
tau  pathology  in  another  recent  study  (Spilsbury  et  al.,  2015).  Therefore  it  remains  to  be
addressed in  future  studies  whether  HFD and tau-related changes  are  connected through
mitochondrial dysfunction or oxidative damage.
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7 Conclusions
The aim of this thesis was to investigate the effects of specific genetic and dietary factors on
AD-related molecular pathology by conducting experiments in well-established in vitro and
in vivo models and analyzing human post mortem brain tissue samples. In these studies, the
special emphasis was on the function of AD-associated ubiquilin-1 (Studies I and II) and on
the influence of dietary nutrient composition (studies III and IV). Following conclusions can
be drawn based on the findings in these studies.
I. Together, the findings from human AD brain and from in vitro and in vivo models in
Study  II  suggest  a  novel  interrelationship  between  ubiquilin-1  and  BACE1,  which
leads to BACE1 stabilization by diverting it from the lysosomal degradation pathway.
This interaction may thereby play a role in the regulation of AΆ accumulation and AD
pathogenensis.
II. Data obtained from study II also indicate that ubiquilin-1 does not alleviate the AD-
associated neuroinflammation in a similar manner as it  has been shown to alleviate
other stress conditions in in vitro models.  Thus ubiquilin-1 may play a divergent roles
during different stress conditions.
III. As a summary of Study I and novel data obtained from Study II,  ubiquilin-1 might
represent a common mechanistic link between different neurodegenerative diseases.
However, the data regarding the effects of ubiquilin-1 in AD and neurodegeneration
is  still  far  from  complete.  At  present,  it  is  quite  evident  that  due  to  its  complex
interactome and functions, ubiquilin-1 would be a complicated therapeutic target in
AD. Future studies will allow better understanding of the effects of ubiquilin-1
modulation on AD-related pathological pathways and whether it possesses
translational potential.
IV. The data from Study III suggest that a HFD, rich in SFAs, increases tau expression and
exon 10 inclusion and this may lead to cognitive decline in mice. The data also suggest
that the expression of 3R-tau and 4R-tau isoforms may be regulated through different
mechanisms. As a conclusion, HFD might associate with increased risk or faster
progression of AD and other neurodegenerative tauopathies.
V. Study  IV  confirmed  that  fish  oil  has  beneficial  effects  in  a  mouse  model  of  AD.
Additional supplementation, with other nutrients supporting neuronal membrane
formation  ,  may  enhance  the  cognitive  benefits  of  fish  oil  by  improving  synaptic
plasticity through AΆ-independent mechanisms. On the other hand, plant sterols may
potentiate the AΆ-lowering effect of DHA/fish oil, but more research is needed to find
a suitable formulation for their long-term use with the aim of AD prevention.
VI. Although the role of dietary lipids or other dietary supplements in AD still remains a
matter of investigation, together the findings from Studies III and IV indicate that
dietary lipids may play a role in the regulation of AD-related pathological
mechanisms and cognitive decline. Thus, dietary modulation may be an effective way
to influence AD risk or progression at a global level.
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exploratory behavior in APdE9 mice. However, it should be noted that the test settings, viz.
the monitoring time and the size of the test cage, were markedly different in the previous
studies as compared to the ones used in the current study. Thus, it is plausible that anxiety-
related dietary effects were not as evident with the shorter monitoring periods used in the
current study. All in all, these data suggest that additional nutrients included in the Fortasyn
may potentiate the beneficial cognitive effects of a fish oil-based diet.
Previous studies have shown that DHA supplementation reduces AΆ burden by several
pleiotropic mechanisms, such as inhibiting Ά-  and ·-secretase activity (Grimm et al.,  2011,
Oksman et al., 2006, Zhao et al., 2011). Consistent with these notions, both Ά- and ·-secretase
were  significantly  inhibited  in  the  brain  of  aged  APdE9  mice  after  9  months  of  dietary
intervention with FO diet. However, in the current study the secretase activities were further
influenced by added nutrients, so that the Ά-secretase activity was not markedly affected by
the FOPS diet, whereas ·-secretase activity was more uniformly reduced by all experimental
diets. In spite of evident secretase inhibition, none of the diets affected the amount of amyloid
plaques or the levels of insoluble AΆ, whereas soluble AΆ levels were reduced only in mice
on FOPS diet. These results are partially in contrast with previous studies, which have shown
that  both  Fortasyn  and  DHA  alone  may  alleviate  AΆ toxicity  and  burden  in  the  brain  of
mouse and rat models of AD (Broersen et al., 2013, de Wilde et al., 2011, Oksman et al., 2006).
However,  it  should  be  taken  into  account  that  in  these  dietary  intervention  studies,  diet
started significantly earlier or the animals were significantly younger at the time of sacrifice.
Therefore, it seems plausible that the beneficial effects of dietary manipulation on amyloid
pathology strongly depends on the onset age and/or duration of the intervention.
Furthermore, the previous reports regarding the effects of dietary DHA on AΆ pathology
have not been unequivocal, and it has been suggested that its beneficial effects may depend
upon the composition of the diet (Amtul et al., 2011, Arsenault et al., 2011, Jansen et al., 2013).
Taken together, as Fortasyn diet was the only diet associated with improved spatial learning
and odor recognition, it is evident that alleviation of APdE9 transgene-related cognitive
impairment by the dietary intervention was unrelated to changes in AΆ levels. Furthermore,
since Fortasyn Connect did not have significant effects on the ROS production, the amount
of active microglia or the levels of proinflammatory LPCs, it is highly unlikely that improved
cognitive performance was mediated by anti-inflammatory or antioxidative properties of
these nutrients.
Finally, based on the current findings, the role of dietary plant sterol supplementation
remains inconclusive. Diet-induced ·-secretase inhibition led to a significant decrease in the
Ά42/40 ratio only in the FOPS group, indicating that plant sterol supplementation leads to
·-secretase modulation. However, whereas the FOPS diet significantly reduced brain
microglial activation, it was also the only diet that significantly increased hippocampal ROS
production  and  neuroinflammation  in  terms  of  increased  LPCs.  In  a  recent  report  these
phospholipids were shown to trigger astrogliosis and neurodegeneration in primary
neuronal  cultures  (Sundaram  et  al.,  2012).  Therefore,  despite  a  promising  action  on  AΆ
accumulation, the plant sterol supplementation may have adverse effects on
neuroinflammation  and  production  of  reactive  oxygen  species,  which  may  prevent  its
otherwise beneficial effects on brain function in the AD model mice.
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